TY  - JOUR
TI  - The DEAD-box protein family of RNA helicases
T2  - Gene
VL  - 367
IS  - 1-2
SP  - 17
EP  - 37
PY  - 2006
DO  - 10.1016/j.gene.2005.10.019
AU  - Cordin O.
AU  - Banroques J.
AU  - Tanner N.K.
AU  - Linder P.
N1  - 施引文献 :483
N1  - Export Date: 2 January 2016
TY  - Review
DB  - Scopus
N1  - 参考文献: Altmann M., Wittmer B., Methot N., Sonenberg N., Trachsel H., The Saccharomyces cerevisiae translation initiation factor Tif3 and its mammalian homologue, eIF-4B, have RNA annealing activity (1995) EMBO J., 14, pp. 3820-3827; 
Anderson J.S.J., Parker R.P., The 3′ to 5′ degradation of yeast mRNAs is a general mechanism for mRNA turnover that requires the SKI2 DEVH box protein and 3′ to 5′ exonucleases of the exosome complex (1998) EMBO J., 17, pp. 1497-1506; 
Askjaer P., Rosendahl R., Kjems J., Nuclear export of the DEAD box An3 protein by CRM1 is coupled to An3 helicase activity (2000) J. Biol. Chem., 275, pp. 11561-11568; 
Aubourg S., Kreis M., Lecharny A., The DEAD box RNA helicase family in Arabidopsis thaliana (1999) Nucleic Acids Res., 27, pp. 628-636; 
Bates G.J., The DEAD box protein p68: A novel transcriptional coactivator of the p53 tumour suppressor (2005) EMBO J., 24, pp. 543-553; 
Benz J., Trachsel H., Baumann U., Crystal structure of ATPase domain of translation initiation factor eIF4A from Saccharomyces cerevisiae-the prototype of the DEAD box protein family (1999) Structure Fold Des., 7, pp. 671-679; 
Bernstein D.A., Zittel M.C., Keck J.L., High-resolution structure of the E. coli RecQ helicase catalytic core (2003) EMBO J., 22, pp. 4910-4921; 
Berthelot K., Muldoon M., Rajkowitsch L., Hughes J., McCarthy J.E., Dynamics and processivity of 40S ribosome scanning on mRNA in yeast (2004) Mol. Microbiol., 51, pp. 987-1001; 
Bi X., Goss D.J., Wheat germ poly(A)-binding protein increases the ATPase and the RNA helicase activity of translation initiation factors eIF4A, eIF4B, and eIF-iso4F (2000) J. Biol. Chem., 275, pp. 17740-17746; 
Bi X., Ren J., Goss D.J., Wheat germ translation initiation factor eIF4B affects eIF4A and eIF4F helicase activity by increasing the ATP binding affinity of eIF4A (2000) Biochemistry, 39, pp. 5758-5765; 
Bizebard T., Ferlenghi I., Iost I., Dreyfus M., Studies on three E. coli DEAD-box helicases point to an unwinding mechanism different from that of model DNA helicases (2004) Biochemistry, 43, pp. 7857-7866; 
Blum S., ATP hydrolysis by initiation factor 4A is required for translation initiation in Saccharomyces cerevisiae (1992) Proc. Natl. Acad. Sci. U. S. A., 89, pp. 7664-7668; 
Carmel A.B., Matthews B.W., Crystal structure of the BstDEAD N-terminal domain: A novel DEAD protein from Bacillus stearothermophilus (2004) RNA, 10, pp. 66-74; 
Carpousis A.J., The Escherichia coli RNA degradosome: Structure, function and relationship in other ribonucleolytic multienzyme complexes (2002) Biochem. Soc. Trans., 30, pp. 150-155; 
Carpousis A.J., Vanzo N.F., Raynal L.C., MRNA degradation. a tale of poly(A) and multiprotein machines (1999) Trends Genet., 15, pp. 24-28; 
Caruthers J.M., McKay D.B., Helicase structure and mechanism (2002) Curr. Opin. Struct. Biol., 12, pp. 123-133; 
Caruthers J.M., Johnson E.R., McKay D.B., Crystal structure of yeast initiation factor 4A, a DEAD-box RNA helicase (2000) Proc. Natl. Acad. Sci. U. S. A., 97, pp. 3080-3085; 
Chamot D., Colvin K.R., Kujat-Choy S.L., Owttrim G.W., RNA structural rearrangement via unwinding and annealing by the cyanobacterial RNA helicase, CrhR (2005) J. Biol. Chem., 280, pp. 2036-2044; 
Chan C.C., EIF4A3 is a novel component of the exon junction complex (2004) RNA, 10, pp. 200-209; 
Chang T.-H., Latus L.J., Liu Z., Abbott J.M., Genetic interactions of conserved regions in the DEAD-box protein Prp28p (1998) Nucleic Acids Res., 25, pp. 5033-5040; 
Charollais J., Pflieger D., Vinh J., Dreyfus M., Iost I., The DEAD-box RNA helicase SrmB is involved in the assembly of 50S ribosomal subunits in Escherichia coli (2003) Mol. Microbiol., 48, pp. 1253-1265; 
Charollais J., Dreyfus M., Iost I., CsdA, a cold-shock RNA helicase from Escherichia coli, is involved in the biogenesis of 50S ribosomal subunit (2004) Nucleic Acids Res., 32, pp. 2751-2759; 
Chen J.Y.-F., Stands L., Staley J.P., Jackups Jr. R.R., Latus L.J., Chang T.-H., Specific alterations of U1-C protein or U1 small nuclear RNA can eliminate the requirement of Prp28p, an essential DEAD box splicing factor (2001) Mol. Cell, 7, pp. 227-232; 
Chuang R.-Y., Weaver P.L., Liu Z., Chang T.-H., Requirement of the DEAD-box protein Ded1p for messenger RNA translation (1997) Science, 275, pp. 1468-1471; 
Coburn G.A., Miao X., Briant D.J., MacKie G.A., Reconstitution of a minimal RNA degradosome demonstrates functional coordination between a 3′ exonuclease and a DEAD-box RNA helicase (1999) Genes Dev., 13, pp. 2594-2603; 
Coller J.M., Tucker M., Sheth U., Valencia-Sanchez M.A., Parker R., The DEAD box helicase, Dhh1p, functions in mRNA decapping and interacts with both the decapping and deadenylase complexes (2001) RNA, 7, pp. 1717-1727; 
Cordin O., Tanner N.K., Doere M., Linder P., Banroques J., The newly discovered Q motif of DEAD-box RNA helicases regulates RNA-binding and helicase activity (2004) EMBO J., 23, pp. 2478-2487; 
Daugeron M.C., Kressler D., Linder P., Dbp9p, a putative ATP-dependent RNA helicase involved in 60S-ribosomal-subunit biogenesis, functionally interacts with Dbp6p (2001) RNA, 7, pp. 1317-1334; 
De La Cruz J., Iost I., Kressler D., Linder P., The p20 and Ded1 proteins have antagonistic roles in eIF4E-dependent translation in Saccharomyces cerevisiae (1997) Proc. Natl. Acad. Sci. U. S. A., 94, pp. 5201-5206; 
De La Cruz J., Kressler D., Tollervey D., Linder P., Dob1p (Mtr4p) is a putative ATP-dependent RNA helicase required for the 3′ end formation of 5.8S rRNA in Saccharomyces cerevisiae (1998) EMBO J., 17, pp. 1128-1140; 
De La Cruz J., Kressler D., Linder P., Unwinding RNA in Saccharomyces cerevisiae: DEAD-box proteins and related families (1999) Trends Biochem. Sci., 24, pp. 192-198; 
De La Cruz J., Kressler D., Linder P., Ribosomal subunit assembly (2003) The Nucleolus, pp. 263-290. , M.O.J. Olson Kluver Academic/Plenum Publishers New York; 
Diges C.M., Uhlenbeck O.C., Escherichia coli DbpA is an RNA helicase that requires hairpin 92 of 23S rRNA (2001) EMBO J., 20, pp. 5503-5512; 
Diges C.M., Uhlenbeck O.C., Escherichia coli DbpA is a 3′->5′ RNA helicase (2005) Biochemistry, 44, pp. 7093-7911; 
Dillingham M.S., Soultanas P., Wigley D.B., Site-directed mutagenesis of motif III in PcrA helicase reveals a role in coupling ATP hydrolysis to strand separation (1999) Nucleic Acids Res., 27, pp. 3310-3317; 
Dziembowski A., The yeast mitochondrial degradosome. Its composition, interplay between RNA helicase and RNase activities and the role in mitochondrial RNA metabolism (2003) J. Biol. Chem., 278, pp. 1603-1611; 
Endoh H., Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha (1999) Mol. Cell. Biol., 19, pp. 5363-5372; 
Estruch F., Cole C.N., An early function during transcription for the yeast mRNA export factor Dbp5p/Rat8p suggested by its genetic and physical interactions with transcription factor IIH components (2003) Mol. Biol. Cell., 14, pp. 1664-1676; 
Fairman M.E., Protein displacement by DExH/D "rNA helicases" without duplex unwinding (2004) Science, 304, pp. 730-734; 
Ferraiuolo M.A., A nuclear translation-like factor eIF4AIII is recruited to the mRNA during splicing and functions in nonsense-mediated decay (2004) Proc. Natl. Acad. Sci. U. S. A., 101, pp. 4118-4123; 
Flores-Rozas H., Hurwitz J., Characterization of a new RNA helicase from nuclear extracts of HeLa cells which translocates in the 5′ to 3′ direction (1993) J. Biol. Chem., 268, pp. 21372-21383; 
Fuller-Pace F.V., Nicol S.M., Reid A.D., Lane D.P., DbpA: A DEAD box protein specifically activated by 23S rRNA (1993) EMBO J., 12, pp. 3619-3626; 
Gallivan J.P., McGarvey M.J., The importance of the Q motif in the ATPase activity of a viral helicase (2003) FEBS Lett., 554, pp. 485-488; 
Gatfield D., The DExH/D protein HEL/UAP56 is essential for mRNA nuclear export in Drosophila (2001) Curr. Biol., 11, pp. 1716-1721; 
Gillian A.L., Svaren J., The Ddx20/DP103 dead box protein represses transcriptional activation by Egr2/Krox-20 (2004) J. Biol. Chem., 279, pp. 9056-9063; 
Gorbalenya A.E., Koonin E.V., Helicases: Amino acid sequence comparisons and structure-function relationships (1993) Curr. Opin. Struct. Biol., 3, pp. 419-429; 
Gorbalenya A.E., Koonin E.V., Donchenko A.P., Blinov V.M., A novel superfamily of nucleoside triphosphate-binding motif containing proteins which are probably involved in duplex unwinding in DNA and RNA replication and recombination (1988) FEBS Lett., 235, pp. 16-24; 
Grifo J.A., Abramson R.D., Satler C.A., Merrick W.C., RNA-stimulated ATPase activity of eukaryotic initiation factors (1984) J. Biol. Chem., 259, pp. 8648-8654; 
Henn A., Shi S.P., Zarivach R., Ben-Zeev E., Sagi I., The RNA helicase DbpA exhibits a markedly different conformation in the ADP-bound state when compared with the ATP- or RNA-bound states (2002) J. Biol. Chem., 277, pp. 46559-4665; 
Hieronymus H., Silver P.A., Genome-wide analysis of RNA-protein interactions illustrates specificity of the mRNA export machinery (2003) Nat. Genet., 33, pp. 155-161; 
Hirling H., Scheffner M., Restle T., Stahl H., RNA helicase activity associated with the human p68 protein (1989) Nature, 339, pp. 562-564; 
Hodge C.A., Colot H.V., Stafford P., Cole C.N., Rat8p/Dbp5p is a shuttling transport factor that interacts with Rat7p/Nup159p and Gle1p and suppresses the mRNA export defect of xpo1-1 cells (1999) EMBO J., 18, pp. 5778-5788; 
Honig A., Auboeuf D., Parker M.M., O'Malley B.W., Berget S.M., Regulation of alternative splicing by the ATP-dependent DEAD-box RNA helicase p72 (2002) Mol. Cell. Biol., 22, pp. 5698-5707; 
Huang Y., Liu Z.R., The ATPase, RNA unwinding, and RNA binding activities of recombinant p68 RNA helicase (2002) J. Biol. Chem., 277, pp. 12810-12815; 
Hunt J.F., Nucleotide control of interdomain interactions in the conformational reaction cycle of SecA (2002) Science, 297, pp. 2018-2026; 
Iggo R.D., Lane D.P., Nuclear protein p68 is an RNA-dependent ATPase (1989) EMBO J., 8, pp. 1827-1831; 
Iost I., Dreyfus M., Linder P., Ded1p, a DEAD-box protein required for translation initiation in Saccharomyces cerevisiae, is an RNA helicase (1999) J. Biol. Chem., 274, pp. 17677-17683; 
Jamieson D.J., Beggs J.D., A suppressor of yeast spp81/ded1 mutations encodes a very similar putative ATP-dependent RNA helicase (1991) Mol. Microbiol., 5, pp. 805-812; 
Jamieson D.J., Rahe B., Pringle J., Beggs J.D., A suppressor of a yeast splicing mutation (prp8-1) encodes a putative ATP-dependent RNA helicase (1991) Nature, 349, pp. 715-717; 
Jankowsky E., Gross C.H., Shumann S., Pyle A.M., The DexH protein NPH-II is a processive and directional molecular motor for unwinding RNA (2000) Nature, 403, pp. 447-451; 
Johnson E.R., McKay D.B., Crystallographic structure of the amino terminal domain of yeast initiation factor 4A, a representative DEAD-box RNA helicase (1999) RNA, 5, pp. 1526-1534; 
Karginov F.V., Uhlenbeck O.C., Interaction of Escherichia coli DbpA with 23S rRNA in different functional states of the enzyme (2004) Nucleic Acids Res., 32, pp. 3028-3032; 
Kawaoka J., Jankowsky E., Pyle A.M., Backbone tracking by the SF2 helicase NPH-II (2004) Nat. Struct. Mol. Biol., 11, pp. 526-530; 
Keene J.D., Organizing mRNA export (2003) Nat. Genet., 33, pp. 111-112; 
Kikuma T., Dbp9p, a member of the DEAD box protein family, exhibits DNA helicase activity (2004) J. Biol. Chem., 279, pp. 20692-20698; 
Kim J.L., Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: The crystal structure provides insights into the mode of unwinding (1998) Structure, 6, pp. 89-100; 
Korolev S., Hsieh J., Gauss G.H., Lohman T.M., Waksman G., Major domain swiveling revealed by the crystal structures of complexes of E. coli Rep helicase bound to single-stranded DNA and ADP (1997) Cell, 90, pp. 635-647; 
Korolev S., Yao N., Lohman T.M., Weber P.C., Waksman G., Comparisons between the structures of HCV and Rep helicases reveal structural similarities between SF1 and SF2 super-families of helicases (1998) Protein Sci., 7, pp. 605-610; 
Kossen K., Uhlenbeck O.C., Cloning and biochemical characterization of Bacillus subtilis YxiN, a DEAD protein specifically activated by 23S rRNA: Delineation of a novel sub-family of bacterial DEAD proteins (1999) Nucleic Acids Res., 27, pp. 3811-3820; 
Kossen K., Karginov F.V., Uhlenbeck O.C., The carboxy-terminal domain of the DExDH protein YxiN is sufficient to confer specificity for 23S rRNA (2002) J. Mol. Biol., 324, pp. 625-636; 
Kressler D., Linder P., De La Cruz J., Protein trans-acting factors involved in ribosome biogenesis in Saccharomyces cerevisiae (1999) Mol. Cell. Biol., 19, pp. 7897-7912; 
Kuang W.F., Hepatitis C virus NS3 RNA helicase activity is modulated by the two domains of NS3 and NS4A (2004) Biochem. Biophys. Res. Commun., 317, pp. 211-217; 
Ladomery M., Wade E., Sommerville J., Xp54, the Xenopus homologue of human RNA helicase p54, is an integral component of stored mRNP particles in oocytes (1997) Nucleic Acids Res., 25, pp. 965-973; 
Lamm G.M., Nicol S.M., Fuller-Pace F.V., Lamond A.I., P72: A human nuclear DEAD box protein highly related to p68 (1996) Nucleic Acids Res., 24, pp. 3739-3747; 
Li Q., Eukaryotic translation initiation factor 4AIII (eIF4AIII) is functionally distinct from eIF4AI and eIF4AII (1999) Mol. Cell. Biol., 19, pp. 7336-7346; 
Liang L., Diehl-Jones W., Lasko P., Localization of vasa protein to the Drosophila pole plasm is independent of its RNA-binding and helicase activities (1994) Development, 120, pp. 1201-1211; 
Libri D., Graziani N., Saguez C., Boulay J., Multiple roles for the yeast SUB2/yUAP56 gene in splicing (2001) Genes Dev., 15, pp. 36-41; 
Linder P., Yeast RNA helicases of the DEAD-box family involved in translation initiation (2003) Biol. Cell, 95, pp. 157-167; 
Linder P., Stutz F., MRNA export: Travelling with DEAD box proteins (2001) Curr. Biol., 11, pp. 961-R963; 
Linder P., Birth of the D-E-A-D box (1989) Nature, 337, pp. 121-122; 
Liu Z.R., P68 RNA helicase is an essential human splicing factor that acts at the U1 snRNA-5′ splice site duplex (2002) Mol. Cell. Biol., 22, pp. 5443-5450; 
Lorkovic Z.J., Herrmann R.G., Oelmuller R., PRH75, a new nucleus-localized member of the DEAD-box protein family from higher plants (1997) Mol. Cell. Biol., 17, pp. 2257-2265; 
Lorsch J.R., Herschlag D., The DEAD box protein eIF4A. 1. a minimal kinetic and thermodynamic framework reveals coupled binding of RNA and nucleotide (1998) Biochemistry, 37, pp. 2180-2193; 
Lorsch J.R., Herschlag D., The DEAD box protein eIF4A. 2. a cycle of nucleotide and RNA-dependent conformational changes (1998) Biochemistry, 37, pp. 2194-2206; 
Lüking A., Stahl U., Schmidt U., The protein family of RNA helicases (1998) Crit. Rev. Biochem. Mol. Biol., 33, pp. 259-296; 
Minshall N., Thom G., Standart N., A conserved role of a DEAD box helicase in mRNA masking (2001) RNA, 7, pp. 1728-1742; 
Morlang S., Weglohner W., Franceschi F., Hera from Thermus thermophilus: The first thermostable DEAD-box helicase with an RNase P protein motif (1999) J. Mol. Biol., 294, pp. 795-805; 
Nicol S.M., Fuller-Pace F.V., The "dEAD box" protein DbpA interacts specifically with the peptidyltransferase center in 23S rRNA (1995) Proc. Natl. Acad. Sci. U. S. A., 92, pp. 11681-11685; 
O'Day C.-L., Dalbadie-Mcfarland G., Abelson J., The Saccharomyces cerevisiae Prp5 protein has RNA-dependent ATPase activity with specificity for U2 small nuclear RNA (1996) J. Biol. Chem., 271, pp. 33261-33267; 
Ogilvie V.C., The highly related DEAD box RNA helicases p68 and p72 exist as heterodimers in cells (2003) Nucleic Acids Res., 31, pp. 1470-1480; 
Oh J.Y., Kim J., ATP hydrolysis of the DEAD box protein Rok1p is required for in vivo ROK1 function (1999) Nucleic Acids Res., 27, pp. 2753-2759; 
Okanami M., Meshi T., Iwabuchi M., Characterization of a DEAD box ATPase/RNA helicase protein of Arabidopsis thaliana (1998) Nucleic Acids Res., 26, pp. 2638-2643; 
Osborne A.R., Clemons Jr. W.M., Rapoport T.A., A large conformational change of the translocation ATPase SecA (2004) Proc. Natl. Acad. Sci. U. S. A., 101, pp. 10937-10942; 
Palacios I.M., Gatfield D., St Johnston D., Izaurralde E., An eIF4AIII-containing complex required for mRNA localization and nonsense-mediated mRNA decay (2004) Nature, 427, pp. 753-757; 
Patel S.S., Picha K.M., Structure and function of hexameric helicases (2000) Annu. Rev. Biochem., 69, pp. 651-697; 
Pause A., Sonenberg N., Mutational analysis of a DEAD box RNA helicase: The mammalian translation initiation factor eIF-4A (1992) EMBO J., 11, pp. 2643-2654; 
Pause A., Méthot N., Sonenberg N., The HRIGRXXR region of the DEAD box RNA helicase eukaryotic translation initiation factor 4A is required for RNA binding and ATP hydrolysis (1993) Mol. Cell. Biol., 13, pp. 6789-6798; 
Peck M.L., Herschlag D., Adenosine 5′-O-(3-thio)triphosphate (ATPgammaS) is a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A (2003) RNA, 9, pp. 1180-1187; 
Polach K.J., Uhlenbeck O.C., Cooperative binding of ATP and RNA substrates to the DEAD/H protein DbpA (2002) Biochemistry, 41, pp. 3693-3702; 
Pugh G.E., Nicol S.M., Fuller-Pace F.V., Interaction of the Escherichia coli DEAD box protein DbpA with 23 S ribosomal RNA (1999) J. Mol. Biol., 292, pp. 771-778; 
Py B., Higgins C.F., Krisch H.M., Carpousis A.J., A DEAD-box RNA helicase in the Escherichia coli RNA degradosome (1996) Nature, 381, pp. 169-172; 
Reed R., Hurt E., A conserved mRNA export machinery coupled to pre-mRNA splicing (2002) Cell, 108, pp. 523-531; 
Rocak S., Linder P., DEAD-box proteins: The driving forces behind RNA metabolism (2004) Nat. Rev. Mol. Cell. Biol., 5, pp. 232-241; 
Rocak S., Emery B., Tanner N.K., Linder P., Characterization of the ATPase and unwinding activities of the yeast DEAD-box protein Has1p and the analysis of the roles of the conserved motifs (2005) Nucleic Acids Res., 33, pp. 999-1009; 
Rogers G.W.J., Richter N.J., Merrick W.C., Biochemical and kinetic characterization of the RNA helicase activity of eukaryotic initiation factor 4A (1999) J. Biol. Chem., 274, pp. 12236-12244; 
Rogers G.W.J., Lima W.F., Merrick W.C., Further characterization of the helicase activity of eIF4A. Substrate specificity (2001) J. Biol. Chem., 276, pp. 12598-12608; 
Rogers G.W.J., Richter N.J., Lima W.F., Merrick W.C., Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F (2001) J. Biol. Chem., 276, pp. 30914-30922; 
Rogers Jr. G.W., Komar A.A., Merrick W.C., EIF4A: The godfather of the DEAD box helicases (2002) Prog. Nucleic Acid Res. Mol. Biol., 72, pp. 307-331; 
Rossler O.G., Straka A., Stahl H., Rearrangement of structured RNA via branch migration structures catalysed by the highly related DEAD-box proteins p68 and p72 (2001) Nucleic Acids Res., 29, pp. 2088-2096; 
Rozen F., Pelletier J., Trachsel H., Sonenberg N., A lysine substitution in the ATP-binding site of eucaryotic initiation factor 4A abrogates nucleotide-binding activity (1989) Mol. Cell. Biol., 9, pp. 4061-4063; 
Rozen F., Edery I., Meerovitch K., Dever T.E., Merrick W.C., Sonenberg N., Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A and 4F (1990) Mol. Cell. Biol., 10, pp. 1134-1144; 
Schmid S.R., Linder P., Translation initiation factor 4A from Saccharomyces cerevisiae: Analysis of residues conserved in the D-E-A-D family of RNA helicases (1991) Mol. Cell. Biol., 11, pp. 3463-3471; 
Schmitt C., Dbp5, a DEAD-box protein required for mRNA export, is recruited to the cytoplasmic fibrils of nuclear pore complex via a conserved interaction with CAN/Nup159p (1999) EMBO J., 18, pp. 4332-4347; 
Schneider S., Schwer B., Functional domains of the yeast splicing factor prp22p (2001) J. Biol. Chem., 276, pp. 21184-21191; 
Schneider S., Campodonico E., Schwer B., Motifs IV and V in the DEAH box splicing factor Prp22 are important for RNA unwinding, and helicase-defective Prp22 mutants are suppressed by Prp8 (2004) J. Biol. Chem., 279, pp. 8617-8626; 
Schwer B., Meszaros T., RNA helicase dynamics in pre-mRNA splicing (2000) EMBO J., 19, pp. 6582-6591; 
Sharma V., Crystal structure of Mycobacterium tuberculosis SecA, a preprotein translocating ATPase (2003) Proc. Natl. Acad. Sci. U. S. A., 100, pp. 2243-2248; 
Sheth U., Parker R., Decapping and decay of messenger RNA occur in cytoplasmic processing bodies (2003) Science, 300, pp. 805-808; 
Shi H., Cordin O., Minder C.M., Linder P., Xu R.M., Crystal structure of the human ATP-dependent splicing and export factor UAP56 (2004) Proc. Natl. Acad. Sci. U. S. A., 101, pp. 17628-17633; 
Shibuya T., Tange T.O., Sonenberg N., Moore M.J., EIF4AIII binds spliced mRNA in the exon junction complex and is essential for nonsense-mediated decay (2004) Nat. Struct. Mol. Biol., 11, pp. 346-351; 
Shiratori A., Shibata T., Arisawa M., Hanaoka F., Murakami Y., Eki T., Systematic identification, classification, and characterization of the open-reading frames which encode novel helicase-related proteins in Saccharomyces cerevisiae by gene disruption and Northern analysis (1999) YEAST, 15, pp. 219-253; 
Silverman E., Edwalds-Gilbert G., Lin R.J., DExD/H-box proteins and their partners: Helping RNA helicases unwind (2003) Gene, 312, pp. 1-16; 
Smillie D.A., Sommerville J., RNA helicase p54 (DDX6) is a shuttling protein involved in nuclear assembly of stored mRNP particles (2002) J. Cell Sci., 115, pp. 395-407; 
Sonenberg N., Dever T.E., Eukaryotic translation initiation factors and regulators (2003) Curr. Opin. Struct. Biol., 13, pp. 56-63; 
Soultanas P., Wigley D.B., Unwinding the 'Gordian knot' of helicase action (2001) Trends Biochem. Sci., 26, pp. 47-54; 
Soultanas P., Dillingham M.S., Velankar S.S., Wigley D.B., DNA binding mediates conformational changes and metal ion coordination in the active site of PcrA helicase (1999) J. Mol. Biol., 290, pp. 137-148; 
Staley J.P., Guthrie C., An RNA switch at the 5′ splice site requires ATP and the DEAD box protein Prp28p (1999) Mol. Cell, 3, pp. 55-64; 
Stevens S.W., Composition and functional characterization of the yeast spliceosomal penta-snRNP (2002) Mol. Cell, 9, pp. 31-44; 
Story R.M., Steitz T.A., Structure of the recA protein-ADP complex (1992) Nature, 355, pp. 374-376; 
Story R.M., Li H., Abelson J.N., Crystal structure of a DEAD box protein from the hyperthermophile Methanococcus jannaschii (2001) Proc. Natl. Acad. Sci. U. S. A., 98, pp. 1465-1470; 
Strasser K., Hurt E., Splicing factor Sub2p is required for nuclear mRNA export through its interaction with Yra1p (2001) Nature, 413, pp. 648-652; 
Subramanya H.S., Bird L.E., Brannigan J.A., Wigley D.B., Crystal structure of a DExx box DNA helicase (1996) Nature, 384, pp. 379-383; 
Svitkin Y.V., The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5′ secondary structure (2001) RNA, 7, pp. 382-394; 
Tanner N.K., The newly identified Q motif of DEAD box helicases is involved in adenine recognition (2003) Cell Cycle, 2, pp. 18-19; 
Tanner N.K., Linder P., DExD/H box RNA helicases: From generic motors to specific dissociation functions (2001) Mol. Cell, 8, pp. 251-262; 
Tanner N.K., Cordin O., Banroques J., Doère M., Linder P., The Q motif. a newly identified motif in DEAD box helicases may regulate aTP binding and hydrolysis (2003) Mol. Cell, 11, pp. 127-138; 
Theis K., Chen P.J., Skorvaga M., Van Houten B., Kisker C., Crystal structure of UvrB, a DNA helicase adapted for nucleotide excision repair (1999) EMBO J., 18, pp. 6899-6907; 
Tomei L., Failla C., Santolini E., De Francesco R., La Monica N., NS3 is a serine protease required for processing of hepatitis C virus polyprotein (1993) J. Virol., 67, pp. 4017-4026; 
Tschochner H., Hurt E., Pre-ribosomes on the road from the nucleolus to the cytoplasm (2003) Trends Cell Biol., 13, pp. 255-263; 
Tseng S.S.-I., Weaver P.L., Liu Y., Hitomi M., Tartakoff A.M., Chang T.-H., Dbp5p, a cytosolic RNA helicase, is required for poly(A) + RNA export (1998) EMBO J., 17, pp. 2651-2662; 
Tsu C.A., Uhlenbeck O.C., Kinetic analysis of the RNA-dependent adenosinetriphoshate activity of DbpA, an Escherichia coli DEAD protein specific for 23S ribosomal RNA (1998) Biochemistry, 37, pp. 16989-16996; 
Tsu C.A., Kossen K., Uhlenbeck O.C., The Escherichia coli DEAD protein DbpA recognizes a small RNA hairpin in 23S rRNA (2001) RNA, 7, pp. 702-709; 
Tuteja N., Tuteja R., Prokaryotic and eukaryotic DNA helicases. Essential molecular motor proteins for cellular machinery (2004) Eur. J. Biochem., 271, pp. 1835-1848; 
Tuteja N., Tuteja R., Unraveling DNA helicases. Motif, structure, mechanism and function (2004) Eur. J. Biochem., 271, pp. 1849-1863; 
Valdez B.C., Structural domains involved in the RNA folding activity of RNA helicase II/Gu protein (2000) Eur. J. Biochem., 267, pp. 6395-6402; 
Valdez B.C., Henning D., Perumal K., Busch H., RNA-unwinding and RNA-folding activities of RNA helicase II/Gu-two activities in separate domains of the same protein (1997) Eur. J. Biochem., 250, pp. 800-807; 
Valdez B.C., Perlaky L., Henning D., Expression, cellular localization, and enzymatic activities of RNA helicase II/Gu(beta) (2002) Exp. Cell. Res., 276, pp. 249-263; 
Vanzo N.F., Ribonuclease e organizes the protein interactions in the Escherichia coli RNA degradosome (1998) Genes Dev., 12, pp. 2770-2781; 
Velankar S.S., Soultanas P., Dillingham M.S., Subramanya H.S., Wigley D.B., Crystal structures of complexes of PcrA DNA helicase with a DNA substrate indicate an inchworm mechanism (1999) Cell, 97, pp. 75-84; 
Walker J.E., Saraste M., Runswick M.J., Gay N.J., Distantly related sequences in the α- And β-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold (1982) EMBO J., 1, pp. 945-951; 
Wassarman D.A., Steitz J.A., Alive with DEAD proteins (1991) Nature, 349, pp. 463-464; 
Watanabe M., A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor alpha coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA (2001) EMBO J., 20, pp. 1341-1352; 
Weirich C.S., Erzberger J.P., Berger J.M., Weis K., The N-terminal domain of Nup159 forms a beta-propeller that functions in mRNA export by tethering the helicase Dbp5 to the nuclear pore (2004) Mol. Cell, 16, pp. 749-760; 
Wilson B.J., Bates G.J., Nicol S.M., Gregory D.J., Perkins N.D., Fuller-Pace F.V., The p68 and p72 DEAD box RNA helicases interact with HDAC1 and repress transcription in a promoter-specific manner (2004) BMC Mol. Biol., 5, p. 11; 
Xu Y.Z., Newnham C.M., Kameoka S., Huang T., Konarska M.M., Query C.C., Prp5 bridges U1 and U2 snRNPs and enables stable U2 snRNP association with intron RNA (2004) EMBO J., 23, pp. 376-385; 
Yan X., Mouillet J.F., Ou Q., Sadovsky Y., A novel domain within the DEAD-box protein DP103 is essential for transcriptional repression and helicase activity (2003) Mol. Cell. Biol., 23, pp. 414-423; 
Yao N., Structure of the hepatitis C virus RNA helicase domain (1997) Nature Struct. Biol., 4, pp. 463-467; 
Yu E., Owttrim G.W., Characterization of the cold stress-induced cyanobacterial DEAD-box protein CrhC as an RNA helicase (2000) Nucleic Acids Res., 28, pp. 3926-3934; 
Zhao J., Jin S.B., Bjorkroth B., Wieslander L., Daneholt B., The mRNA export factor Dbp5 is associated with Balbiani ring mRNP from gene to cytoplasm (2002) EMBO J., 21, pp. 1177-1187; 
Zhao R., Shen J., Green M.R., MacMorris M., Blumenthal T., Crystal structure of UAP56, a DExD/H-box protein involved in pre-mRNA splicing and mRNA export (2004) Structure, 12, pp. 1373-1381
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-33344473656&partnerID=40&md5=fa0daf3b3379f9b5a0e9f9c8a0d8744c
ER  - 

TY  - JOUR
TI  - Genes mirror geography within Europe
T2  - Nature
VL  - 456
IS  - 7218
SP  - 98
EP  - 101
PY  - 2008
DO  - 10.1038/nature07331
AU  - Novembre J.
AU  - Johnson T.
AU  - Bryc K.
AU  - Kutalik Z.
AU  - Boyko A.R.
AU  - Auton A.
AU  - Indap A.
AU  - King K.S.
AU  - Bergmann S.
AU  - Nelson M.R.
AU  - Stephens M.
AU  - Bustamante C.D.
N1  - 施引文献 :469
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Jakobsson M., Genotype, haplotype and copy-number variation in worldwide human populations (2008) Nature, 451, pp. 998-1003; 
Li J.Z., Worldwide human relationships inferred from genome-wide patterns of variation (2008) Science, 319, pp. 1100-1104; 
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls (2007) Nature, 447, pp. 661-678. , Wellcome Trust Case Control Consortium; 
Tian C., Analysis and application of European genetic substructure using 300K SNP information (2008) PLoS Genet, 4, pp. e4; 
Price A.L., Discerning the ancestry of European Americans in genetic association studies (2008) PLoS Genet, 4, pp. e236; 
Shriver M.D., Kittles R.A., Genetic ancestry and the search for personalized genetic histories (2004) Nature Rev. Genet, 5, pp. 611-618; 
Nelson M.R., The Population Reference Sample (POPRES): A resource for population, disease, and pharmacological genetics research Am. J. Hum. Genet, , in the press; 
Patterson N., Price A., Reich D., Population structure and eigenanalysis (2006) PLoS Genet, 2, pp. e190; 
Novembre J., Stephens M., Interpreting principal component analyses of spatial population genetic variation (2008) Nature Genet, 40, pp. 646-649; 
Menozzi P., Piazza A., Cavalli-Sforza L., Synthetic maps of human gene frequencies in Europeans (1978) Science, 201, pp. 786-792; 
Campbell C.D., Demonstrating stratification in a European American population (2005) Nature Genet, 37, pp. 868-872; 
Price A.L., Principal components analysis corrects for stratification in genome-wide association studies (2006) Nature Genet, 38, pp. 904-909; 
McCarthy M.I., Genome-wide association studies for complex traits: Consensus, uncertainty and challenges (2008) Nature Rev. Genet, 9, pp. 356-369; 
Zhu X., Zhang S., Zhao H., Cooper R.S., Association mapping, using a mixture model for complex traits (2002) Genet. Epidemiol, 23, pp. 181-196; 
Weedon M.N., Genome-wide association analysis identifies 20 loci that influence adult height (2008) Nature Genet, 40, pp. 575-583; 
Lettre G., Identification of ten loci associated with height highlights new biological pathways in human growth (2008) Nature Genet, 40, pp. 584-591; 
Cavalli-Sforza L.L., Menozzi P., Piazza A., (1994) The History and Geography of Human Genes, p. 292. , Princeton Univ. Press; 
Bauchet M., Measuring European population stratification with microarray genotype data (2007) Am. J. Hum. Genet, 80, pp. 948-956; 
Weir B.S., Cockerham C.C., Estimating F-statistics for the analysis of population structure (1984) Evolution, 38, pp. 1358-1370; 
Eberle M.A., Kruglyak L., An analysis of strategies for discovery of single nucleotide polymorphisms (2000) Genet. Epidemiol, 19, pp. S29-S35; 
Clark A.G., Hubisz M.J., Bustamante C.D., Williamson S.H., Nielsen R., Ascertainment bias in studies of human genome-wide polymorphism (2005) Genome Res, 15, pp. 1496-1502; 
Slatkin M., Rare alleles as indicators of gene flow (1985) Evolution, 39, pp. 53-65; 
Falush D., Stephens M., Pritchard J.K., Inference of population structure using multilocus genotype data: Linked loci and correlated allele frequencies (2003) Genetics, 164, pp. 1567-1587; 
Tang H., Coram M., Wang P., Zhu X., Risch N., Reconstructing genetic ancestry blocks in admixed individuals (2006) Am. J. Hum. Genet, 79, pp. 1-12; 
Hellenthal, G., Auton, A. & Falush, D. Inferring human colonization history using a copying model. PLoS Genet. 4, e1000078 (2008)Kooner J., Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides (2008) Nature Genet, 40, pp. 149-151; 
Firmann, M. et al. The CoLaus study: A population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc. Dis. 8, 6 (2008)Purcell S., PLINK: A tool set for whole-genome association and population-based linkage analyses (2007) Am. J. Hum. Genet, 81, pp. 559-575
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-55549115654&partnerID=40&md5=c13b896821fc13986b224f9c54c9d734
ER  - 

TY  - JOUR
TI  - Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations
T2  - Nature Genetics
VL  - 41
IS  - 4
SP  - 460
EP  - 464
PY  - 2009
DO  - 10.1038/ng.339
AU  - Gudmundsson J.
AU  - Sulem P.
AU  - Gudbjartsson D.F.
AU  - Jonasson J.G.
AU  - Sigurdsson A.
AU  - Bergthorsson J.T.
AU  - He H.
AU  - Blondal T.
AU  - Geller F.
AU  - Jakobsdottir M.
AU  - Magnusdottir D.N.
AU  - Matthiasdottir S.
AU  - Stacey S.N.
AU  - Skarphedinsson O.B.
AU  - Helgadottir H.
AU  - Li W.
AU  - Nagy R.
AU  - Aguillo E.
AU  - Faure E.
AU  - Prats E.
AU  - Saez B.
AU  - Martinez M.
AU  - Eyjolfsson G.I.
AU  - Bjornsdottir U.S.
AU  - Holm H.
AU  - Kristjansson K.
AU  - Frigge M.L.
AU  - Kristvinsson H.
AU  - Gulcher J.R.
AU  - Jonsson T.
AU  - Rafnar T.
AU  - Hjartarsson H.
AU  - Mayordomo J.I.
AU  - De La Chapelle A.
AU  - Hrafnkelsson J.
AU  - Thorsteinsdottir U.
AU  - Kong A.
AU  - Stefansson K.
N1  - 施引文献 :165
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Goldgar D.E., Easton D.F., Cannon-Albright L.A., Skolnick M.H., Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands (1994) J. Natl. Cancer Inst, 86, pp. 1600-1608; 
Czene K., Lichtenstein P., Hemminki K., Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database (2002) Int. J. Cancer, 99, pp. 260-266; 
Amundadottir L.T., Cancer as a complex phenotype: Pattern of cancer distribution within and beyond the nuclear family (2004) PLoS Med, 1, pp. e65; 
Hrafnkelsson J., Tulinius H., Jonasson J.G., Sigvaldason H., Familial non-medullary thyroid cancer in Iceland (2001) J. Med. Genet, 38, pp. 189-191; 
Baida A., Strong association of chromosome 1p12 loci with thyroid cancer susceptibility (2008) Cancer Epidemiol. Biomarkers Prev, 17, pp. 1499-1504; 
Jazdzewski K., Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma (2008) Proc. Natl. Acad. Sci. USA, 105, pp. 7269-7274; 
Jazdzewski K., (2009) Proc. Natl. Acad. Sci. USA, , Polymorphic mature microRNAs from passenger strand of premiR-146a contribute to thyroid cancer, advance online publication, doi:10.1073/pnas.0812591106 21 January; 
He H., A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24 (2009) Cancer Res, 69, pp. 625-631; 
Kondo T., Ezzat S., Asa S.L., Pathogenetic mechanisms in thyroid follicular-cell neoplasia (2006) Nat. Rev. Cancer, 6, pp. 292-306; 
DeLellis R.A., Pathology and genetics of thyroid carcinoma (2006) J. Surg. Oncol, 94, pp. 662-669; 
Marx S.J., Molecular genetics of multiple endocrine neoplasia types 1 and 2 (2005) Nat. Rev. Cancer, 5, pp. 367-375; 
Kebebew E., Greenspan F.S., Clark O.H., Woeber K.A., McMillan A., Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors (2005) Cancer, 103, pp. 1330-1335; 
Gudbjartsson D.F., Many sequence variants affecting diversity of adult human height (2008) Nat. Genet, 40, pp. 609-615; 
Devlin B., Roeder K., Genomic control for association studies (1999) Biometrics, 55, pp. 997-1004; 
Kutyavin I.V., A novel endonuclease IV post-PCR genotyping system (2006) Nucleic Acids Res, 34, pp. e128; 
Dathan N., Parlato R., Rosica A., De Felice M., Di Lauro R., Distribution of the titf2/foxe1 gene product is consistent with an important role in the development of foregut endoderm, palate, and hair (2002) Dev. Dyn, 224, pp. 450-456; 
De Felice M., A mouse model for hereditary thyroid dysgenesis and cleft palate (1998) Nat. Genet, 19, pp. 395-398; 
Parlato R., An integrated regulatory network controlling survival and migration in thyroid organogenesis (2004) Dev. Biol, 276, pp. 464-475; 
Clifton-Bligh R.J., Mutation of the gene encoding human TTF-2 associated with thyroid agenesis, cleft palate and choanal atresia (1998) Nat. Genet, 19, pp. 399-401; 
Zhang P., Immunohistochemical analysis of thyroid-specific transcription factors in thyroid tumors (2006) Pathol. Int, 56, pp. 240-245; 
Sequeira M.J., Thyroid transcription factor-2 gene expression in benign and malignant thyroid lesions (2001) Thyroid, 11, pp. 995-1001; 
Gulcher J.R., Kristjansson K., Gudbjartsson H., Stefansson K., Protection of privacy by third-party encryption in genetic research in Iceland (2000) Eur. J. Hum. Genet, 8, pp. 739-742; 
Gretarsdottir S., The gene encoding phosphodiesterase 4D confers risk of ischemic stroke (2003) Nat. Genet, 35, pp. 131-138; 
Falk C.T., Rubinstein P., Haplotype relative risks: An easy reliable way to construct a proper control sample for risk calculations (1987) Ann. Hum. Genet, 51, pp. 227-233; 
Mantel N., Haenszel W., Statistical aspects of the analysis of data from retrospective studies of disease (1959) J. Natl. Cancer Inst, 22, pp. 719-748; 
Gudmundsson J., Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes (2007) Nat. Genet, 39, pp. 977-983; 
Rafnar T., Sequence variants at the TERT-CLPTM1L locus associate with many cancer types (2009) Nat. Genet, 41, pp. 221-227
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-63449092713&partnerID=40&md5=821e04883a4fe76aae226f544f3a4b0c
ER  - 

TY  - JOUR
TI  - Thyroid cancer epidemiology and prognostic variables
T2  - Clinical Oncology
VL  - 22
IS  - 6
SP  - 395
EP  - 404
PY  - 2010
DO  - 10.1016/j.clon.2010.05.004
AU  - Sipos J.A.
AU  - Mazzaferri E.L.
N1  - 施引文献 :144
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R., A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 (1998) Cancer, 83, pp. 2638-2648; 
Smallridge R.C., Marlow L.A., Copland J.A., Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies (2009) Endocr Relat Cancer, 16, pp. 17-44; 
American Cancer Society Cancer facts and figures 2009, , http://www.cancer.org, Available at:, (last accessed 25 January 2010); 
Ferlay J., Bray F., Pisani P., Parkin D.M., (2001) GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. Ver. 1.0. IARC Cancer Base No. 5, , http://www-dep.iarc.fr/globocan/globocan.html, IARC Press, Lyon, Available at:, (last accessed 2 March 2010); 
Kosary C.L., Cancer of the thyroid (2007) SEER survival monograph: cancer survival among adults. U.S. SEER program, 1988-2001, patient and tumor characteristics, , National Cancer Institute, SEER Program, NIH, Bethesda, MD, L.A.G. Ries, J.L. Young, G.E. Keel, M.P. Eisner, Y.D. Lin, M.J. Horner (Eds.); 
Ries L.A.G., Harkins D., Krapcho D., SEER Cancer statistics review, 1997-2003, , http://seer.cancer.gov/csr/1975_2001/results_merged/sect_25_thyroid.pdf, Available at:, (last accessed 7 January 2010); 
Kilfoy B.A., Zheng T., Holford T.R., International patterns and trends in thyroid cancer incidence, 1973-2002 (2009) Cancer Causes Control, 20, pp. 525-531; 
Ries L.A.G., Eisner M.P., Kosary C.L., (2010) SEER Cancer statistics review, 1975-2001, , http://seer_cancer.gov/csr/1975_2001/, National Cancer Institute, Bethesda, MD, Available at:, (last accessed 25 January 2010); 
Colonna M., Grande E., Jonasson J.G., Variation in relative survival of thyroid cancers in Europe: results from the analysis on 21 countries over the period 1983-1994 (EUROCARE-3 study) (2006) Eur J Cancer, 42, pp. 2598-2608. , Eurocare Working Group; 
Horner M.J., Ries L.A.G., Krapcho M., (2009) SEER stat fact sheets, , http://seer.cancer.gov/statfacts/html/thyro.html, National Cancer Institute, Bethesda, MD, Available at:, (last accessed 25 January 2010); 
Davies L., Welch H.G., Increasing incidence of thyroid cancer in the United States, 1973-2002 (2006) JAMA, 295, pp. 2164-2167; 
de Matos P.S., Ferreira A.P., Ward L.S., Prevalence of papillary microcarcinoma of the thyroid in Brazilian autopsy and surgical series (2006) Endocr Pathol, 17, pp. 165-173; 
Solares C.A., Penalonzo M.A., Xu M., Orellana E., Occult papillary thyroid carcinoma in postmortem species: prevalence at autopsy (2005) Am J Otolaryngol, 26, pp. 87-90; 
Yoshimoto Y., Ezaki H., Etoh R., Hiraoka T., Akiba S., Prevalence rate of thyroid diseases among autopsy cases of the atomic bomb survivors in Hiroshima, 1951-1985 (1995) Radiat Res, 141, pp. 278-286; 
Enewold L., Zhu K., Ron E., Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005 (2009) Cancer Epidemiol Biomarkers Prev, 18, pp. 784-791; 
Chen A.Y., Jemal A., Ward E.M., Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005 (2009) Cancer, 115, pp. 3801-3807; 
Rego-Iraeta A., Perez-Mendez L.F., Mantinan B., Garcia-Mayor R.V., Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma (2009) Thyroid, 19, pp. 333-340; 
Mazzaferri E.L., Managing small thyroid cancers (2006) JAMA, 295, pp. 2179-2182; 
Chem K.T., Rosai J., Follicular variant of thyroid papillary carcinoma: a clinicopathologic study of six cases (1977) Am J Surg Pathol, 1, pp. 123-130; 
Clavel-Chapelon F., Guillas G., Tondeur L., Kernaleguen C., Boutron-Ruault M.C., Risk of differentiated thyroid cancer in relation to adult weight, height, and body shape over life: the French E3N cohort (2010) Int J Cancer, 126 (12), pp. 2984-2990; 
Zielinski J.M., Garner M.J., Band P.R., Health outcomes of low-dose ionizing radiation exposure among medical workers: a cohort study of the Canadian national dose registry of radiation workers (2009) Int J Occup Med Environ Health, 22, pp. 149-156; 
Baker S.R., Bhatti W.A., The thyroid cancer epidemic: is it the dark side of the CT revolution? (2006) Eur J Radiol, 60, pp. 67-69; 
Kolonel L.N., Hankin J.H., Wilkens L.R., Fukunaga F.H., Hinds M.W., An epidemiologic study of thyroid cancer in Hawaii (1990) Cancer Causes Control, 1, pp. 223-234; 
Ron E., Kleinerman R.A., Boice J.D., LiVolsi V.A., Flannery J.T., Fraumeni J.F., A population-based case-control study of thyroid cancer (1987) J Natl Cancer Inst, 79, pp. 1-12; 
McDonald T.A., A perspective on the potential health risks of PBDEs (2002) Chemosphere, 46, pp. 745-755; 
Zuurbier M., Leijs M., Schoeters G., ten Tusscher G., Koppe J.G., Children's exposure to polybrominated diphenyl ethers (2006) Acta Paediatr Suppl, 95, pp. 65-70; 
Burningham A.R., Krishnan J., Davidson B.J., Ringel M.D., Burman K.D., Papillary and follicular variant of papillary carcinoma of the thyroid: initial presentation and response to therapy (2005) Otolaryngol Head Neck Surg, 132, pp. 840-844; 
Passler C., Prager G., Scheuba C., Follicular variant of papillary thyroid carcinoma: a long-term follow-up (2003) Arch Surg, 138, pp. 1362-1366; 
Zidan J., Karen D., Stein M., Rosenblatt E., Basher W., Kuten A., Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival (2003) Cancer, 97, pp. 1181-1185; 
Leung A.K., Chow S.M., Law S.C., Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma (2008) Laryngoscope, 118, pp. 32-38; 
Volante M., Collini P., Nikiforov Y.E., Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach (2007) Am J Surg Pathol, 31, pp. 1256-1264; 
Mazzaferri E.L., Jhiang S.M., Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer (1994) Am J Med, 97, pp. 418-428; 
Mazzaferri E.L., Management of low-risk differentiated thyroid cancer (2007) Endocr Pract, 13, pp. 498-512; 
Mazzaferri E.L., Thyroid carcinoma: papillary and follicular (1993) Endocrine tumors, pp. 278-333. , Blackwell Scientific Publications Inc, Cambridge, MA, E.L. Mazzaferri, N. Samaan (Eds.); 
Kouvaraki M.A., Shapiro S.E., Fornage B.D., Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer (2003) Surgery, 134, pp. 946-954; 
Stulak J.M., Grant C.S., Farley D.R., Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer (2006) Arch Surg, 141, pp. 489-494; 
Bonnet S., Hartl D., Leboulleux S., Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment (2009) J Clin Endocrinol Metab, 94, pp. 1162-1167; 
Ito Y., Higashiyama T., Takamura Y., Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection (2007) World J Surg, 31, pp. 2085-2091; 
Ito Y., Uruno T., Nakano K., An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid (2003) Thyroid, 13, pp. 381-387; 
Kumar A., Bal C.S., Differentiated thyroid cancer (2003) Indian J Pediatr, 70, pp. 707-713; 
Bhattacharyya N.A., Population-based analysis of survival factors in differentiated and medullary thyroid carcinoma (2003) Otolaryngol Head Neck Surg, 128, pp. 115-123; 
Hay I.D., Bergstralh E.J., Goellner J.R., Ebersold J.R., Grant C.S., Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989 (1993) Surgery, 114, pp. 1050-1057; 
Shaha A.R., Shah J.P., Loree T.R., Risk group stratification and prognostic factors in papillary carcinoma of thyroid (1996) Ann Surg Oncol, 3, pp. 534-538; 
Podnos Y.D., Smith D., Wagman L.D., Ellenhorn J.D., The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer (2005) Am Surg, 71, pp. 731-734; 
Zaydfudim V., Feurer I.D., Griffin M.R., Phay J.E., The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma (2008) Surgery, 144, pp. 1070-1077; 
Gemsenjager E., Heitz P.U., Seifert B., Martina B., Schweizer I., Differentiated thyroid carcinoma. Follow-up of 264 patients from one institution for up to 25 years (2001) Swiss Med Wkly, 131, pp. 157-163; 
Chiang F.Y., Lin J.C., Lee K.W., Thyroid tumors with preoperative recurrent laryngeal nerve palsy: clinicopathologic features and treatment outcome (2006) Surgery, 140, pp. 413-417; 
McCaffrey J.C., Evaluation and treatment of aerodigestive tract invasion by well-differentiated thyroid carcinoma (2000) Cancer Control, 7, pp. 246-252; 
Brierley J., Tsang R., Panzarella T., Bana N., Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years (2005) Clin Endocrinol (Oxf), 63, pp. 418-427; 
Jukkola A., Bloigu R., Ebeling T., Salmela P., Blanco G., Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications (2004) Endocr Relat Cancer, 11, pp. 571-579; 
Lee S.H., Lee S.S., Jin S.M., Kim J.H., Rho Y.S., Predictive factors for central compartment lymph node metastasis in thyroid papillary microcarcinoma (2008) Laryngoscope, 118, pp. 659-662; 
Leboulleux S., Rubino C., Baudin E., Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis (2005) J Clin Endocrinol Metab, 90, pp. 5723-5729; 
Benbassat C.A., Mechlis-Frish S., Hirsch D., Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer (2006) World J Surg, 30, pp. 1088-1095; 
Durante C., Haddy N., Baudin E., Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy (2006) J Clin Endocrinol Metab, 91, pp. 2892-2899; 
Lee J., Soh E.Y., Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis: clinical outcomes and prognostic factors (2010) Ann Surg, 251, pp. 114-119; 
Sampson E., Brierley J.D., Le L.W., Rotstein L., Tsang R.W., Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis (2007) Cancer, 110, pp. 1451-1456; 
Fugazzola L., Puxeddu E., Avenia N., Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature (2006) Endocr Relat Cancer, 13, pp. 455-464; 
Elisei R., Ugolini C., Viola D., BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study (2008) J Clin Endocrinol Metab, 93, pp. 3943-3949; 
Kebebew E., Weng J., Bauer J., The prevalence and prognostic value of BRAF mutation in thyroid cancer (2007) Ann Surg, 246, pp. 466-470; 
Lupi C., Giannini R., Ugolini C., Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma (2007) J Clin Endocrinol Metab, 92, pp. 4085-4090; 
Brzezianska E., Pastuszak-Lewandoska D., Wojciechowska K., Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population (2007) Neuro Endocrinol Lett, 28, pp. 351-359; 
Fugazzola L., Mannavola D., Cirello V., BRAF mutations in an Italian cohort of thyroid cancers (2004) Clin Endocrinol (Oxf), 61, pp. 239-243; 
Hay I.D., Gonzalez-Losada T., Reinalda M.S., Honetschlager J.A., Richards M.L., Thompson G.B., Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008 (2010) World J Surg, 34 (6), pp. 1192-1202; 
Dottorini M.E., Differentiated thyroid carcinoma in childhood (2000) Rays, 25, pp. 245-255; 
Yeh M.W., Demircan O., Ituarte P., Clark O.H., False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma (2004) Thyroid, 14, pp. 207-215; 
Hay I.D., Grant C.S., Taylor W.F., McConahey W.M., Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system (1987) Surgery, 102, pp. 1088-1095; 
Bilimoria K.Y., Bentrem D.J., Ko C.Y., Extent of surgery affects survival for papillary thyroid cancer (2007) Ann Surg, 246, pp. 375-381; 
Bilimoria K.Y., Bentrem D.J., Linn J.G., Utilization of total thyroidectomy for papillary thyroid cancer in the United States (2007) Surgery, 142, pp. 906-913; 
Sawka A.M., Thephamongkhol K., Brouwers M., Thabane L., Browman G., Gerstein H.C., Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer (2004) J Clin Endocrinol Metab, 89, pp. 3668-3676; 
Hay I.D., McConahey W.M., Goellner J.R., Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000 (2002) Trans Am Clin Climatol Assoc, 113, pp. 241-260; 
Cooper D.S., Doherty G.M., Haugen B.R., Management guidelines for patients with thyroid nodules and differentiated thyroid cancer (2009) Thyroid, 19, pp. 1167-1214. , Revised American Thyroid Association; 
McGriff N.J., Csako G., Gourgiotis L., Lori C.G., Pucino F., Sarlis N.J., Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer (2002) Ann Med, 34, pp. 554-564; 
Pujol P., Daures J.P., Nsakala N., Baldet L., Bringer J., Jaffiol C., Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer (1996) J Clin Endocrinol Metab, 81, pp. 4318-4323; 
Jonklaas J., Sarlis N.J., Litofsky D., Outcomes of patients with differentiated thyroid carcinoma following initial therapy (2006) Thyroid, 16, pp. 1229-1242; 
Sherman S.I., Brierley J.D., Sperling M., Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group (1998) Cancer, 83, pp. 1012-1021; 
Brierley J.D., Panzarella T., Tsang R.W., Gospodarowicz M.K., O'Sullivan B., A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example (1997) Cancer, 79, pp. 2414-2423; 
Pacini F., Schlumberger M., Dralle H., Elisei R., Smit J.W., Wiersinga W., European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium (2006) Eur J Endocrinol, 154, pp. 787-803; 
Loh K.C., Greenspan F.S., Gee L., Miller T.R., Yeo P.P., Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients (1997) J Clin Endocrinol Metab, 82, pp. 3553-3562
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-77954761901&partnerID=40&md5=cd02b0791d8c7b50a5027e2b2673329a
ER  - 

TY  - JOUR
TI  - Risk factors for thyroid cancer: An epidemiological review focused on nutritional factors
T2  - Cancer Causes and Control
VL  - 20
IS  - 1
SP  - 75
EP  - 86
PY  - 2009
DO  - 10.1007/s10552-008-9219-5
AU  - Dal Maso L.
AU  - Bosetti C.
AU  - La Vecchia C.
AU  - Franceschi S.
N1  - 施引文献 :113
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Ferlay J., Bray F., Pisani P., Parkin D.M., GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide (2004) IARC CancerBase No.5, Version 2.0., , IARC Press, Lyon, France; 
Verdecchia A., Francisci S., Brenner H., Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data (2007) Lancet Oncol, 8, pp. 784-796. , 10.1016/S1470-2045(07)70246-2; 
Kosary C.L., Cancer of the thyroid (2007) NIH Pub. No. 07-6215, , http://seer.cancer.gov/publications/survival/surv_thyroid.pdf, Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (eds) SEER survival monograph: cancer survival among adults: U.S. SEER program, 1988-2001, patient and tumor characteristics. National Cancer Institute, SEER Program, Bethesda, MD. Available at:; 
De Lellis R.A., Lloyd R.V., Heitz P.U., Eng C., (2004) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs, , IARC Press Lyon, France; 
Cancer incidence in five continents (2007) IARC Sci Publ No. 160, 9. , Curado MP, Edwards B, Shin HR et al (eds) IARC, Lyon; 
Liu S., Semenciw R., Ugnat A.M., Mao Y., Increasing thyroid cancer incidence in Canada, 1970-1996: Time trends and age-period-cohort effects (2001) Br J Cancer, 85, pp. 1335-1339. , 10.1054/bjoc.2001.2061; 
Verkooijen H.N., Fioretta G., Pache J.C., Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland (2003) Cancer Causes Control, 14, pp. 13-17. , 10.1023/A:1022593923603; 
Reynolds R.M., Weir J., Stockton D.L., Brewster D.H., Sandeep T.C., Strachan M.W.J., Changing trends in incidence and mortality of thyroid cancer in Scotland (2005) Clin Endocrinol, 62, pp. 156-162. , 10.1111/j.1365-2265.2004.02187.x; 
Davies L., Welch H.G., Increasing incidence of thyroid cancer in the United States, 1973-2002 (2006) JAMA, 295, pp. 2164-2167. , 10.1001/jama.295.18.2164; 
Feldt-Rasmussen U., Iodine and cancer (2001) Thyroid, 11, pp. 483-486. , 10.1089/105072501300176435; 
Negri E., Ron E., Franceschi S., A pooled analysis of case-control studies of thyroid cancer. I. Methods (1999) Cancer Causes Control, 10, pp. 131-142. , 10.1023/A:1008851613024; 
Preston-Martin S., Franceschi S., Ron E., Negri E., Thyroid cancer pooled analysis from 14 case-control studies: What have we learned? (2003) Cancer Causes Control, 14, pp. 787-789. , 10.1023/A:1026312203045; 
Rossing M.A., Cushing K.L., Voigt L.F., Wicklund K.G., Daling J.R., Risk of papillary thyroid cancer in women in relation to smoking and alcohol consumption (2000) Epidemiology, 11, pp. 49-54. , 10.1097/00001648-200001000-00011; 
Horn-Ross P.L., Morris S.J., Lee M.M., Iodine and thyroid cancer risk among women in a multiethnic population: The Bay Area Thyroid Cancer Study (2001) Cancer Epidemiol Biomarkers Prev, 10, pp. 979-985; 
Memon A., Darif M., Al-Saleh K., Suresh A., Epidemiology of reproductive and hormonal factors in thyroid cancer: Evidence from a case-control study in the Middle East (2002) Int J Cancer, 97, pp. 82-89. , 10.1002/ijc.1573; 
Zivaljevic V., Vlajinac H., Jankovic R., Marinkovic J., Diklic A., Paunovic I., Case-control study of anaplastic thyroid cancer (2006) Tumori, 90, pp. 9-12. , 10.1159/000091608; 
Troung T., Orsi L., Dubourdieu D., Rougier Y., Hémon D., Guénel P., Role of goiter and of menstrual and reproductive factors in thyroid cancer: A population-based case-control study in New Caledonia (South Pacific), a very high incidence area (2005) Am J Epidemiol, 161, pp. 1056-1065. , 10.1093/aje/kwi136; 
Wong E.Y., Ray R., Gao D.L., Reproductive history, occupational exposures, and thyroid cancer risk among women textile workers in Shanghai, China (2006) Int Arch Environ Health, 79, pp. 251-258. , 10.1007/s00420-005-0036-9; 
Iribarren C., Haselkorn T., Tekawa I.S., Friedman G.D., Cohort study of thyroid cancer in a San Francisco Bay Area population (2001) Int J Cancer, 93, pp. 745-750. , 10.1002/ijc.1377; 
Navarro Silvera S.A., Miller A.B., Rohan T.E., Risk factors for thyroid cancer: A prospective cohort study (2005) Int J Cancer, 116, pp. 433-438. , 10.1002/ijc.21079; 
Engeland A., Tretli S., Akslen L.A., Bjørge T., Body size and thyroid cancer in two million Norwegian men and women (2006) Br J Cancer, 95, pp. 366-370. , 10.1038/sj.bjc.6603249; 
(1998) IARC Handbooks of Cancer Prevention. Vitamin a, , IARC Working Group on the Evaluation of Cancer-preventive Agents. IARC WHO Lyon, France; 
(1998) IARC Handbooks of Cancer Prevention. Carotenoids, , IARC Working Group on the Evaluation of Cancer-preventive Agents. IARC WHO Lyon, France; 
(2003) IARC Handbooks of Cancer Prevention. Fruit and Vegetables, , IARC Working Group on the Evaluation of Cancer-preventive Strategies. IARC Press Lyon, France; 
Franceschi S., Dal Maso L., Capen C.C., Dybing E., Rice J.M., Wilbourn J.D., Hormonal imbalances and thyroid cancers in humans (1999) Species Differences in Thyroid, Kidney and Urinary Bladder Carcinogenesis, pp. 33-43. , IARC Lyon, France; 
Kane A.B., Boffetta P., Saracci R., Wilbourn J.D., (1996) Mechanisms of Fibre Carcinogenesis, , IARC Lyon, France; 
Ron E., Schottenfeld S., Fraumeni Jr. J.R., Epidemiology of thyroid cancer (1996) Cancer Epidemiology and Prevention, pp. 1000-1021. , Oxford University Press Oxford; 
(2002) IARC Handbooks of Cancer Prevention. Weight Control and Physical Activity, , IARC Working Group on the Evaluation of Cancer-preventive Strategies. IARC Press Lyon, France; 
De Benoist B., Andersson M., Egli I., Takkouche B., Allen H., (2004) Iodine Status Worldwide. WHO Global Database on Iodine Deficiency, , World Health Organization Geneva; 
Willett W.C., Rothman K.J., Greenland S., Nutritional epidemiology (1998) Modern Epidemiology, pp. 623-642. , 2 Lippincott-Raven Publishers Philadelphia; 
Ron E., Lubin J.H., Shore R.E., Thyroid cancer after exposure to external radiation: A pooled analysis of seven studies (1995) Radiat Res, 141, pp. 259-277. , 10.2307/3579003; 
Moysich K.B., Menezes R.J., Michalek A.M., Chernobyl-related ionising radiation exposure and cancer risk: An epidemiological review (2002) Lancet Oncol, 3, pp. 269-279. , 10.1016/S1470-2045(02)00727-1; 
Cardis E., Kesminiene A., Ivanov V., Risk of thyroid cancer after exposure to 131I in childhood (2005) J Natl Cancer Inst, 97, pp. 724-732; 
Liska J., Altanerova V., Galbavy S., Stvrtina S., Brtko J., Thyroid tumors: Histological classification and genetic factors involved in the development of thyroid cancer (2005) Endocr Regul, 39, pp. 73-83; 
Hemminki K., Eng C., Chen B., Familial risks for nonmedullary thyroid cancer (2005) Clin Endocrinol Metab, 90, pp. 5747-5753. , 10.1210/jc.2005-0935; 
Xing M., BRAF mutation in thyroid cancer (2005) Endocr Relat Cancer, 12, pp. 245-262. , 10.1677/erc.1.0978; 
Kondo T., Ezzat S., Asa S.L., Pathogenic mechanisms in thyroid follicular-cell neoplasia (2006) Nature Rev Cancer, 6, pp. 292-306. , 10.1038/nrc1836; 
Schlumberger M.J., Papillary and follicular thyroid carcinoma (1998) N Engl J Med, 338, pp. 297-306. , 10.1056/NEJM199801293380506; 
Franceschi S., Preston-Martin S., Dal Maso L., A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases (1999) Cancer Causes Control, 10, pp. 583-595. , 10.1023/A:1008907227706; 
Knudsen N., Laurberg P., Perrild H., Bülow I., Ovesen L., Jørgensen T., Risk factors for goiter and thyroid nodules (2002) Thyroid, 12, pp. 879-888. , 10.1089/105072502761016502; 
Galanti M.R., Granath F., Cnattingius S., Ekbom-Schnell A., Ekbom A., Cigarette smoking and the risk of goitre and thyroid nodules amongst parous women (2005) J Intern Med, 258, pp. 257-264. , 10.1111/j.1365-2796.2005.01523.x; 
Rasmussen L.B., Ovesen L., Bülow I., Relations between various measures of iodine intake and thyroid volume, thyroid nodularity, and serum thyroglobulin1-3 (2002) Am J Clin Nutr, 76, pp. 1069-1076; 
Memon A., Varghese A., Suresh A., Benign thyroid disease and dietary factors in thyroid cancer: A case-control study in Kuwait (2002) Br J Cancer, 86, pp. 1745-1750. , 10.1038/sj.bjc.6600303; 
Surks M.I., Chopra I.J., Mariash C.N., Nicoloff J.T., Solomon D.H., American thyroid association guidelines for use of laboratory tests in thyroid disorders (1990) J Am Med Assoc, 263, pp. 1529-1532. , 10.1001/jama.263.11.1529; 
Williams E.D., Doniach I., Bjarnason O., Michie W., Thyroid cancer in iodide rich area: A histopathological study (1977) Cancer, 39, pp. 215-222; 
Negri E., Dal Maso L., Ron E., A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors (1999) Cancer Causes Control, 10, pp. 143-145. , 10.1023/A:1008880429862; 
La Vecchia C., Ron E., Franceschi S., A pooled analysis of case-control studies of thyroid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones (1999) Cancer Causes Control, 10, pp. 157-166. , 10.1023/A:1008832513932; 
Rossing M.A., Voigt L.F., Wiklund K.G., Williams M., Daling J.R., Use of exogenous hormones and risk of papillary thyroid cancer (Washington, United States) (1998) Cancer Causes Control, 9, pp. 341-349. , 10.1023/A:1008833422577; 
Sakoda L.C., Horn-Ross P.L., Reproductive and menstrual history and papillary thyroid cancer risk: The San Francisco Bay Area Thyroid Cancer Study (2002) Cancer Epidemiol Biomarkers Prev, 11, pp. 51-57; 
Gaitan E., Goitrogens in food and water (1990) Annu Rev Nutr, 10, pp. 21-39. , 10.1146/annurev.nu.10.070190.000321; 
Nagataki S., Nyström E., Epidemiology and primary prevention of thyroid cancer (2002) Thyroid, 12, pp. 889-896. , 10.1089/105072502761016511; 
Lind P., Langsteger W., Molnar M., Gallowitsch H.J., Mikosch P., Gomez I., Epidemiology of thyroid diseases in iodine sufficiency (1998) Thyroid, 8, pp. 1179-1183; 
Franceschi S., Iodine intake and thyroid carcinoma-a potential risk factor (1998) Exp Clin Endocrinol Diab, 106, pp. 38-S44. , Suppl 3; 
Delange F., Lecomte P., Iodine supplementation: Benefits outweigh risks (2000) Drug Saf, 22, pp. 89-95. , 10.2165/00002018-200022020-00001; 
Weissel M., Legal augmentation of iodine content in table salt from 10 to 20 mg Kl/kg: Documented effects a decade later (2003) Exp Clin Endocrinol Diab, 111, pp. 187-190. , 10.1055/s-2003-40461; 
Kolonel L.N., Hankin J.H., Wilkens L.R., Fukunaga F.H., Hinds M.W., An epidemiologic study of thyroid cancer in Hawaii (1990) Cancer Causes Control, 1, pp. 223-234. , 10.1007/BF00117474; 
Glattre E., Haldorsen T., Berg J.P., Stensvold I., Solvoll K., Norwegian case-control study testing the hypothesis that seafood increases the risk of thyroid cancer (1993) Cancer Causes Control, 4, pp. 11-16. , 10.1007/BF00051708; 
Bosetti C., Kolonel L., Negri E., A pooled analysis of case-control studies of thyroid cancer. VI. Fish and shellfish consumption (2001) Cancer Causes Control, 12, pp. 375-382. , 10.1023/A:1011267123398; 
Kanno J., Matsouoka C., Furuta K., Tumor promoting effect of goitrogens on the rat thyroid (1999) Toxicol Pathol, 18, pp. 239-246; 
Bosetti C., Negri E., Kolonel L., A pooled analysis of case-control studies of thyroid cancer. VII. Cruciferous and other vegetables (International) (2002) Cancer Causes Control, 13, pp. 765-775. , 10.1023/A:1020243527152; 
Yin F., Giuliano A.E., Van Herle A.J., Growth inhibitory effects of flavonoids in human thyroid cancer cell lines (1999) Thyroid, 9, pp. 369-376; 
Steinmetz K., Potter J.D., Vegetables, fruit, and cancer prevention (1996) J Am Diet Assoc, 96, pp. 1027-1039. , 10.1016/S0002-8223(96)00273-8; 
Horn-Ross P.L., Hoggatt K.J., Lee M.M., Phytoestrogens and thyroid cancer risk: The San Francisco Bay Area Thyroid Cancer Study (2002) Cancer Epidemiol Biomarkers Prev, 11, pp. 43-49; 
Berg J.P., Glattre E., Haldorsen T., Longchain serum fatty acids and risk of thyroid cancer: A population-based case-control study in Norway (1994) Cancer Causes Control, 5, pp. 433-439. , 10.1007/BF01694757; 
Franceschi S., Levi F., Negri E., Fassina A., La Vecchia C., Diet and thyroid cancer: A pooled analysis of four European case-control studies (1991) Int J Cancer, 48, pp. 395-398. , 10.1002/ijc.2910480315; 
Galanti M.R., Hansson L., Bergstrom R., Diet and the risk of papillary and follicular thyroid carcinoma: A population-based case-control study in Sweden and Norway (1997) Cancer Causes Control, 8, pp. 205-214. , 10.1023/A:1018424430711; 
Markaki I., Linos D., Linos A., The influence of dietary patterns on the development of thyroid cancer (2003) Eur J Cancer, 39, pp. 1912-1919. , 10.1016/S0959-8049(03)00432-5; 
MacK W.J., Preston-Martin S., Dal Maso L., A pooled analysis of case-control studies of thyroid cancer: Cigarette smoking and consumption of alcohol, coffee, and tea (2003) Cancer Causes Control, 14, pp. 773-785. , 10.1023/A:1026349702909; 
Glattre E., Thomassen Y., Thoresen S., Lund-Larsen P.G., Theodorsen L., Aaseth J., Prediagnostic serum selenium in a case-control study of thyroid cancer (1989) Int J Epidemiol, 18, pp. 45-49. , 10.1093/ije/18.1.45; 
D'Avanzo B., Ron E., La Vecchia C., Franceschi S., Negri E., Ziegler R., Selected micronutrient intake and thyroid carcinoma risk (1997) Cancer, 79, pp. 2186-2192; 
Fioretti F., Tavani A., Gallus S., Franceschi S., Negri E., La Vecchia C., Case-control study of thyroid cancer in northern Italy: Attributable risk (1999) Int J Epidemiol, 28, pp. 626-630. , 10.1093/ije/28.4.626; 
Haselkorn T., Stewart S.L., Horn-Ross P.L., Why are thyroid cancer rates so high in Southeast Asian women living in the United States? the Bay area Thyroid cancer study (2003) Cancer Epidemiol Biomarkers Prev, 12, pp. 1444-1450; 
Ron E., Kleinerman R.A., Boice Jr. J.D., Livolsi V.A., Flannery J.T., Fraumeni Jr. J.R., A population-based case-control study of thyroid cancer (1987) J Natl Cancer Inst, 79, pp. 1-12; 
MacK W., Preston-Martin S., Bernstein L., Qian D., Lifestyle and other risk factors for thyroid cancer in Los Angeles County females (2002) Ann Epidemiol, 12, pp. 395-401. , 10.1016/S1047-2797(01)00281-2; 
Dal Maso L., La Vecchia C., Franceschi S., A pooled analysis of thyroid cancer studies. V. Anthropometric factors (2000) Cancer Causes Control, 11, pp. 137-144. , 10.1023/A:1008938520101; 
Negri E., Ron E., Franceschi S., Risk factors for medullary thyroid carcinoma: A pooled analysis (2002) Cancer Causes Control, 13, pp. 365-372. , 10.1023/A:1015263718760; 
Vella V., Sciacca L., Pandini G., The IGF system in thyroid cancer: New concepts (2001) J Clin Pathol Mol Pathol, 54, pp. 121-125; 
Thissein J.-P., Ketelslegers J.-M., Underwood L.E., Nutritional regulation of the insulin-like growth factors (1994) Endocr Rev, 15, pp. 80-101. , 10.1210/er.15.1.80; 
Wingren G., Hatschek T., Axelson O., Determinants of papillary cancer of the thyroid (1993) Am J Epidemiol, 138, pp. 482-491; 
Rossing M.A., Remler R., Voigt L.F., Wicklund K.G., Daling J.R., Recreational physical activity and risk of papillary thyroid cancer (United States) (2001) Cancer Causes Control, 12, pp. 881-885. , 10.1023/A:1013757030600; 
(2007) Food Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective, , World Cancer Research Fund, American Institute for Cancer Research. American Institute for Cancer Research Washington, DC; 
Willett W.C., Schottenfeld S., Fraumeni Jr. J.R., Diet and nutrition (2006) Cancer Epidemiology and Prevention, pp. 405-421. , 3 Oxford University Press Oxford
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-58249105246&partnerID=40&md5=652e3d5bf175cb8692a8a69cd9ab8e33
ER  - 

TY  - JOUR
TI  - Mapping of an autoimmunity susceptibility locus (AIS1) to chromosome 1p31.3-p32.2
T2  - Human Molecular Genetics
VL  - 11
IS  - 6
SP  - 661
EP  - 667
PY  - 2002
AU  - Alkhateeb A.
AU  - Stetler G.L.
AU  - Old W.
AU  - Talbert J.
AU  - Uhlhorn C.
AU  - Taylor M.
AU  - Fox A.
AU  - Miller C.
AU  - Dills D.G.
AU  - Ridgway E.C.
AU  - Bennett D.C.
AU  - Fain P.R.
AU  - Spritz R.A.
N1  - 施引文献 :91
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Marrack P., Kappler J., Kotzin B.L., Autoimmune disease: Why and where it occurs (2001) Nat. Med, 7, pp. 899-905; 
Harsoulis P., Kanakoudi-Tsakalidis F., Vyzantiadis A., Minas A., Cassimos C., Autoimmunity and vitiligo (1978) Arch. Dermatol, 114, p. 1554; 
Nordlund J.J., Ortonne J.-P., Vitiligo vulgaris (1998) The Pigmentary System, pp. 513-551. , Nordlund,J.J., Boissy,R.E., Hearing,V.J., King,R.A. and Ortonne,J.-P. (eds), Oxford University Press, New York; 
Hahn S.-K., Nordlund J.J., Vitiligo (2000), Blackwell Science, Oxford, UKJacobson D.L., Gange S.J., Rose N.R., Graham N.M., Epidemiology and estimated population burden of selected autoimmune diseases in the United States (1997) Clin. Immunol. Immunopathol, 84, pp. 223-243; 
Cockayne E.A., Inherited Abnormalities of the Skin and Appendages (1933), Oxford University Press, London, UKMerelender J., Rywlin J., Heredity of acquired vitiligo (vitiligo in three generations) (1940) Acta Derm. Venereol. (Stockh.), 21, pp. 583-585; 
Mehta N.R., Shah K.C., Theodore C., Vyas V.P., Patel A.B., Epidemiological study of vitiligo in Surat area (1973) Indian J. Med. Res, 61, pp. 145-154; 
Carnevale A., Zavala C., Castillo V.D., Maldonado R.R., Tamayo L., Analisis genetico de 127 familias con vitiligo (1980) Rev. Invest. Clin, 32, pp. 37-41; 
Hafez M., Sharaf L., El-Nabi S.M.A., The genetics of vitiligo (1983) Acta Derm. Venereol. (Stockh.), 63, pp. 249-251; 
Das S.K., Majumder P.P., Majumdar T.K., Haldar B., Studies on vitiligo. II. Familial aggregation and genetics (1985) Genet. Epidemiol, 2, pp. 255-262; 
Majumder P.P., Das S.K., Li C.C., A genetical model for vitiligo (1988) Am. J. Hum. Genet, 43, pp. 119-125; 
Majumder P.P., Nordlund J.J., Nath S.K., Pattern of familial aggregation of vitiligo (1993) Arch. Dermatol, 129, pp. 994-998; 
Bhatia P.S., Mohan L., Pandey O.N., Singh K.K., Arora S.K., Mukhija R.D., Genetic nature of vitiligo (1992) J. Dermatol. Sci, 4, pp. 180-184; 
Nath S.K., Majumder P.P., Nordlund J.J., Genetic epidemiology of vitiligo: Multilocus recessivity cross-validated (1994) Am. J. Hum. Genet, 55, pp. 981-990; 
Mohr J., Vitiligo in a pair of monovular twins (1951) Acta Genet. Stat. Med, 2, pp. 252-255; 
Siemens H.W., Die Zwillingspathologie der Vitiligo (1953) Acta Genet. Med. Gemellol. (Roma), 2, pp. 118-124; 
Baker J.R. Jr., Immunologic aspects of endocrine diseases (1992) J. Am. Med. Assoc, 268, pp. 2899-2903; 
Riley W.J., Autoimmune polyglandular syndromes (1992) Horm. Res, 38 (SUPPL. 2), pp. 9-15; 
Redondo M.J., Eisenbarth G.S., Autoimmune polyendocrine syndrome type II (1999) Molecular Mechanisms of Endocrine and Organ Specific Autoimmunity, pp. 41-61. , Eisenbarth,G.S. (ed.), R.G. Landes Co., Austin, TX; 
Yee C., Thompson J.A., Roche P., Byrd D.R., Lee P.P., Piepkorn M., Kenyon K., Greenberg P.D., Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of cell-mediated vitiligo (2000) J. Exp. Med, 192, pp. 1637-1644; 
Nagai H., Hara I., Horikawa T., Oka M., Kamidono S., Ichihashi M., Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration (2000) J. Invest. Dermatol, 115, pp. 1059-1064; 
Canaris G.J., Manowitz M.R., Mayor G., Ridgway E.C., The Colorado thyroid disease prevalence study (2000) Arch. Intern. Med, 160, pp. 526-534; 
Hollowell J.G., Staehling N.W., Flanders W.D., Hannon W.H., Gunter E.W., Spencer C.A., Braverman L.E., Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) (2002) J. Clin. Endocrinol. Metab, 87, pp. 489-499; 
Howitz J., Brodthagen H., Schwartz M., Thomsen K., Prevalence of vitiligo: Epidemiological survey on the Isle of Bornholm, Denmark (1977) Arch. Dermatol, 113, pp. 47-52; 
Tomer Y., Barbesino G., Greenberg D.A., Concepcion E., Davies T.F., Mapping the major susceptibility loci for familial Graves' and Hashimoto's diseases: Evidence for genetic heterogeneity and gene interactions (1999) J. Clin. Endocrinol. Metab, 84, pp. 4656-4664; 
Zamani M., Spaepen M., Sghar S.S., Huang C., Westerhof W., Nieuweboer-Krobotova L., Cassiman J.J., Linkage and association of HLA class II genes with vitiligo in a Dutch population (2001) Br. J. Dermatol, 145, pp. 90-94; 
Heward J.M., Allahabadia A., Daykin J., Carr-Smith J., Daly A., Armitage M., Dodson P.M., Gough S.C.L., Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: Replication using a population case control and family-based study (1998) J. Clin. Endocrinol. Metab, 83, pp. 3394-3397; 
Chen Q.-Y., Huang W., She J.-X., Baxter F., Volpe R., Maclaren N.K., HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective (1999) J. Clin. Endocrinol. Metab, 84, pp. 3182-3186; 
Chen Q.-Y., Nadell D., Zhang X.-Y., Kukreja A., Huang Y.-J., Wise J., Svec F., Vargas A., The human leukocyte antigen HLA DRB3*0202/DQA1*0501 haplotype is associated with Graves' disease in African (2000) Americans J. Clin. Endocrinol. Metab, 85, pp. 1545-1549; 
Spencer C.A., LoPresti J.S., Patel A., Guttler R.B., Eigen A., Shen D., Gray D., Nicoloff J.T., Applications of a new chemiluminometric thyrotropin assay to subnormal measurement (1990) J. Clin. Endocrinol. Metab, 70, pp. 453-460; 
Nelson J.C., Tomei R.T., Direct determination of free thyroxin in undiluted serum by equilibrium dialysis/radioimmunoassay (1988) Clin. Chem, 34, pp. 1737-1744; 
Spencer C., Takauchi M., Kazarosyan M., Wong C., Guttler R., Singer P., Fatima S., Nicoloff J., Serum thyroglobulin autoantibodies: Prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma (1997) J. Clin. Endocrinol. Metab, 83, pp. 1121-1127; 
O'Connell J.R., Weeks D.E., PedCheck: A program for identification of genotype incompatibilities in linkage analysis (1998) Am. J. Hum. Genet, 63, pp. 259-266; 
Cottingham R.W. Jr., Idury R.M., Schäffer A.A., Faster sequential genetic linkage computations (1993) Am. J. Hum. Genet, 53, pp. 252-263; 
Kruglyak L., Daly M.J., Reeve-Daly M.P., Lander E.S., Parametric and nonparametric linkage analysis: A unified multipoint approach (1996) Am. J. Hum. Genet, 58, pp. 1347-1363; 
Sobel E., Lange K., Descent graphs in pedigree analysis: Applications to haplotyping, location scores, and marker sharing statistics (1996) Am. J. Hum. Genet, 58, pp. 1323-1337
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-18344388283&partnerID=40&md5=9db987c0effe097483f91551f9d9a519
ER  - 

TY  - JOUR
TI  - Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups
T2  - Thyroid
VL  - 20
IS  - 5
SP  - 465
EP  - 473
PY  - 2010
DO  - 10.1089/thy.2008.0281
AU  - Yu G.-P.
AU  - Li J.C.-L.
AU  - Branovan D.
AU  - McCormick S.
AU  - Schantz S.P.
N1  - 施引文献 :80
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Zheng T., Holford T.R., Chen Y., Ma J.Z., Flannery J., Liu W., Russi M., Boyle P., Time trend and age-period-cohort effect on incidence of thyroid cancer in Connecticut, 1935-1992 (1996) International Journal of Cancer, 67 (4), pp. 504-509. , DOI 10.1002/(SICI)1097-0215(19960807)67:4<504::AID-IJC7>3.0.CO;2-W; 
Pottern L.M., Stone B.J., Day N.E., Pickle L.W., Fraumeni Jr. J.F., Thyroid cancer in Connecticut, 1935-1975: An analysis by cell type (1980) Am. J. Epidemiol, 112, pp. 764-774; 
Weiss W., Changing incidence of thyroid cancer (1979) J. Natl. Cancer Inst., 62, pp. 1137-1142; 
Takahashi T., Schoemaker M.J., Trott K.R., Simon S.L., Fujimori K., Nakashima N., Fukao A., Saito H., The relationship of thyroid cancer with radiation exposure from nuclear weapon testing in the Marshall Islands (2003) J. Epidemiol Jpn. Epidemiol Assoc., 13, pp. 99-107; 
Kerber R.A., Till J.E., Simon S.L., Lyon J.L., Thomas D.C., Preston-Martin S., Rallison M.L., Stevens W., A cohort study of thyroid disease in relation to fallout from nuclear weapons testing (1993) JAMA, 270, pp. 2076-2082; 
Gilbert E.S., Tarone R., Bouville A., Ron E., Thyroid cancer rates and 131I doses from Nevada atmospheric nuclear bomb tests (1998) J. Natl. Cancer Inst., 90, pp. 1654-1660; 
Kazakov V.S., Demidchik E.P., Astakhova L.N., Thyroid cancer after Chernobyl (1992) Nature, 359, pp. 21-22; 
Catelinois O., Verger P., Colonna M., Rogel A., Hemon D., Tirmarche M., Projecting the time trend of thyroid cancers: Its impact on assessment of radiation-induced cancer risks (2004) Health Phys., 87, pp. 606-614; 
Ron E., Lubin J.H., Shore R.E., Mabuchi K., Modan B., Pottern L.M., Schneider A.B., Boice Jr. J.D., Thyroid cancer after exposure to external radiation: A pooled analysis of seven studies (1995) Radiat Res., 141, pp. 259-277; 
Prokop M., Optimizing dosage in thoracic computerized tomography (2001) Radiologe, 41, pp. 269-278; 
Golding S.J., Shrimpton P.C., Commentary. Radiation dose in CT: Are we meeting the challenge? (2002) Br. J. Radiol., 75, pp. 1-4; 
Maitino A.J., Levin D.C., Parker L., Rao V.M., Sunshine J.H., Nationwide trends in rates of utilization of noninvasive diagnostic imaging among the Medicare population between 1993 and 1999 (2003) Radiology, 227 (1), pp. 113-117. , DOI 10.1148/radiol.2272020617; 
Brenner D., Elliston C., Hall E., Berdon W., Estimated risks of radiation-induced fatal cancer from pediatric CT (2001) AJR, 176, pp. 289-296; 
Davies L., Welch H.G., Increasing incidence of thyroid cancer in the United States, 1973-2002 (2006) JAMA, 295, pp. 2164-2167; 
Kent W.D., Hall S.F., Isotalo P.A., Houlden R.L., George R.L., Groome P.A., Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease (2007) CMAJ, 177, pp. 1357-1361; 
Lloyd R., DeLellis R., Heitz P., Eng C., (2004) World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Endocrine Organs, , IARC Press International Agency for Research on Cancer, Lyon, France; 
Miller B.A., Kolonel L.N., Bernstein L., Young J.J.L., Swanson G.M., West D., Key C.R., Alexander G.A., (1996) Racial/Ethnic Patterns of Cancer in the United States, 1988-1992, , National Cancer Institute, Bethesda, MD; 
(2004) Stata Base Reference Manual, S-Z, 4, pp. 312-317. , StataCorp, Release 8. Stata Press, College Station, Texas; 
Canto M.T., Chu K.C., Annual cancer incidence rates for Hispanics in the United States: Surveillance, epidemiology, and end results, 1992-1996 (2000) Cancer, 88, pp. 2642-2652; 
Armitage P., Berry G., Matthews J.N.S., (2002) Statistical Methods in Medical Research, p. 675. , Blackwell Publishing, Oxford; 
Swan J., Breen N., Coates R.J., Rimer B.K., Lee N.C., Progress in cancer screening practices in the United States: Results from the the 2000 national health interview survey (2000) Cancer, 97, pp. 1528-1540; 
Fenton J.J., Tancredi D.J., Green P., Franks P., Baldwin L.M., Persistent racial and ethnic disparities in up-to-date colorectal cancer testing in medicare enrollees (2009) J. Am. Geriatr Soc., 57, pp. 412-418; 
Joseph D.A., Rim S.H., Seeff L.C., Use of colorectal cancer tests-United States, 2002, 2004, and 2006 (2008) MMWR Morbid Mortal Wkly Rep., 57, pp. 253-258; 
Adams E.K., Breen N., Joski P.J., Impact of the National Breast and Cervical Cancer Early Detection Program on mammography and Pap test utilization among white, Hispanic, and African American women: 1996-2000 (2007) Cancer, 109, pp. 348-358; 
Clark J.R., Eski S.J., Freeman J.L., Risk of malignancy in Filipinos with thyroid nodules-a matched pair analysis (2006) Head Neck, 28, pp. 427-431; 
Folkman J., Kalluri R., Cancer without disease (2004) Nature, 427, p. 787; 
Colonna M., Grosclaude P., Remontet L., Schvartz C., Mace-Lesech J., Velten M., Guizard A., Esteve J., Incidence of thyroid cancer in adults recorded by French cancer registries (1978-1997) (2002) Eur. J. Cancer, 38, pp. 1762-1768; 
Sali D., Cardis E., Sztanyik L., Auvinen A., Bairakova A., Dontas N., Grosche B., Valerianova Z., Cancer consequences of the chernobyl accident in Europe outside the former USSR: A review (1996) Int. J. Cancer, 67, pp. 343-352; 
(2000) Sources and Effects of Ionizing Radiation, , United Nations Scientific Committee on the Effects of Atomic Radiation, United Nations, New York; 
Brenner D.J., Hall E.J., Computed tomography-an increasing source of radiation exposure (2007) N Engl. J. Med., 357, pp. 2277-2284; 
Frumkin H., Jacobson A., Gansler T., Thun M.J., Cellular phones and risk of brain tumors (2001) CA Cancer J. Clin., 51, pp. 137-141; 
Hardell L., Carlberg M., Soderqvist F., Mild K.H., Morgan L.L., Long-term use of cellular phones and brain tumours: Increased risk associated with use for >l or =10 years (2007) Occup Environ Med., 64, pp. 626-632; 
Koyu A., Cesur G., Ozguner F., Akdogan M., Mollaoglu H., Ozen S., Effects of 900 MHz electromagnetic field on TSH and thyroid hormones in rats (2005) Toxicol Lett., 157, pp. 257-262; 
Rajkovic V., Matavulj M., Gledic D., Lazetic B., Evaluation of rat thyroid gland morphophysiological status after three months exposure to 50Hz electromagnetic field (2003) Tissue Cell., 35, pp. 223-231
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-77952358783&partnerID=40&md5=1f75c041744c0bdcb2befeca55ead4f1
ER  - 

TY  - JOUR
TI  - Discovery of common variants associated with low TSH levels and thyroid cancer risk
T2  - Nature Genetics
VL  - 44
IS  - 3
SP  - 319
EP  - 322
PY  - 2012
DO  - 10.1038/ng.1046
AU  - Gudmundsson J.
AU  - Sulem P.
AU  - Gudbjartsson D.F.
AU  - Jonasson J.G.
AU  - Masson G.
AU  - He H.
AU  - Jonasdottir A.
AU  - Sigurdsson A.
AU  - Stacey S.N.
AU  - Johannsdottir H.
AU  - Th Helgadottir H.
AU  - Li W.
AU  - Nagy R.
AU  - Ringel M.D.
AU  - Kloos R.T.
AU  - De Visser M.C.H.
AU  - Plantinga T.S.
AU  - Den Heijer M.
AU  - Aguillo E.
AU  - Panadero A.
AU  - Prats E.
AU  - Garcia-Castaao A.
AU  - De Juan A.
AU  - Rivera F.
AU  - Walters G.B.
AU  - Bjarnason H.
AU  - Tryggvadottir L.
AU  - Eyjolfsson G.I.
AU  - Bjornsdottir U.S.
AU  - Holm H.
AU  - Olafsson I.
AU  - Kristjansson K.
AU  - Kristvinsson H.
AU  - T Magnusson O.
AU  - Thorleifsson G.
AU  - Gulcher J.R.
AU  - Kong A.
AU  - Kiemeney L.A.
AU  - Jonsson T.
AU  - Hjartarson H.
AU  - Mayordomo J.I.
AU  - Netea-Maier R.T.
AU  - De La Chapelle A.
AU  - Hrafnkelsson J.
AU  - Thorsteinsdottir U.
AU  - Rafnar T.
AU  - Stefansson K.
N1  - 施引文献 :63
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Goldgar D.E., Easton D.F., Cannon-Albright L.A., Skolnick M.H., Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands (1994) Journal of the National Cancer Institute, 86 (21), pp. 1600-1608; 
Czene K., Lichtenstein P., Hemminki K., Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database (2002) International Journal of Cancer, 99 (2), pp. 260-266. , DOI 10.1002/ijc.10332; 
Amundadottir L.T., Cancer as a complex phenotype: Pattern of cancer distribution within and beyond the nuclear family (2004) PLoS Med., 1, pp. e65; 
Hrafnkelsson J., Tulinius H., Jonasson J.G., Sigvaldason H., Familial non-medullary thyroid cancer in Iceland (2001) J. Med. Genet., 38, pp. 189-191; 
Kondo T., Ezzat S., Asa S.L., Pathogenetic mechanisms in thyroid follicular-cell neoplasia (2006) Nat. Rev. Cancer, 6, pp. 292-306; 
Delellis R.A., Pathology and genetics of thyroid carcinoma (2006) J. Surg. Oncol., 94, pp. 662-669; 
Baida A., Strong association of chromosome 1p12 loci with thyroid cancer susceptibility (2008) Cancer Epidemiol. Biomarkers Prev., 17, pp. 1499-1504; 
Jazdzewski K., Murray E.L., Franssila K., Jarzab B., Schoenberg D.R., De La Chapelle A., Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma (2008) Proceedings of the National Academy of Sciences of the United States of America, 105 (20), pp. 7269-7274. , http://www.pnas.org/cgi/reprint/105/20/7269, DOI 10.1073/pnas.0802682105; 
Jazdzewski K., Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer (2009) Proc. Natl. Acad. Sci. USA, 106, pp. 1502-1505; 
He H., A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24 (2009) Cancer Res., 69, pp. 625-631; 
Gudmundsson J., Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations (2009) Nat. Genet., 41, pp. 460-464; 
Landa I., The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors (2009) PLoS Genet., 5, pp. e1000637; 
Takahashi M., The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl (2010) Hum. Mol. Genet., 19, pp. 2516-2523; 
Kong A., Detection of sharing by descent, long-range phasing and haplotype imputation (2008) Nat. Genet., 40, pp. 1068-1075; 
Kong A., Fine-scale recombination rate differences between sexes, populations and individuals (2010) Nature, 467, pp. 1099-1103; 
Panicker V., A locus on chromosome 1p36 is associated with thyrotropin and thyroid function as identified by genome-wide association study (2010) Am. J. Hum. Genet., 87, pp. 430-435; 
Arnaud-Lopez L., Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function (2008) Am. J. Hum. Genet., 82, pp. 1270-1280; 
Medici M., A large-scale association analysis of 68 thyroid hormone pathway genes with serum TSH and FT 4 levels (2011) Eur. J. Endocrinol., 164, pp. 781-788; 
Kutyavin I.V., A novel endonuclease IV post-PCR genotyping system (2006) Nucleic Acids Res., 34, pp. e128; 
Parlato R., Rosica A., Rodriguez-Mallon A., Affuso A., Postiglione M.P., Arra C., Mansouri A., De Felice M., An integrated regulatory network controlling survival and migration in thyroid organogenesis (2004) Developmental Biology, 276 (2), pp. 464-475. , DOI 10.1016/j.ydbio.2004.08.048, PII S0012160604006190; 
Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., Brynjolfsson J., Stefansson K., Neuregulin 1 and susceptibility to schizophrenia (2002) American Journal of Human Genetics, 71 (4), pp. 877-892; 
Garcia-Barcelo M.M., Genome-wide association study identifies NRG1 as a susceptibility locus for Hirschsprung's disease (2009) Proc. Natl. Acad. Sci. USA, 106, pp. 2694-2699; 
Emilsson V., Thorleifsson G., Zhang B., Leonardson A.S., Zink F., Zhu J., Carlson S., Stefansson K., Genetics of gene expression and its effect on disease (2008) Nature, 452 (7186), pp. 423-428. , DOI 10.1038/nature06758, PII NATURE06758; 
Teumer A., Genome-wide association study identifies four genetic loci associated with thyroid volume and goiter risk (2011) Am. J. Hum. Genet., 88, pp. 664-673; 
Gulcher J.R., Kristjansson K., Gudbjartsson H., Stefansson K., Protection of privacy by third-party encryption in genetic research in Iceland (2000) Eur. J. Hum. Genet., 8, pp. 739-742; 
Wetzels J.F.M., Kiemeney L.A.L.M., Swinkels D.W., Willems H.L., Heijer M.D., Age- and gender-specific reference values of estimated GFR in Caucasians: The Nijmegen Biomedical Study (2007) Kidney International, 72 (5), pp. 632-637. , DOI 10.1038/sj.ki.5002374, PII 5002374; 
Kutyavin I.V., A novel endonuclease IV post-PCR genotyping system (2006) Nucleic Acids Res., 34, pp. e128; 
He H., Olesnanik K., Nagy R., Liyanarachchi S., Prasad M.L., Stratakis C.A., Kloos R.T., De La Chapelle A., Allelic variation in gene expression in thyroid tissue (2005) Thyroid, 15 (7), pp. 660-667. , DOI 10.1089/thy.2005.15.660; 
Sulem P., Identification of low-frequency variants associated with gout and serum uric acid levels (2011) Nat. Genet., 43, pp. 1127-1130; 
Rafnar T., Mutations in BRIP1 confer high risk of ovarian cancer (2011) Nat. Genet., 43, pp. 1104-1107; 
Stacey S.N., A germline variant in the TP53 polyadenylation signal confers cancer susceptibility (2011) Nat. Genet., 43, pp. 1098-1103
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-84862777075&partnerID=40&md5=7e86488df57a1beb0e70d3000280aeb3
ER  - 

TY  - JOUR
TI  - CCAAT/enhancer-binding protein β: Its role in breast cancer and associations with receptor tyrosine kinases
T2  - Expert Reviews in Molecular Medicine
VL  - 11
PY  - 2009
DO  - 10.1017/S1462399409001033
AU  - Zahnow C.A.
N1  - 施引文献 :62
N1  - Export Date: 2 January 2016
TY  - Review
DB  - Scopus
C7  - e12
N1  - 参考文献: Cao Z., Umek R.M., McKnight S.L., Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells (1991) Genes and Development, 5 (9), pp. 1538-1552; 
Diehl A.M., Roles of CCAAT/enhancer-binding proteins in regulation of liver regenerative growth (1998) Journal of Biological Chemistry, 273, pp. 30843-30846; 
Poli V., The role of C/EBP isoforms in the control of inflammatory and native immunity functions (1998) Journal of Biological Chemistry, 273, pp. 29279-29282; 
Zahnow C.A., CCAAT/enhancer binding proteins in normal mammary development and breast cancer (2002) Breast Cancer Research, 4, pp. 113-121; 
Ramji D.P., Foka P., CCAAT/enhancer-binding proteins: Structure, function and regulation (2002) Biochemical Journal, 365 (3), pp. 561-575. , DOI 10.1042/BJ20020508; 
Sebastian T., Johnson P.F., Stop and go: Anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta (2006) Cell Cycle, 5, pp. 953-957; 
Kowenz-Leutz E., Twamley G., Ansieau S., Leutz A., Novel mechanism of C/EBPbeta (NF-M) transcriptional control: Activation through derepression (1994) Genes and Development, 8 (22), pp. 2781-2791; 
Williams S.C., CRP2 (C/EBP beta) contains a bipartite regulatory domain that controls transcriptional activation, DNA binding and cell specificity (1995) EMBO Journal, 14, pp. 3170-3183; 
Angerer N.D., A short conserved motif is required for repressor domain function in the myeloid-specific transcription factor CCAAT/ enhancer-binding protein epsilon (1999) Journal of Biological Chemistry, 274, pp. 4147-4154; 
Williamson E.A., Xu H.N., Gombart A.F., Verbeek W., Chumakov A.M., Friedman A.D., Koeffler H.P., Identification of transcriptional activation and repression domains in human CCAAT/enhancer-binding protein epsilon (1998) Journal of Biological Chemistry, 273 (24), pp. 14796-14804. , DOI 10.1074/jbc.273.24.14796; 
Mink S., Haenig B., Klempnauer K.-H., Interaction and functional collaboration of p300 and C/EBPbeta (1997) Molecular and Cellular Biology, 17 (11), pp. 6609-6617; 
Nerlov C., Ziff E.B., CCAAT/ enhancer binding protein-alpha amino acid motifs with dual TBP and TFIIB binding ability co-operate to activate transcription in both yeast and mammalian cells (1995) EMBO Journal, 14, pp. 4318-4328; 
Graves B.J., Johnson P.F., McKnight S.L., Homologous recognition of a promoter domain common to the MSV LTR and the HSV tk gene (1986) Cell, 44 (4), pp. 565-576; 
Johnson P.F., Identification of a rat liver nuclear protein that binds to the enhancer core element of three animal viruses (1987) Genes and Development, 1, pp. 133-146; 
Landschulz W.H., Isolation of a recombinant copy of the gene encoding C/EBP (1988) Genes and Development, 2, pp. 786-800; 
Descombes P., LAP, a novel member of the C/EBP gene family, encodes a liver-enriched transcriptional activator protein (1990) Genes and Development, 4, pp. 1541-1551; 
Chang C.J., Molecular cloning of a transcription factor, AGP/EBP, that belongs to members of the C/EBP family (1990) Molecular and Cellular Biology, 10, pp. 6642-6653; 
Akira S., A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family (1990) EMBO Journal, 9, pp. 1897-1906; 
Poli V., Mancini F.P., Cortese R., IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP (1990) Cell, 63, pp. 643-653; 
Descombes P., Schibler U., A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA (1991) Cell, 67 (3), pp. 569-579; 
Ossipow V., Descombes P., Schibler U., CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials (1993) Proceedings of the National Academy of Sciences of the United States of America, 90 (17), pp. 8219-8223; 
Calkhoven C.F., Muller C., Leutz A., Translational control of C/EBPalpha and C/EBPbeta isoform expression (2000) Genes and Development, 14 (15), pp. 1920-1932; 
Xiong W., Hsieh C.-C., Kurtz A.J., Rabek J.P., Papaconstantinou J., Regulation of CCAAT/enhancer-binding protein-beta isoform synthesis by alternative translational initiation at multiple AUG start sites (2001) Nucleic Acids Research, 29 (14), pp. 3087-3098; 
Lin F.T., A 30-kDa alternative translation product of the CCAAT/enhancer binding protein alpha message: Transcriptional activator lacking antimitotic activity (1993) Proceedings of the National Academy of Sciences of the United States of America, 90, pp. 9606-9610; 
Welm A.L., Timchenko N.A., Darlington G.J., C/EBPalpha regulates generation of C/EBPbeta isoforms through activation of specific proteolytic cleavage (1999) Molecular and Cellular Biology, 19 (3), pp. 1695-1704; 
Yamanaka R., CCAAT/enhancer binding protein epsilon is preferentially upregulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing (1997) Proceedings of the National Academy of Sciences of the United States of America, 94, pp. 6462-6467; 
Vinson C.R., Sigler P.B., McKnight S.L., Scissors-grip model for DNA recognition by a family of leucine zipper proteins (1989) Science, 246 (4932), pp. 911-916; 
Agre P., Johnson P.F., McKnight S.L., Cognate DNA binding specificity retained after leucine zipper exchange between GCN4 and C/EBP (1989) Science, 246 (4932), pp. 922-926; 
Moll J.R., Acharya A., Gal J., Mir A.A., Vinson C., Magnesium is required for specific DNA binding of the CREB B-ZIP domain (2002) Nucleic Acids Research, 30 (5), pp. 1240-1246; 
Osada S., Yamamoto H., Nishihara T., Imagawa M., DNA binding specificity of the CCAAT/enhancer-binding protein transcription factor family (1996) Journal of Biological Chemistry, 271 (7), pp. 3891-3896. , DOI 10.1074/jbc.271.7.3891; 
Ron D., Habener J.F., CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription (1992) Genes and Development, 6, pp. 439-453; 
Ubeda M., Wang X.-Z., Zinszner H., Wu I., Habener J.F., Ron D., Stress-induced binding of the transcription factor CHOP to a novel DNA control element (1996) Molecular and Cellular Biology, 16 (4), pp. 1479-1489; 
Cooper C., Ig/EBP (C/EBP gamma) is a transdominant negative inhibitor of C/EBP family transcriptional activators (1995) Nucleic Acids Research, 23, pp. 4371-4377; 
Lekstrom-Himes J.A., The role of C/ EBP(epsilon) in the terminal stages of granulocyte differentiation (2001) Stem Cells, 19, pp. 125-133; 
Grimm S.L., Rosen J.M., The Role of C/EBPbeta in Mammary Gland Development and Breast Cancer (2003) Journal of Mammary Gland Biology and Neoplasia, 8 (2), pp. 191-204. , DOI 10.1023/A:1025900908026, Transcription Factors in Mammary Gland Biology and Neoplasia; 
Vinson C., Classification of human BZIP proteins based on dimerization properties (2002) Molecular and Cellular Biology, 22, pp. 6321-6335; 
Takiguchi M., The C/EBP family of transcription factors in the liver and other organs (1998) International Journal of Experimental Pathology, 79, pp. 369-391; 
Nakajima T., Kinoshita S., Sasagawa T., Sasaki K., Naruto M., Kishimoto T., Akira S., Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6 (1993) Proceedings of the National Academy of Sciences of the United States of America, 90 (6), pp. 2207-2211; 
Zhu S., Yoon K., Sterneck E., Johnson P.F., Smart R.C., CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling (2002) Proceedings of the National Academy of Sciences of the United States of America, 99 (1), pp. 207-212. , DOI 10.1073/pnas.012437299; 
Mo X., Kowenz-Leutz E., Xu H., Leutz A., Ras Induces Mediator Complex Exchange on C/EBPbeta (2004) Molecular Cell, 13 (2), pp. 241-250. , DOI 10.1016/S1097-2765(03)00521-5; 
Liao J., CCAAT/enhancer-binding protein beta (C/EBPbeta) and C/EBPdelta contribute to growth hormone-regulated transcription of c-fos (1999) Journal of Biological Chemistry, 274, pp. 31597-31604; 
Piwien-Pilipuk G., Growth hormone regulates phosphorylation and function of CCAAT/enhancer-binding protein beta by modulating Akt and glycogen synthase kinase-3 (2001) Journal of Biological Chemistry, 276, pp. 19664-19671; 
Tang Q.Q., Sequential phosphorylation of CCAAT enhancer-binding protein beta by MAPK and glycogen synthase kinase 3beta is required for adipogenesis (2005) Proceedings of the National Academy of Sciences of the United States of America, 102, pp. 9766-9771; 
Wegner M., Cao Z., Rosenfeld M.G., Calcium-regulated phosphorylation within the leucine zipper of C/EBP beta (1992) Science, 256, pp. 370-373; 
Buck M., Phosphorylation of rat serine 105 or mouse threonine 217 in C/EBP beta is required for hepatocyte proliferation induced by TGF alpha (1999) Molecular Cell, 4, pp. 1087-1092; 
Buck M., Poli V., Hunter T., Chojkier M., C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival (2001) Molecular Cell, 8 (4), pp. 807-816. , DOI 10.1016/S1097-2765(01)00374-4; 
Metz R., Ziff E., cAMP stimulates the C/EBP-related transcription factor rNFIL-6 to trans-locate to the nucleus and induce c-fos transcription (1991) Genes and Development, 5 (10), pp. 1754-1766; 
Trautwein C., Caelles C., Van Der G.P., Hunter T., Karin M., Chojkier M., Transactivation by NF-IL6/LAP is enhanced by phosphorylation of its activation domain (1993) Nature, 364 (6437), pp. 544-547. , DOI 10.1038/364544a0; 
Trautwein C., Van Der G.P., Karin M., Hunter T., Chojkier M., Protein kinase A and C site-specific phosphorylations of LAP (NF-IL6) modulate its binding affinity to DNA recognition elements (1994) Journal of Clinical Investigation, 93 (6), pp. 2554-2561; 
Mahoney C.W., Phosphorylation of CCAAT-enhancer binding protein by protein kinase C attenuates site-selective DNA binding (1992) Journal of Biological Chemistry, 267, pp. 19396-19403; 
Chinery R., Brockman J.A., Dransfield D.T., Coffey R.J., Antioxidant-induced nuclear translocation of CCAAT/enhancer-binding protein beta. A critical role for protein kinase A-mediated phosphorylation of Ser 299 (1997) Journal of Biological Chemistry, 272 (48), pp. 30356-30361. , DOI 10.1074/jbc.272.48.30356; 
Shuman J.D., Sebastian T., Kaldis P., Copeland T.D., Zhu S., Smart R.C., Johnson P.F., Cell cycle-dependent phosphorylation of C/EBPbeta mediates oncogenic cooperativity between C/EBPbeta and H-Ras V12 (2004) Molecular and Cellular Biology, 24 (17), pp. 7380-7391. , DOI 10.1128/MCB.24.17.7380-7391.2004; 
Cesena T.I., Cardinaux J.-R., Kwok R., Schwartz J., CCAAT/enhancer-binding protein (C/EBP) beta is acetylated at multiple lysines: Acetylation of C/EBPbeta at lysine 39 modulates its ability to activate transcription (2007) Journal of Biological Chemistry, 282 (2), pp. 956-967. , http://www.jbc.org/cgi/reprint/282/2/956, DOI 10.1074/jbc.M511451200; 
Cesena T.I., Acetylation and deacetylation regulate CCAAT/enhancer binding protein beta at K39 in mediating gene transcription (2008) Molecular and Cellular Endocrinology, 289, pp. 94-101; 
Wiper-Bergeron N., Salem H.A., Tomlinson J.J., Wu D., Hache R.J.G., Glucocorticoid-stimulated preadipocytes differentiation is mediated through acetylation of C/EBPbeta by GCN5 (2007) Proceedings of the National Academy of Sciences of the United States of America, 104 (8), pp. 2703-2708. , DOI 10.1073/pnas.0607378104; 
Xu M., Nie L., Kim S.-H., Sun X.-H., STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta (2003) EMBO Journal, 22 (4), pp. 893-904. , DOI 10.1093/emboj/cdg094; 
Pless O., G9a-mediated lysine methylation alters the function of CCAAT/ enhancer-binding protein-beta (2008) Journal of Biological Chemistry, 283, pp. 26357-26363; 
Melchior F., SUMO-nonclassical ubiquitin (2000) Annual Review of Cell and Developmental Biology, 16, pp. 591-626; 
Eaton E.M., Sealy L., Modification of CCAAT/enhancer-binding protein-beta by the small ubiquitin-like modifier (SUMO) family members, SUMO-2 and SUMO-3 (2003) Journal of Biological Chemistry, 278 (35), pp. 33416-33421. , DOI 10.1074/jbc.M305680200; 
Berberich-Siebelt F., SUMOylation interferes with CCAAT/enhancer-binding protein beta-mediated c-myc repression, but not IL-4 activation in T cells (2006) Journal of Immunology, 176, pp. 4843-4851; 
Kowenz-Leutz E., Leutz A., A C/ EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes (1999) Molecular Cell, 4, pp. 735-743; 
Ness S.A., Kowenz-Leutz E., Casini T., Graf T., Leutz A., Myb and NF-M: Combinatorial activators of myeloid genes in heterologous cell types (1993) Genes and Development, 7 (5), pp. 749-759; 
Burk O., Mink S., Ringwald M., Klempnauer K.-H., Synergistic activation of the chicken mim-1 gene by v-myb and C/EBP transcription factors (1993) EMBO Journal, 12 (5), pp. 2027-2038; 
Su W.C., Differential activation of a C/ EBP beta isoform by a novel redox switch may confer the lipopolysaccharide-inducible expression of interleukin-6 gene (2003) Journal of Biological Chemistry, 278, pp. 51150-51158; 
Qiu X., Distinct functions of CCAAT enhancer-binding protein isoforms in the regulation of manganese superoxide dismutase during interleukin-1beta stimulation (2008) Journal of Biological Chemistry, 283, pp. 25774-25785; 
Eaton E.M., Characterization of C/ EBPbeta isoforms in normal versus neoplastic mammary epithelial cells (2001) Journal of Cellular Physiology, 189, pp. 91-105; 
Ishiguro K., Xavier R., Homer-3 regulates activation of serum response element in T cells via its EVH1 domain (2004) Blood, 103 (6), pp. 2248-2256. , DOI 10.1182/blood-2003-08-2671; 
Lee Y.M., Transcriptional induction of the alpha-1 acid glycoprotein (AGP) gene by synergistic interaction of two alternative activator forms of AGP/enhancer-binding protein (C/EBPbeta) and NF-kappaB or Nopp140 (1996) Molecular and Cellular Biology, 16, pp. 4257-4263; 
Zahnow C.A., Cardiff R.D., Laucirica R., Medina D., Rosen J.M., A role for CCAAT/enhancer binding protein beta-liver-enriched inhibitory protein in mammary epithelial cell proliferation (2001) Cancer Research, 61 (1), pp. 261-269; 
Harrison J.R., Huang Y.-F., Wilson K.A., Kelly P.L., Adams D.J., Gronowicz G.A., Clark S.H., Col1a1 promoter-targeted expression of p20 CCAAT enhancer-binding protein beta (C/EBPbeta), a truncated C/EBPbeta isoform, causes osteopenia in transgenic mice (2005) Journal of Biological Chemistry, 280 (9), pp. 8117-8124. , DOI 10.1074/jbc.M410076200; 
Savage T., Bennett T., Huang Y.-F., Kelly P.L., Durant N.E., Adams D.J., Mina M., Harrison J.R., Mandibular phenotype of p20C/EBPbeta transgenic mice: Reduced alveolar bone mass and site-specific dentin dysplasia (2006) Bone, 39 (3), pp. 552-564. , DOI 10.1016/j.bone.2006.01.164, PII S8756328206003620; 
An M.R., Hsieh C.-C., Reisner P.D., Rabek J.P., Scott S.G., Kuninger D.T., Papaconstantinou J., Evidence for posttranscriptional regulation of C/EBPalpha and C/EBPbeta isoform expression during the lipopolysaccharide-mediated acute-phase response (1996) Molecular and Cellular Biology, 16 (5), pp. 2295-2306; 
Williams P., Ratajczak T., Lee S.C., Ringold G.M., AGP/EBP(LAP) expressed in rat hepatoma cells interacts with multiple promoter sites and is necessary for maximal glucocorticoid induction of the rat alpha-1 acid glycoprotein gene (1991) Molecular and Cellular Biology, 11 (10), pp. 4959-4965; 
Ratajczak T., Multiple elements within the glucocorticoid regulatory unit of the rat alpha 1-acid glycoprotein gene are recognition sites for C/EBP (1992) Journal of Biological Chemistry, 267, pp. 11111-11119; 
Nishio Y., A nuclear factor for interleukin-6 expression (NF-IL6) and the glucocorticoid receptor synergistically activate transcription of the rat alpha 1-acid glycoprotein gene via direct protein-protein interaction (1993) Molecular and Cellular Biology, 13, pp. 1854-1862; 
Isshiki H., Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene (1990) Molecular and Cellular Biology, 10, pp. 2757-2764; 
Hu H.M., The C/EBP bZIP domain can mediate lipopolysaccharide induction of the proinflammatory cytokines interleukin-6 and monocyte chemoattractant protein-1 (2000) Journal of Biological Chemistry, 275, pp. 16373-16381; 
Matsusaka T., Fujikawa K., Nishio Y., Mukaida N., Matsushima K., Kishimoto T., Akira S., Transcription factors NF-IL6 and NF-kappaB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8 (1993) Proceedings of the National Academy of Sciences of the United States of America, 90 (21), pp. 10193-10197. , DOI 10.1073/pnas.90.21.10193; 
Stein B., Cogswell P.C., Baldwin Jr. A.S., Functional and physical associations between NF-kappaB and C/EBP family members: A rel domain-bZIP interaction (1993) Molecular and Cellular Biology, 13 (7), pp. 3964-3974; 
Christian M., Pohnke Y., Kempf R., Gellersen B., Brosens J.J., Functional association of PR and CCAAT/enhancer-binding protein beta isoforms: Promoter-dependent cooperation between PR-B and liver-enriched inhibitory protein, or liver-enriched activatory protein and PR-A in human endometrial stromal cells (2002) Molecular Endocrinology, 16 (1), pp. 141-154. , DOI 10.1210/me.16.1.141; 
Kalkhoven E., Wissink S., Van Der S.P.T., Van Der B.B., Negative interaction between the RelA(p65) subunit of NF-kappaB and the progesterone receptor (1996) Journal of Biological Chemistry, 271 (11), pp. 6217-6224. , DOI 10.1074/jbc.271.11.6217; 
Hata K., Nishimura R., Ueda M., Ikeda F., Matsubara T., Ichida F., Hisada K., Yoneda T., A CCAAT/enhancer binding protein beta isoform, liver-enriched inhibitory protein, regulates commitment of osteoblasts and adipocytes (2005) Molecular and Cellular Biology, 25 (5), pp. 1971-1979. , DOI 10.1128/MCB.25.5.1971-1979.2005; 
Tang Q.-Q., Otto T.C., Lane M.D., CCAAT/enhancer-binding protein beta is required for mitotic clonal expansion during adipogenesis (2003) Proceedings of the National Academy of Sciences of the United States of America, 100 (3), pp. 850-855. , DOI 10.1073/pnas.0337434100; 
Vegesna V., Takeuchi S., Hofmann W.-K., Ikezoe T., Tavor S., Krug U., Fermin A.C., Koeffler H.P., C/EBP-beta, C/EBP-delta PU.1, AML1 genes: Mutational analysis in 381 samples of hematopoietic and solid malignancies (2002) Leukemia Research, 26 (5), pp. 451-457. , DOI 10.1016/S0145-2126(01)00150-3, PII S0145212601001503; 
Mastracci T.L., Shadeo A., Colby S.M., Tuck A.B., O'Malley F.P., Bull S.B., Lam W.L., Andrulis I.L., Genomic alterations in lobular neoplasia: A microarray comparative genomic hybridization signature for early neoplastic proliferation in the breast (2006) Genes Chromosomes and Cancer, 45 (11), pp. 1007-1017. , DOI 10.1002/gcc.20368; 
Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Chinnaiyan A.M., ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform (2004) Neoplasia, 6 (1), pp. 1-6; 
Alaoui-Jamali M.A., Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors (2003) Cancer Research, 63, pp. 3764-3774; 
Van't Veer L.J., Gene expression profiling predicts clinical outcome of breast cancer (2002) Nature, 415, pp. 530-536; 
Gruvberger S., Ringner M., Chen Y., Panavally S., Saal L.H., Borg A., Ferno M., Meltzer P.S., Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns (2001) Cancer Research, 61 (16), pp. 5979-5984; 
Van De Vijver M.J., A gene-expression signature as a predictor of survival in breast cancer (2002) New England Journal of Medicine, 347, pp. 1999-2009; 
Yang F., Foekens J.A., Yu J., Sieuwerts A.M., Timmermans M., Klijn J.G.M., Atkins D., Jiang Y., Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways (2006) Oncogene, 25 (9), pp. 1413-1419. , DOI 10.1038/sj.onc.1209165, PII 1209165; 
Saal L.H., Johansson P., Holm K., Gruvberger-Saal S.K., She Q.-B., Maurer M., Koujak S., Parsons R., Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity (2007) Proceedings of the National Academy of Sciences of the United States of America, 104 (18), pp. 7564-7569. , DOI 10.1073/pnas.0702507104; 
Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., Chen H., Park M., Stromal gene expression predicts clinical outcome in breast cancer (2008) Nature Medicine, 14 (5), pp. 518-527. , DOI 10.1038/nm1764, PII NM1764; 
Ma X.J., A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen (2004) Cancer Cell, 5, pp. 607-616; 
Zahnow C.A., Younes P., Laucirica R., Rosen J.M., Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant- negative transcription factor, in human breast cancer (1997) Journal of the National Cancer Institute, 89 (24), pp. 1887-1891; 
Milde-Langosch K., Loning T., Bamberger A.-M., Expression of the CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBPdeltain breast cancer: Correlations with clinicopathologic parameters and cell-cycle regulatory proteins (2003) Breast Cancer Research and Treatment, 79 (2), pp. 175-185. , DOI 10.1023/A:1023929504884; 
Gomis R.R., Alarcon C., Nadal C., Van Poznak C., Massague J., C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells (2006) Cancer Cell, 10 (3), pp. 203-214. , DOI 10.1016/j.ccr.2006.07.019, PII S1535610806002479; 
Seagroves T.N., Krnacik S., Raught B., Gay J., Burgess-Beusse B., Darlington G.J., Rosen J.M., C/EBPbeta, but not C/EBPalpha, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland (1998) Genes and Development, 12 (12), pp. 1917-1928; 
Robinson G.W., Johnson P.F., Hennighausen L., Sterneck E., The C/EBPbeta transcription factor regulates epithelial cell proliferation and differentiation in the mammary gland (1998) Genes and Development, 12 (12), pp. 1907-1916; 
Seagroves T.N., Lydon J.P., Hovey R.C., Vonderhaar B.K., Rosen J.M., C/EBPbeta (CCAAT/enhancer binding protein) controls cell fate determination during mammary gland development (2000) Molecular Endocrinology, 14 (3), pp. 359-368. , DOI 10.1210/me.14.3.359; 
Uematsu S., The C/EBP beta isoform 34-kDa LAP is responsible for NF-IL-6-mediated gene induction in activated macrophages, but is not essential for intracellular bacteria killing (2007) Journal of Immunology, 179, pp. 5378-5386; 
Baldwin B.R., Timchenko N.A., Zahnow C.A., Epidermal Growth Factor Receptor Stimulation Activates the RNA Binding Protein CUG-BP1 and Increases Expression of C/EBPbeta-LIP in Mammary Epithelial Cells (2004) Molecular and Cellular Biology, 24 (9), pp. 3682-3691. , DOI 10.1128/MCB.24.9.3682-3691.2004; 
Bundy L.M., Sealy L., CCAAT/enhancer binding protein beta (C/EBPbeta)-2 transforms normal mammary epithelial cells and induces epithelial to mesenchymal transition in culture (2003) Oncogene, 22 (6), pp. 869-883. , DOI 10.1038/sj.onc.1206216; 
Zhou J., Gurates B., Yang S., Sebastian S., Bulun S.E., Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: An epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta 1 (2001) Cancer Research, 61 (5), pp. 2328-2334; 
Combates N.J., Rzepka R.W., Chen Y.-N.P., Cohen D., NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter (1994) Journal of Biological Chemistry, 269 (47), pp. 29715-29719; 
Conze D., Weiss L., Regen P.S., Bhushan A., Weaver D., Johnson P., Rincon M., Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells (2001) Cancer Research, 61 (24), pp. 8851-8858; 
Chen G.K., Sale S., Tan T., Ermoian R.P., Sikic B.I., CCAAT/Enhancer-Binding Protein beta (Nuclear Factor for Interleukin 6) Transactivates the Human MDR1 Gene by Interaction with an Inverted CCAAT Box in Human Cancer Cells (2004) Molecular Pharmacology, 65 (4), pp. 906-916. , DOI 10.1124/mol.65.4.906; 
Leonessa F., Clarke R., ATP binding cassette transporters and drug resistance in breast cancer (2003) Endocrine-Related Cancer, 10 (1), pp. 43-73. , DOI 10.1677/erc.0.0100043; 
Wessells J., Yakar S., Johnson P.F., Critical Prosurvival Roles for C/EBPbeta and Insulin-Like Growth Factor I in Macrophage Tumor Cells (2004) Molecular and Cellular Biology, 24 (8), pp. 3238-3250. , DOI 10.1128/MCB.24.8.3238-3250.2004; 
Yoon K., Zhu S., Ewing S.J., Smart R.C., Decreased survival of C/EBPbeta-deficient keratinocytes is due to aberrant regulation of p53 levels and function (2007) Oncogene, 26 (3), pp. 360-367. , DOI 10.1038/sj.onc.1209797, PII 1209797; 
Ewing S.J., C/EBPbeta represses p53 to promote cell survival downstream of DNA damage independent of oncogenic Ras and p19(Arf) (2008) Cell Death and Differentiation, 15, pp. 1734-1744; 
Buck M., Turler H., Chojkier M., LAP (NF-IL-6), a tissue-specific transcriptional activator, is an inhibitor of hepatoma cell proliferation (1994) EMBO Journal, 13 (4), pp. 851-860; 
Zhu S., Oh H.-S., Shim M., Sterneck E., Johnson P.F., Smart R.C., C/EBPbeta modulates the early events of keratinocyte differentiation involving growth arrest and keratin 1 and keratin 10 expression (1999) Molecular and Cellular Biology, 19 (10), pp. 7181-7190; 
Johnson P.F., Molecular stop signs: Regulation of cell-cycle arrest by C/EBP transcription factors (2005) Journal of Cell Science, 118, pp. 2545-2555; 
Sebastian T., Malik R., Thomas S., Sage J., Johnson P.F., C/EBPbeta cooperates with RB:E2F to implement Ras V12-induced cellular senescence (2005) EMBO Journal, 24 (18), pp. 3301-3312. , DOI 10.1038/sj.emboj.7600789, PII 7600789; 
Acosta J.C., Chemokine signaling via the CXCR2 receptor reinforces senescence (2008) Cell, 133, pp. 1006-1018; 
Kuilman T., Michaloglou C., Vredeveld L.C.W., Douma S., Van Doorn R., Desmet C.J., Aarden L.A., Peeper D.S., Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network (2008) Cell, 133 (6), pp. 1019-1031. , DOI 10.1016/j.cell.2008.03.039, PII S009286740800620X; 
Schlessinger J., Ligand-induced, receptormediated dimerization and activation of EGF receptor (2002) Cell, 110, pp. 669-672; 
Hynes N.E., Lane H.A., ERBB receptors and cancer: The complexity of targeted inhibitors (2005) Nature Reviews Cancer, 5 (5), pp. 341-354. , DOI 10.1038/nrc1609; 
Zahnow C.A., ErbB receptors and their ligands in the breast (2006) Expert Rev Molecular Medicine, 8, pp. 1-21; 
Walker R.A., Dearing S.J., Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas (1999) Breast Cancer Research and Treatment, 53 (2), pp. 167-176. , DOI 10.1023/A:1006194700667; 
Di F.P.P., Pierce J.H., Kraus M.H., erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells (1987) Science, 237 (4811), pp. 178-182; 
Allred D.C., Overexpression of HER-2/ neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer (1992) Human Pathology, 23, pp. 974-979; 
Arcidiacono M.V., Sato T., Alvarez-Hernandez D., Yang J., Tokumoto M., Gonzalez-Suarez I., Lu Y., Dusso A.S., EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease (2008) Journal of the American Society of Nephrology, 19 (2), pp. 310-320. , DOI 10.1681/ASN.2007040406; 
He D., Natarajan V., Stern R., Gorshkova I.A., Solway J., Spannhake E.Wm., Zhao Y., Lysophosphatidic acid-induced transactivation of epidermal growth factor receptor regulates cyclo-oxygenase-2 expression and prostaglandin E 2 release via C/EBPbeta in human bronchial epithelial cells (2008) Biochemical Journal, 412 (1), pp. 153-162. , DOI 10.1042/BJ20071649; 
Dickson C., Spencer-Dene B., Dillon C., Fantl V., Tyrosine kinase signalling in breast cancer fibroblast growth factors and their receptors (2000) Breast Cancer Research, 2 (3), pp. 191-196. , DOI 10.1186/bcr53; 
Eswarakumar V.P., Lax I., Schlessinger J., Cellular signaling by fibroblast growth factor receptors (2005) Cytokine and Growth Factor Reviews, 16 (2 SPEC. ISS.), pp. 139-149. , DOI 10.1016/j.cytogfr.2005.01.001; 
Klagsbrun M., Baird A., A dual receptor system is required for basic fibroblast growth factor activity (1991) Cell, 67 (2), pp. 229-231; 
Tsukamoto A.S., Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice (1988) Cell, 55, pp. 619-625; 
Welm B.E., Freeman K.W., Chen M., Contreras A., Spencer D.M., Rosen J.M., Inducible dimerization of FGFR1: Development of a mouse model to analyze progressive transformation of the mammary gland (2002) Journal of Cell Biology, 157 (4), pp. 703-714. , DOI 10.1083/jcb.200107119; 
Penault-Llorca F., Expression of FGF and FGF receptor genes in human breast cancer (1995) International Journal of Cancer, 61, pp. 170-176; 
Zammit C., Coope R., Gomm J.J., Shousha S., Johnston C.L., Coombes R.C., Fibroblast growth factor 8 is expressed at higher levels in lactating human breast and in breast cancer (2002) British Journal of Cancer, 86 (7), pp. 1097-1103; 
Tamaru N., Hishikawa Y., Ejima K., Nagasue N., Inoue S., Muramatsu M., Hayashi T., Koji T., Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer (2004) Laboratory Investigation, 84 (11), pp. 1460-1471. , DOI 10.1038/labinvest.3700166; 
Theodorou V., Boer M., Weigelt B., Jonkers J., Van Der V.M., Hilkens J., Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas (2004) Oncogene, 23 (36), pp. 6047-6055. , DOI 10.1038/sj.onc.1207816; 
Reis-Filho J.S., Simpson P.T., Turner N.C., Lambros M.B., Jones C., Mackay A., Grigoriadis A., Ashworth A., FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas (2006) Clinical Cancer Research, 12 (22), pp. 6652-6662. , DOI 10.1158/1078-0432.CCR-06-1164; 
Meijer D., Sieuwerts A.M., Look M.P., Van Agthoven T., Foekens J.A., Dorssers L.C.J., Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer (2008) Endocrine-Related Cancer, 15 (1), pp. 101-111. , DOI 10.1677/ERC-07-0080; 
Luqmani Y.A., Graham M., Coombes R.C., Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues (1992) British Journal of Cancer, 66, pp. 273-280; 
Hunter D.J., Kraft P., Jacobs K.B., Cox D.G., Yeager M., Hankinson S.E., Wacholder S., Chanock S.J., A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer (2007) Nature Genetics, 39 (7), pp. 870-874. , DOI 10.1038/ng2075, PII NG2075; 
Easton D.F., Genome-wide association study identifies novel breast cancer susceptibility loci (2007) Nature, 447, pp. 1087-1093; 
Meyer K.B., Allele-specific upregulation of FGFR2 increases susceptibility to breast cancer (2008) PLoS Biology, 6, pp. e108; 
Kagan B.L., Henke R.T., Cabal-Manzano R., Stoica G.E., Nguyen Q., Wellstein A., Riegel A.T., Complex regulation of the fibroblast growth factor-binding protein in MDA-MB-468 breast cancer cells by CCAAT/enhancer-binding protein beta (2003) Cancer Research, 63 (7), pp. 1696-1705; 
Czubayko F., Smith R.V., Chung H.C., Wellstein A., Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors (1994) Journal of Biological Chemistry, 269 (45), pp. 28243-28248; 
Papa V., Pezzino V., Costantino A., Belfiore A., Giuffrida D., Frittitta L., Vannelli G.B., Vigneri R., Elevated insulin receptor content in human breast cancer (1990) Journal of Clinical Investigation, 86 (5), pp. 1503-1510; 
Holdaway I.M., Friesen H.G., Hormone binding by human mammary carcinoma (1977) Cancer Research, 37, pp. 1946-1952; 
Milazzo G., Insulin receptor expression and function in human breast cancer cell lines (1992) Cancer Research, 52, pp. 3924-3930; 
Finlayson C.A., Chappell J., Leitner J.W., Goalstone M.L., Garrity M., Nawaz S., Ciaraldi T.P., Draznin B., Enhanced insulin signaling via Shc in human breast cancer (2003) Metabolism: Clinical and Experimental, 52 (12), pp. 1606-1611. , DOI 10.1016/S0026-0495(03)00311-1; 
Pekonen F., Partanen S., Makinen T., Rutanen E.-M., Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer (1988) Cancer Research, 48 (5), pp. 1343-1347; 
Foekens J.A., Portengen H., Van Putten W.L.J., Trapman A.M.A.C., Reubi J.-C., Alexieva-Figusch J., Klijn J.G.M., Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer (1989) Cancer Research, 49 (24 I), pp. 7002-7009; 
Bonneterre J., Peyrat J.P., Beuscart R., Demaille A., Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer (1990) Cancer Research, 50 (21), pp. 6931-6935; 
Surmacz E., Function of the IGF-I receptor in breast cancer (2000) Journal of Mammary Gland Biology and Neoplasia, 5, pp. 95-105; 
Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M.E., Koo J., Madarnas Y., Hartwick W., Hood N., Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study (2002) Journal of Clinical Oncology, 20 (1), pp. 42-51. , DOI 10.1200/JCO.20.1.42; 
Pasanisi P., Metabolic syndrome as a prognostic factor for breast cancer recurrences (2006) International Journal of Cancer, 119, pp. 236-238; 
Pasanisi P., Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis (2008) Cancer Epidemiology Biomarkers & Prevention, 17, pp. 1719-1722; 
Papa V., Costantino A., Belfiore A., Insulin receptor: What role in breast cancer? (1997) Trends in Endocrinology and Metabolism, 8 (8), pp. 306-312. , DOI 10.1016/S1043-2760(97)00114-8, PII S1043276097001148; 
Lut M., Seufert J., Habener J.F., Pancreatic beta-cell-specific repression of insulin gene transcription by (1997) Journal of Biological Chemistry, 272 (45), pp. 28349-28359. , DOI 10.1074/jbc.272.45.28349; 
Seufert J., Weir G.C., Habener J.F., Differential expression of the insulin gene transcriptional repressor CCAAT/enhancer-binding protein beta and transactivator islet duodenum homeobox- 1 in rat pancreatic beta cells during the development of diabetes mellitus (1998) Journal of Clinical Investigation, 101 (11), pp. 2528-2539; 
Shen C.N., Glucocorticoids suppress beta-cell development and induce hepatic metaplasia in embryonic pancreas (2003) Biochemical Journal, 375, pp. 41-50; 
Wang L., Shao J., Muhlenkamp P., Liu S., Klepcyk P., Ren J., Friedman J.E., Increased insulin receptor substrate-1 and enhanced skeletal muscle insulin sensitivity in mice lacking CCAAT/enhancer-binding protein beta (2000) Journal of Biological Chemistry, 275 (19), pp. 14173-14181. , DOI 10.1074/jbc.M000764200; 
Foti D., Iuliano R., Chiefari E., Brunetti A., A nucleoprotein complex containing Sp1, C/EBPbeta, and HMGI-Y controls human insulin receptor gene transcription (2003) Molecular and Cellular Biology, 23 (8), pp. 2720-2732. , DOI 10.1128/MCB.23.8.2720-2732.2003; 
MacDougald O.A., Insulin regulates transcription of the CCAAT/enhancer binding protein (C/EBP) alpha, beta, and delta genes in fully-differentiated 3T3-L1 adipocytes (1995) Journal of Biological Chemistry, 270, pp. 647-654; 
Le Lay S., Insulin and sterol-regulatory element-binding protein-1c (SREBP-1C) regulation of gene expression in 3T3-L1 adipocytes. Identification of CCAAT/enhancer-binding protein beta as an SREBP-1C target (2002) Journal of Biological Chemistry, 277, pp. 35625-35634; 
Duong D.T., Waltner-Law M.E., Sears R., Sealy L., Granner D.K., Insulin inhibits hepatocellular glucose production by utilizing liver-enriched transcriptional inhibitory protein to disrupt the association of CREB-binding protein and RNA polymerase II with the phosphoenolpyruvate carboxykinase gene promoter (2002) Journal of Biological Chemistry, 277 (35), pp. 32234-32242. , DOI 10.1074/jbc.M204873200; 
Bosch F., Sabater J., Valera A., Insulin inhibits liver expression of the CCAAT/enhancerbinding protein beta (1995) Diabetes, 44, pp. 267-271; 
Sekine O., Insulin activates CCAAT/ enhancer binding proteins and proinflammatorygene expression through the phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells (2002) Journal of Biological Chemistry, 277, pp. 36631-36639; 
Guo S., Insulin suppresses transactivation by CAAT/enhancer-binding proteins beta (C/EBPbeta). Signaling to p300/ CREB-binding protein by protein kinase B disrupts interaction with the major activation domain of C/EBPbeta (2001) Journal of Biological Chemistry, 276, pp. 8516-8523; 
Grimm S.L., Seagroves T.N., Kabotyanski E.B., Hovey R.C., Vonderhaar B.K., Lydon J.P., Miyoshi K., Rosen J.M., Disruption of steroid and prolactin receptor patterning in the mammary gland correlates with a block in lobuloalveolar development (2002) Molecular Endocrinology, 16 (12), pp. 2675-2691. , DOI 10.1210/me.2002-0239; 
Nolten L.A., Expression of the insulin-like growth factor I gene is stimulated by the liver-enriched transcription factors C/EBP alpha and LAP (1994) Molecular Endocrinology, 8, pp. 1636-1645; 
Umayahara Y., Kajimoto Y., Fujitani Y., Gorogawa S.-I., Yasuda T., Kuroda A., Ohtoshi K., Hori M., Protein kinase C-dependent, CCAAT/enhancer-binding protein beta-mediated expression of insulin-like growth factor I gene (2002) Journal of Biological Chemistry, 277 (18), pp. 15261-15270. , DOI 10.1074/jbc.M110827200; 
Umayahara Y., CCAAT/enhancer-binding protein delta is a critical regulator of insulin-like growth factor-I gene transcription in osteoblasts (1999) Journal of Biological Chemistry, 274, pp. 10609-10617; 
McCarthy T.L., Ji C., Chen Y., Kim K., Centrella M., Time- and dose-related interactions between glucocorticoid and cyclic adenosine 3′,5′-monophosphate on CCAAT/enhancer-binding protein-dependent insulin-like growth factor I expression by osteoblasts (2000) Endocrinology, 141 (1), pp. 127-137. , DOI 10.1210/en.141.1.127; 
Nerlov C., The C/EBP family of transcription factors: A paradigm for interaction between gene expression and proliferation control (2007) Trends in Cell Biology, 17, pp. 318-324; 
Brennan P., Donev R., Hewamana S., Targeting transcription factors for therapeutic benefit (2008) Molecular Biosystems, 4, pp. 909-919; 
Minucci S., Pelicci P.G., Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer (2006) Nature Reviews Cancer, 6 (1), pp. 38-51. , DOI 10.1038/nrc1779; 
Liu X., Wang L., Zhao K., Thompson P.R., Hwang Y., Marmorstein R., Cole P.A., The structural basis of protein acetylation by the p300/CBP transcriptional coactivator (2008) Nature, 451 (7180), pp. 846-850. , DOI 10.1038/nature06546, PII NATURE06546; 
Zheng Y., Thompson P.R., Cebrat M., Wang L., Devlin M.K., Alani R.M., Cole P.A., Selective HAT Inhibitors as Mechanistic Tools for Protein Acetylation (2004) Methods in Enzymology, 376, pp. 188-199. , DOI 10.1016/S0076-6879(03)76012-1; 
Kohno M., Pouyssegur J., Targeting the ERK signaling pathway in cancer therapy (2006) Annals of Medicine, 38 (3), pp. 200-211. , DOI 10.1080/07853890600551037, PII H81834426841; 
Yuan T.L., Cantley L.C., PI3K pathway alterations in cancer: Variations on a theme (2008) Oncogene, 27, pp. 5497-5510; 
Gilmore T.D., Herscovitch M., Inhibitors of NF-kappaB signaling: 785 and counting (2006) Oncogene, 25 (51), pp. 6887-6899. , DOI 10.1038/sj.onc.1209982, PII 1209982; 
Dey A., Verma C.S., Lane D.P., Updates on p53: Modulation of p53 degradation as a therapeutic approach (2008) British Journal of Cancer, 98, pp. 4-8; 
Mees C., Nemunaitis J., Senzer N., Transcription factors: Their potential as targets for an individualized therapeutic approach to cancer (2009) Cancer Gene Therapy, 16, pp. 103-112; 
Rizzo P., Rational targeting of Notch signaling in cancer (2008) Oncogene, 27, pp. 5124-5131; 
Rishi V., Potter T., Laudeman J., Reinhart R., Silvers T., Selby M., Stevenson T., Vinson C., A high-throughput fluorescence-anisotropy screen that identifies small molecule inhibitors of the DNA binding of B-ZIP transcription factors (2005) Analytical Biochemistry, 340 (2), pp. 259-271. , DOI 10.1016/j.ab.2005.02.012; 
Turkson J., Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation (2001) Journal of Biological Chemistry, 276, pp. 45443-45455; 
Berg T., Cohen S.B., Desharnais J., Sonderegger C., Maslyar D.J., Goldberg J., Boger D.L., Vogt P.K., Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts (2002) Proceedings of the National Academy of Sciences of the United States of America, 99 (6), pp. 3830-3835. , DOI 10.1073/pnas.062036999; 
Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Liu E.A., In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 (2004) Science, 303 (5659), pp. 844-848. , DOI 10.1126/science.1092472; 
Efeyan A., Ortega-Molina A., Velasco-Miguel S., Herranz D., Vassilev L.T., Serrano M., Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin (2007) Cancer Research, 67 (15), pp. 7350-7357. , http://cancerres.aacrjournals.org/cgi/reprint/67/15/7350, DOI 10.1158/0008-5472.CAN-07-0200; 
Olenyuk B.Z., Zhang G.-J., Klco J.M., Nickols N.G., Kaelin Jr. W.G., Dervan P.B., Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist (2004) Proceedings of the National Academy of Sciences of the United States of America, 101 (48), pp. 16768-16773. , DOI 10.1073/pnas.0407617101; 
Kozak M., An analysis of vertebrate mRNA sequences: Intimations of translational control (1991) Journal of Cell Biology, 115, pp. 887-903; 
Raught B., Gingras A.-C., James A., Medina D., Sonenberg N., Rosen J.M., Expression of a translationally regulated, dominant-negative CCAAT/enhancer-binding protein beta isoform and up-regulation of the eukaryotic translation initiation factor 2alpha are correlated with neoplastic transformation of mammary epithelial cells (1996) Cancer Research, 56 (19), pp. 4382-4386; 
Lincoln A.J., Monczak Y., Williams S.C., Johnson P.F., Inhibition of CCAAT/enhancer-binding protein alpha and beta translation by upstream open reading frames (1998) Journal of Biological Chemistry, 273 (16), pp. 9552-9560. , DOI 10.1074/jbc.273.16.9552; 
Li Y., Differential control of the CCAAT/enhancer-binding protein beta (C/ EBPbeta) products liver-enriched transcriptional activating protein (LAP) and liver-enriched transcriptional inhibitory protein (LIP) and the regulation of gene expression during the response to endoplasmic reticulum stress (2008) Journal of Biological Chemistry, 283, pp. 22443-22456; 
Sterneck E., Tessarollo L., Johnson P.F., An essential role for C/EBPbeta in female reproduction (1997) Genes and Development, 11 (17), pp. 2153-2162; 
Millward C.A., Mice with a deletion in the gene for CCAAT/enhancer-binding protein beta are protected against diet-induced obesity (2007) Diabetes, 56, pp. 161-167; 
Carmona M.C., Defective thermoregulation, impaired lipid metabolism, but preserved adrenergic induction of gene expression in brown fat of mice lacking C/EBPbeta (2005) Biochemistry Journal, 389, pp. 47-56; 
Croniger C.M., Millward C., Yang J., Kawai Y., Arinze I.J., Liu S., Harada-Shiba M., Hanson R.W., Mice with a deletion in the gene for CCAAT/enhancer-binding protein beta have an attenuated response to cAMP and impaired carbohydrate metabolism (2001) Journal of Biological Chemistry, 276 (1), pp. 629-638. , DOI 10.1074/jbc.M007576200; 
Liu S., Croniger C., Arizmendi C., Harada-Shiba M., Ren J., Poli V., Hanson R.W., Friedman J.E., Hypoglycemia and impaired hepatic glucose production in mice with a deletion of the C/EBPbeta gene (1999) Journal of Clinical Investigation, 103 (2), pp. 207-213; 
Greenbaum L.E., Li W., Cressman D.E., Peng Y., Ciliberto G., Poli V., Taub R., CCAAT enhancer-binding protein beta is required for normal hepatocyte proliferation in mice after partial hepatectomy (1998) Journal of Clinical Investigation, 102 (5), pp. 996-1007; 
Tominaga H., CCAAT/Enhancer-binding Protein {beta} Promotes Osteoblast Differentiation by Enhancing Runx2 Activity with ATF4 (2008) Molecular Biology of the Cell, 19, pp. 5373-5386; 
Tanaka T., Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages (1995) Cell, 80, pp. 353-361; 
Screpanti I., Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice (1995) EMBO Journal, 14, pp. 1932-1941; 
Tanaka T., Yoshida N., Kishimoto T., Akira S., Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdeltagene (1997) EMBO Journal, 16 (24), pp. 7432-7443. , DOI 10.1093/emboj/16.24.7432
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-65349107367&partnerID=40&md5=9eb61997bc66c0af30f575e825d605a5
ER  - 

TY  - JOUR
TI  - The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl
T2  - Human Molecular Genetics
VL  - 19
IS  - 12
SP  - 2516
EP  - 2523
PY  - 2010
DO  - 10.1093/hmg/ddq123
AU  - Takahashi M.
AU  - Saenko V.A.
AU  - Rogounovitch T.I.
AU  - Kawaguchi T.
AU  - Drozd V.M.
AU  - Takigawa-Imamura H.
AU  - Akulevich N.M.
AU  - Ratanajaraya C.
AU  - Mitsutake N.
AU  - Takamura N.
AU  - Danilova L.I.
AU  - Lushchik M.L.
AU  - Demidchik Y.E.
AU  - Heath S.
AU  - Yamada R.
AU  - Lathrop M.
AU  - Matsuda F.
AU  - Yamashita S.
N1  - 施引文献 :60
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
C7  - ddq123
N1  - 参考文献: Kazakov V.S., Demidchik E.P., Astakhova L.N., Thyroid cancer after Chernobyl (1992) Nature, 359, p. 21; 
Bennett B., Repacholi M., Carr Z., (2006) Report of the UN Chernobyl Forum Expert Group 'Health', , WHO Press, Geneva; 
Cardis E., Kesminiene A., Ivanov V., Malakhova I., Shibata Y., Khrouch V., Drozdovitch V., Vlassov O., Risk of thyroid cancer after exposure to 131I in childhood (2005) J. Natl Cancer Inst., 97, pp. 724-732; 
Tronko M.D., Howe G.R., Bogdanova T.I., Bouville A.C., Epstein O.V., Brill A.B., Likhtarev I.A., Greenebaum E., A cohort study of thyroid cancer and other thyroid diseases after the chornobyl accident: thyroid cancer in Ukraine detected during first screening (2006) J. Natl Cancer Inst., 98, pp. 897-903; 
Williams D., Cancer after nuclear fallout: lessons from the Chernobyl accident (2002) Nat. Rev. Cancer, 2, pp. 543-549; 
Tronko M.D., Brenner A.V., Olijnyk V.A., Robbins J., Epstein O.V., McConnell R.J., Bogdanova T.I., Lubin J.H., Autoimmune thyroiditis and exposure to iodine 131 in the Ukrainian cohort study of thyroid cancer and other thyroid diseases after the Chornobyl accident: results from the first screening cycle (1998-2000) (2006) J. Clin. Endocrinol. Metab., 91, pp. 4344-4351; 
Ron E., Lubin J.H., Shore R.E., Mabuchi K., Modan B., Pottern L.M., Schneider A.B., Boice J.D. Jr., Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies (1995) Radiat. Res., 141, pp. 259-277; 
Pacini F., Vorontsova T., Demidchik E.P., Molinaro E., Agate L., Romei C., Shavrova E., Kuchinskaya E., Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France (1997) J. Clin. Endocrinol. Metab., 82, pp. 3563-3569; 
Jacob P., Bogdanova T.I., Buglova E., Chepurniy M., Demidchik Y., Gavrilin Y., Kenigsberg J., Shinkarev S., Thyroid cancer among Ukrainians and Belarusians who were children or adolescents at the time of the Chernobyl accident (2006) J. Radiol. Prot., 26, pp. 51-67; 
Likhtarev I., Bouville A., Kovgan L., Luckyanov N., Voilleque P., Chepurny M., Questionnaire- and measurement-based individual thyroid doses in Ukraine resulting from the Chornobyl nuclear reactor accident (2006) Radiat. Res., 166, pp. 271-286; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Jonasson J.G., Sigurdsson A., Bergthorsson J.T., He H., Jakobsdottir M., Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations (2009) Nat. Genet., 41, pp. 460-464; 
Landa I., Ruiz-Llorente S., Montero-Conde C., Inglada-Perez L., Schiavi F., Leskela S., Pita G., Ramos I., The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors (2009) PLoS Genet, 5, pp. e1000637; 
(1994) United Nations Scientific Committee on the Effects of Atomic Radiation, 1994 Report to the General Assembly, , UNSCEAR New York; 
Zannini M., Avantaggiato V., Biffali E., Arnone M.I., Sato K., Pischetola M., Taylor B.A., Di Lauro R., TTF-2, a new forkhead protein, shows a temporal expression in the developing thyroid which is consistent with a role in controlling the onset of differentiation (1997) EMBO J., 16, pp. 3185-3197; 
Chadwick B.P., Obermayr F., Frischauf A.M., FKHL15, a new human member of the forkhead gene family located on chromosome 9q22 (1997) Genomics, 41, pp. 390-396; 
Williams E.D., Abrosimov A., Bogdanova T., Demidchik E.P., Ito M., LiVolsi V., Lushnikov E., Tronko M.D., Thyroid carcinoma after Chernobyl latent period, morphology and aggressiveness (2004) Br. J. Cancer, 90, pp. 2219-2224; 
Rogounovitch T.I., Saenko V.A., Ashizawa K., Sedliarou I.A., Namba H., Abrosimov A.Y., Lushnikov E.F., Petoukhova N.S., TP53 codon 72 polymorphism in radiation-associated human papillary thyroid cancer (2006) Oncol. Rep., 15, pp. 949-956; 
Akulevich N.M., Saenko V.A., Rogounovitch T.I., Drozd V.M., Lushnikov E.F., Ivanov V.K., Mitsutake N., Yamashita S., Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma (2009) Endocr. Relat. Cancer, 16, pp. 491-503; 
Stephens L.A., Powell N.G., Grubb J., Jeremiah S.J., Bethel J.A., Demidchik E.P., Bogdanova T.I., Thomas G.A., Investigation of loss of heterozygosity and SNP frequencies in the RET gene in papillary thyroid carcinoma (2005) Thyroid, 15, pp. 100-104; 
Lonn S., Bhatti P., Alexander B.H., Pineda M.A., Doody M.M., Struewing J.P., Sigurdson A.J., Papillary thyroid cancer and polymorphic variants in TSHR- and RET-related genes: a nested case-control study within a cohort of U.S. radiologic technologists (2007) Cancer Epidemiol. Biomarkers Prev., 16, pp. 174-177; 
Sigurdson A.J., Land C.E., Bhatti P., Pineda M., Brenner A., Carr Z., Gusev B.I., Bouville A., Thyroid nodules, polymorphic variants in DNA repair and RET-related genes, and interaction with ionizing radiation exposure from nuclear tests in Kazakhstan (2009) Radiat. Res., 171, pp. 77-88; 
Kruk J.E., Prohl G., Kenigsberg J.I., A radioecological model for thyroid dose reconstruction of the Belarus population following the Chernobyl accident (2004) Radiat. Environ. Biophys., 43, pp. 101-110; 
Bouville A., Likhtarev I.A., Kovgan L.N., Minenko V.F., Shinkarev S.M., Drozdovitch V.V., Radiation dosimetry for highly contaminated Belarusian, Russian and Ukrainian populations, and for less contaminated populations in Europe (2007) Health Phys, 93, pp. 487-501; 
Heath S.C., Gut I.G., Brennan P., McKay J.D., Bencko V., Fabianova E., Foretova L., Kabesch M., Investigation of the fine structure of European populations with applications to disease association studies (2008) Eur. J. Hum. Genet., 16, pp. 1413-1429; 
Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Daly M.J., PLINK: a tool set for whole-genome association and population-based linkage analyses (2007) Am. J. Hum. Genet., 81, pp. 559-575; 
Price A.L., Patterson N.J., Plenge R.M., Weinblatt M.E., Shadick N.A., Reich D., Principal components analysis corrects for stratification in genome-wide association studies (2006) Nat. Genet., 38, pp. 904-909; 
Yamada R., Okada Y., An optimal dose-effect mode trend test for SNP genotype tables (2009) Genet. Epidemiol., 33, pp. 114-127; 
Devlin B., Roeder K., Genomic control for association studies (1999) Biometrics, 55, pp. 997-1004; 
Woolson R.F., Bean J.A., Mantel-Haenszel statistics and direct standardization (1982) Stat. Med., 1, pp. 37-39; 
Barrett J.C., Fry B., Maller J., Daly M.J., Haploview: analysis and visualization of LD and haplotype maps (2005) Bioinformatics, 21, pp. 263-265
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-77955301455&partnerID=40&md5=743ed037004368c37d0da4174ec9b180
ER  - 

TY  - JOUR
TI  - The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type
T2  - Proceedings of the National Academy of Sciences of the United States of America
VL  - 109
IS  - 22
SP  - 8646
EP  - 8651
PY  - 2012
DO  - 10.1073/pnas.1205654109
AU  - Jendrzejewski J.
AU  - He H.
AU  - Radomska H.S.
AU  - Li W.
AU  - Tomsic J.
AU  - Liyanarachchi S.
AU  - Davuluri R.V.
AU  - Nagy R.
AU  - De La Chapelle A.
N1  - 施引文献 :55
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Chen A.Y., Jemal A., Ward E.M., Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005 (2009) Cancer, 115, pp. 3801-3807; 
Howlader N.N.A., (2010) SEER Cancer Statistics Review, 1975-2008, , http://seer.cancer.gov/csr/1975_2008/, National Cancer Institute. Bethesda, MD, Available at Accessed January 22, 2012; 
Schneider A.B., Sarne D.H., Long-term risks for thyroid cancer and other neoplasms after exposure to radiation (2005) Nat Clin Pract Endocrinol Metab, 1, pp. 82-91; 
Goldgar D.E., Easton D.F., Cannon-Albright L.A., Skolnick M.H., Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands (1994) Journal of the National Cancer Institute, 86 (21), pp. 1600-1608; 
Risch N., The genetic epidemiology of cancer: Interpreting family and twin studies and their implications for molecular genetic approaches (2001) Cancer Epidemiol Biomarkers Prev, 10, pp. 733-741; 
Dong C., Hemminki K., Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families (2001) International Journal of Cancer, 92 (1), pp. 144-150; 
Ito Y., Biological behavior and prognosis of familial papillary thyroid carcinoma (2009) Surgery, 145, pp. 100-105; 
Uchino S., Noguchi S., Kawamoto H., Yamashita H., Watanabe S., Yamashita H., Shuto S., Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population (2002) World Journal of Surgery, 26 (8), pp. 897-902. , DOI 10.1007/s00268-002-6615-y; 
De La Chapelle A., Jazdzewski K., MicroRNAs in thyroid cancer (2011) J Clin Endocrinol Metab, 96, pp. 3326-3336; 
Manolio T.A., Finding the missing heritability of complex diseases (2009) Nature, 461, pp. 747-753; 
Gudmundsson J., Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations (2009) Nat Genet, 41, pp. 460-464; 
Takahashi M., The FOXE1 locus is a major genetic determinant for radiation- related thyroid carcinoma in Chernobyl (2010) Hum Mol Genet, 19, pp. 2516-2523; 
Gudmundsson J., Discovery of common variants associated with low TSH levels and thyroid cancer risk (2012) Nat Genet, 44, pp. 319-322; 
Matsuse M., The FOXE1 and NKX2-1 loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population (2011) J Med Genet, 48, pp. 645-648; 
Jones A.M., Thyroid cancer susceptibility polymorphisms: Confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24 (2012) J Med Genet, 49, pp. 158-163. , TCUKIN Consortium; 
Fujita P.A., The UCSC Genome Browser database: Update 2011 (2011) Nucleic Acids Res, 39 (DATABASE ISSUE), pp. D876-D882; 
Mariner P.D., Walters R.D., Espinoza C.A., Drullinger L.F., Wagner S.D., Kugel J.F., Goodrich J.A., Human Alu RNA Is a Modular Transacting Repressor of mRNA Transcription during Heat Shock (2008) Molecular Cell, 29 (4), pp. 499-509. , DOI 10.1016/j.molcel.2007.12.013, PII S1097276508000026; 
Ponicsan S.L., Kugel J.F., Goodrich J.A., Genomic gems: SINE RNAs regulate mRNA production (2010) Curr Opin Genet Dev, 20, pp. 149-155; 
Freedman M.L., Principles for the post-GWAS functional characterization of cancer risk loci (2011) Nat Genet, 43, pp. 513-518; 
Donnelly P., Progress and challenges in genome-wide association studies in humans (2008) Nature, 456, pp. 728-731; 
Hindorff L.A., Potential etiologic and functional implications of genomewide association loci for human diseases and traits (2009) Proc Natl Acad Sci USA, 106, pp. 9362-9367; 
Prensner J.R., Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression (2011) Nat Biotechnol, 29, pp. 742-749; 
Cabili M.N., Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses (2011) Genes Dev, 25, pp. 1915-1927; 
Morley M., Genetic analysis of genome-wide variation in human gene expression (2004) Nature, 430, pp. 743-747; 
Goring H.H.H., Curran J.E., Johnson M.P., Dyer T.D., Charlesworth J., Cole S.A., Jowett J.B.M., Blangero J., Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes (2007) Nature Genetics, 39 (10), pp. 1208-1216. , DOI 10.1038/ng2119, PII NG2119; 
Stranger B.E., Nica A.C., Forrest M.S., Dimas A., Bird C.P., Beazley C., Ingle C.E., Dermitzakis E.T., Population genomics of human gene expression (2007) Nature Genetics, 39 (10), pp. 1217-1224. , DOI 10.1038/ng2142, PII NG2142; 
Van Staveren W.C., Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype (2007) Cancer Res, 67, pp. 8113-8120; 
Pelosi G., Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung (2010) Anticancer Res, 30, pp. 4269-4281; 
Yang L., Han Y., Saurez S.F., Minden M.D., A tumor suppressor and oncogene: The WT1 story (2007) Leukemia, 21 (5), pp. 868-876. , DOI 10.1038/sj.leu.2404624, PII 2404624; 
Pomerance M., Mockey M., Young J., Quillard J., Blondeau J.-P., Expression, hormonal regulation, and subcellular localization of CCAAT/enhancer-binding protein-beta in rat and human thyrocytes (2005) Thyroid, 15 (3), pp. 197-204. , DOI 10.1089/thy.2005.15.197; 
Akagi T., Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells (2008) Br J Cancer, 99, pp. 781-788; 
Flodby P., Barlow C., Kylefjord H., Ahrlund-Richter L., Xanthopoulos K.G., Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein alpha (1996) Journal of Biological Chemistry, 271 (40), pp. 24753-24760. , DOI 10.1074/jbc.271.40.24753; 
Sugahara K., Iyama K.-I., Kimura T., Sano K., Darlington G.J., Akiba T., Takiguchi M., Mice lacking CCAAT/enhancer-binding protein-alpha show hyperproliferation of alveolar type II cells and increased surfactant protein mRNAs (2001) Cell and Tissue Research, 306 (1), pp. 57-63. , DOI 10.1007/s004410100420; 
Tontonoz P., Hu E., Spiegelman B.M., Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor (1994) Cell, 79, pp. 1147-1156; 
McNagny K.M., Sieweke M.H., Doderlein G., Graf T., Nerlov C., Regulation of eosinophil-specific gene expression by a C/EBP-Ets complex and GATA-1 (1998) EMBO Journal, 17 (13), pp. 3669-3680. , DOI 10.1093/emboj/17.13.3669; 
Cassel T.N., Suske G., Nord M., C/EBP alpha and TTF-1 synergistically transactivate the Clara cell secretory protein gene (2000) Annals of the New York Academy of Sciences, 923, pp. 300-302; 
Pabst T., Mueller B.U., Zhang P., Radomska H.S., Narravula S., Schnittger S., Behre G., Tenen D.G., Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia (2001) Nature Genetics, 27 (3), pp. 263-270. , DOI 10.1038/85820; 
Tenen D.G., Disruption of differentiation in human cancer: AML shows the way (2003) Nat Rev Cancer, 3, pp. 89-101; 
Halmos B., Huettner C.S., Kocher O., Ferenczi K., Karp D.D., Tenen D.G., Down-regulation and antiproliferative role of C/EBPalpha in lung cancer (2002) Cancer Research, 62 (2), pp. 528-534; 
Tan E.H., Hooi S.C., Laban M., Wong E., Ponniah S., Wee A., Wang N.-D., CCAAT/enhancer binding protein alpha knock-in mice exhibit early liver glycogen storage and reduced susceptibility to hepatocellular carcinoma (2005) Cancer Research, 65 (22), pp. 10330-10337. , DOI 10.1158/0008-5472.CAN-04-4486; 
Armstrong D.A., Phelps L.N., Vincenti M.P., CCAAT enhancer binding protein-beta regulates matrix metalloproteinase-1 expression in interleukin-1beta-stimulated A549 lung carcinoma cells (2009) Mol Cancer Res, 7, pp. 1517-1524; 
Zahnow C.A., CCAAT/enhancer-binding protein beta: Its role in breast cancer and associations with receptor tyrosine kinases (2009) Expert Rev Mol Med, 11, pp. e12; 
Kel A.E., Gossling E., Reuter I., Cheremushkin E., Kel-Margoulis O.V., Wingender E., MATCH: A tool for searching transcription factor binding sites in DNA sequences (2003) Nucleic Acids Research, 31 (13), pp. 3576-3579. , DOI 10.1093/nar/gkg585
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-84861862859&partnerID=40&md5=553737dcdacb352a5c0ae0f4eabd6d8e
ER  - 

TY  - JOUR
TI  - Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: A population-based analysis
T2  - American Journal of Surgery
VL  - 200
IS  - 4
SP  - 454
EP  - 461
PY  - 2010
DO  - 10.1016/j.amjsurg.2009.11.008
AU  - Morris L.G.T.
AU  - Myssiorek D.
N1  - 施引文献 :53
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Davies L., Welch H., Increasing incidence of thyroid cancer in the United States, 19732002 (2006) JAMA, 295, pp. 2164-2167; 
Hodgson N.C., Button J., Solorzano C.C., Thyroid cancer: Is the incidence still increasing? (2004) Ann Surg Oncol, 11, pp. 1093-1097; 
Haselkorn T., Bernstein L., Preston-Martin S., Descriptive epidemiology of thyroid cancer in Los Angeles County, 197295 (2000) Cancer Causes Control, 11, pp. 163-170; 
Burgess J.R., Tucker P., Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology (2006) Thyroidology, 16, pp. 47-53; 
Clegg L.X., Reichman M.E., Miller B.A., Impact of socioeconomic status on cancer incidence and stage at diagnosis: Selected findings from the Surveillance, Epidemiology and End Results: National Longitudinal Mortality Study (2009) Cancer Causes Control, 20, pp. 417-435; 
Percy C., Fritz A., Jack A., (2000) International Classification of Diseases for Oncology, , 3rd ed. World Health Organization Geneva; 
Hedinger C., Williams E.D., Sobin L.H., (1988) Histological Typing of Thyroid Tumors, , 2nd ed. Springer Berlin; 
Morris L.G., Sikora A.G., Myssiorek D., The basis of racial differences in the incidence of thyroid cancer (2008) Ann Surg Oncol, 15, pp. 1169-1176; 
Kim H.J., Fay M.P., Feuer E.J., Permutation tests for Joinpoint regression with applications to cancer rates (2000) Stat Med, 19, pp. 335-351; 
Verkooijen H.M., Fioretta G., Pache J.C., Diagnostic changes as a reason for an increase in papillary thyroid cancer incidence in Geneva, Switzerland (2003) Cancer Causes Control, 14, pp. 13-17; 
Leenhardt L., Bernier M.O., Boin-Pineau M.H., Advances in diagnostic practices affect thyroid cancer incidence in France (2004) Eur J Endocrinol, 150, pp. 133-139; 
Vanderlaan W., The occurrence of carcinoma of the thyroid gland in autopsy material (1947) N Engl J Med, 237, pp. 221-222; 
Bondeson L., Ljungberg O., Occult thyroid cancer at autopsy in Malmo, Sweden (1981) Cancer, 47, pp. 319-323; 
Heitz P., Moser H., Staub J.J., Thyroid cancer: A study of 573 thyroid tumors and 161 autopsy cases observed over a thirty year period (1976) Cancer, 37, pp. 2329-2337; 
Solares C.A., Penalonzo M.A., Xu M., Occult papillary thyroid carcinoma in postmortem species: Prevalence at autopsy (2005) Am J Otolaryngol, 26, pp. 87-90; 
Harach H.R., Franssila K.O., Wasenius V.M., Occult papillary carcinoma of the thyroid: A "normal" finding in Finland (1985) Cancer, 56, pp. 531-538; 
Belfiore A., Larosa G.L., Laporta G.A., Cancer risk in patients with cold thyroid nodules: Relevance of iodine uptake, sex, age and multinodularity (1992) Am J Med, 93, pp. 363-369; 
Hall E.J., Brenner D.J., Cancer risks from diagnostic radiology (2008) Br J Radiol, 81, pp. 362-378; 
Chen A.Y., Jemal A., Ward E.M., Increasing incidence of differentiated thyroid cancer in the United States, 19882005 (2009) Cancer, 115, pp. 3801-3807; 
Heller K.S., Do all cancers need to be treated?: The role of thyroglobulin in the management of thyroid cancer (2007) Arch Otolaryngol Head Neck Surg, 133, pp. 639-643; 
Hughes C.J., Shaha A.R., Shah J.P., Impact of lymph node metastases in differentiated carcinoma of the thyroid: A matched-pair analysis (1996) Head Neck, 18, pp. 127-132; 
Iribarren C., Haselkorn T., Tekawa I.S., Cohort study of thyroid cancer in a San Francisco Bay Aarea population (2001) Int J Cancer, 93, pp. 745-750; 
Grodski S., Brown T., Sidhu S., Increasing incidence of thyroid cancer is due to increased pathologic detection (2008) Surgery, 144, pp. 1038-1043
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-77957368756&partnerID=40&md5=3b16be7bb833ffbe54b60a73b89a1db5
ER  - 

TY  - JOUR
TI  - Do human RNA helicases have a role in cancer?
T2  - Biochimica et Biophysica Acta - Reviews on Cancer
VL  - 1704
IS  - 1
SP  - 37
EP  - 46
PY  - 2004
DO  - 10.1016/j.bbcan.2004.05.001
AU  - Abdelhaleem M.
N1  - 施引文献 :53
N1  - Export Date: 2 January 2016
TY  - Review
DB  - Scopus
N1  - 参考文献: Lander E.S., Linton L.M., Birren B., Initial sequencing and analysis of the human genome (2001) Nature, 409, pp. 860-921; 
Balvay L., Libri D., Fiszman M.Y., Pre-mRNA secondary structure and the regulation of splicing (1993) BioEssays, 15, pp. 165-169; 
Van Der Velden A.W., Thomas A.A., The role of the 5′ untranslated region of an mRNA in translation regulation during development (1999) Int. J. Biochem. Cell Biol., 31, pp. 87-106; 
Luking A., Stahl U., Schmidt U., The protein family of RNA helicases (1998) Crit. Rev. Biochem. Mol. Biol., 33, pp. 259-296; 
Schmid S.R., Linder P., D-E-A-D protein family of putative RNA helicases (1992) Mol. Microbiol., 6, pp. 283-291; 
Jankowsky E., Gross C.H., Shuman S., Pyle A.M., Active disruption of an RNAprotein interaction by a DExH/D RNA helicase (2001) Science, 291, pp. 121-125; 
Silverman, Edwalds-Gilbert G., Lin R.J., DExD/H-box proteins and their partners: Helping RNA helicases unwind (2003) Gene, 312, pp. 1-16; 
Gorbalenya A.E., Koonin E.V., Donchenko A.P., Blinov V.M., Two related superfamilies of putative helicases involved in replication, recombination, repair and expression of DNA and RNA genomes (1989) Nucleic Acids Res., 17, pp. 4713-4730; 
Linder P., Lasko P.F., Ashburner M., Leroy P., Nielsen P.J., Nishi K., Schnier J., Slonimski P.P., Birth of the D-E-A-D box (1989) Nature, 337, pp. 121-122; 
De La Cruz J., Kressler D., Linder P., Unwinding RNA in Saccharomyces cerevisiae: DEAD-box proteins and related families (1999) Trends Biochem. Sci., 24, pp. 192-198; 
Tanner N.K., Linder P., From RNA helicases to RNPases (2001) Mol. Cell, 8, pp. 251-262; 
Tanner N.K., Cordin O., Banroques J., Doere M., Linder P., The Q motif: A newly identified motif in DEAD box helicases may regulate ATP binding and hydrolysis (2003) Mol. Cell, 11, pp. 127-138; 
Linder P., Gasteiger E., Bairoch A., A comprehensive web resource on RNA helicases from the baker's yeast Saccharomyces cerevisiae (2000) Yeast, 16, pp. 507-509; 
Jankowsky E., Jankowsky A., The DExH/D protein family database (2000) Nucleic Acids Res., 28, pp. 333-334; 
Linder P., Stutz F., MRNA export: Travelling with DEAD box proteins (2001) Curr. Biol., 11, pp. 961-R963; 
Linder P., Tanner N.K., Banroques J., From RNA helicases to RNPases (2001) Trends Biochem. Sci., 26, pp. 339-341; 
Boudet N., Aubourg S., Toffano-Nioche C., Kreis M., Lecharny A., Evolution of intron/exon structure of DEAD helicase family genes in Arabidopsis, Caenorhabditis, and Drosophila (2001) Genome Res., 11, pp. 2101-2114; 
Linder P., Yeast RNA helicases of the DEAD-box family involved in translation initiation (2003) Biol. Cell, 95, pp. 157-167; 
www.helicase.netAbdelhaleem M., Maltais L., Wain H., The human DDX and DHX gene families of putative RNA helicases (2003) Genomics, 81, pp. 618-622; 
Ji W., Chen F., Do T., Do A., Roe B.A., Meisler M.H., DQX1, an RNA-dependent ATPase homolog with a novel DEAQ box: Expression pattern and genomic sequence comparison of the human and mouse genes (2001) Meisler Mamm. Genome, 12, pp. 456-461; 
Abdelhaleem M., The novel helicase homologue DDX32 is down-regulated in acute lymphoblastic leukemia (2002) Leuk. Res., 26, pp. 945-954; 
Vanbrabant A.J., Stan R., Ellis N.A., DNA helicases, genomic instability, and human genetic disease (2000) Annu. Rev. Genomics Hum. Genet., 1, pp. 409-459; 
Hickson I.D., RecQ helicases: Caretakers of the genome (2003) Nat. Rev., Cancer, 3, pp. 169-178; 
Godbout R., Squire J., Amplification of a DEAD box protein gene in retinoblastoma cell lines (1993) Proc. Natl. Acad. Sci. U. S. A., 90, pp. 7578-7582; 
Squire J.A., Thorner P.S., Weitzman S., Maggi J.D., Dirks P., Doyle J., Hale M., Godbout R., Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma (1995) Oncogene, 10, pp. 1417-1422; 
Godbout R., Packer M., Bie W., Overexpression of a DEAD box protein (DDX1) in neuroblastoma and retinoblastoma cell lines (1998) J. Biol. Chem., 273, pp. 21161-21168; 
Karlsson A., Helou K., Walentinsson A., Hedrich H.J., Szpirer C., Levan G., Amplification of Mycn, Ddx1, Rrm2, and Odc1 in rat uterine endometrial carcinomas (2001) Genes Chromosomes Cancer, 31, pp. 345-356; 
Chen H.C., Lin W.C., Tsay Y.G., Lee S.C., Chang C.J., An RNA helicase, DDX1, interacting with poly(A) RNA and heterogeneous nuclear ribonucleoprotein K (2002) J. Biol. Chem., 277, pp. 40403-40409; 
Bleoo S., Sun X., Hendzel M.J., Rowe J.M., Packer M., Godbout R., Association of human DEAD box protein DDX1 with a cleavage stimulation factor involved in 3′-end processing of pre-MRNA (2001) Mol. Biol. Cell, 12, pp. 3046-3059; 
Godbout R., Packer M., Katyal S., Bleoo S., Cloning and expression analysis of the chicken DEAD box gene DDX1 (2002) Biochim. Biophys. Acta, 1574, pp. 63-71; 
Manohar C.F., Salwen H.R., Brodeur G.M., Cohn S.L., Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma (1995) Genes Chromosomes Cancer, 14, pp. 196-203; 
George R.E., Kenyon R.M., McGuckin A.G., Malcolm A.J., Pearson A.D., Lunec J., Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma, United Kingdom Children's Cancer Study Group (1996) Oncogene, 12, pp. 1583-1587; 
Noguchi T., Akiyama K., Yokoyama M., Kanda N., Matsunaga T., Nishi Y., Amplification of a DEAD box gene (DDX1) with the MYCN gene in neuroblastomas as a result of cosegregation of sequences flanking the MYCN locus (1996) Genes Chromosomes Cancer, 15, pp. 129-133; 
Kuroda H., White P.S., Sulman E.P., Manohar C.F., Reiter J.L., Cohn S.L., Brodeur G.M., Physical mapping of the DDX1 gene to 340 kb 5′ of MYCN (1996) Oncogene, 13, pp. 1561-1565; 
Amler L.C., Schurmann J., Schwab M., The DDX1 gene maps within 400 kbp 5′ to MYCN and is frequently coamplified in human neuroblastoma (1996) Genes Chromosomes Cancer, 15, pp. 134-137; 
George R.E., Kenyon R., McGuckin A.G., Kohl N., Kogner P., Christiansen H., Pearson A.D., Lunec J., Analysis of candidate gene co-amplification with MYCN in neuroblastoma (1997) Eur. J. Cancer, 33, pp. 2037-2042; 
Pandita A., Godbout R., Zielenska M., Thorner P., Bayani J., Squire J.A., Relational mapping of MYCN and DDXI in band 2p24 and analysis of amplicon arrays in double minute chromosomes and homogeneously staining regions by use of free chromatin FISH (1997) Genes Chromosomes Cancer, 20, pp. 243-252; 
De Preter K., Speleman F., Combaret V., Lunec J., Laureys G., Eussen B.H., Francotte N., Vandesompele J., Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay (2002) Mod. Path., 15, pp. 159-166; 
Scott D., Elsden J., Pearson A., Lunec J., Genes co-amplified with MYCN in neuroblastoma: Silent passengers or co-determinants of phenotype? (2003) Cancer Lett., 197, pp. 81-86; 
Rogers Jr. G.W., Komar A.A., Merrick W.C., EIF4A: The godfather of the DEAD box helicases (2002) Prog. Nucleic Acid Res. Mol. Biol., 72, pp. 307-331; 
Li Q., Imataka H., Morino S., Rogers Jr. G.W., Richter-Cook N.J., Merrick W.C., Sonenberg N., Eukaryotic translation initiation factor 4AIII (eIF4AIII) is functionally distinct from eIF4AI and eIF4AII (1999) Mol. Cell. Biol., 19, pp. 7336-7346; 
Rogers G.W., Richter N.J., Lima W.F., Merrick W.C., Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F (2001) J. Biol. Chem., 276, pp. 30914-30922; 
Pause A., Sonenberg N., Mutational analysis of a DEAD box RNA helicase: The mammalian translation initiation factor eIF-4A (1992) EMBO J., 11, pp. 2643-2654; 
Pause A., Methot N., Sonenberg N., The HRIGRXXR region of the DEAD box RNA helicase eukaryotic translation initiation factor 4A is required for RNA binding and ATP hydrolysis (1993) Mol. Cell. Biol., 13, pp. 6789-6798; 
Caruthers J.M., Johnson E.R., McKay D.B., Crystal structure of yeast initiation factor 4A, a DEAD-box RNA helicase (2000) Proc. Natl. Acad. Sci. U. S. A., 97, pp. 13080-13085; 
Gingras C., Raught B., Sonenberg N., EIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation (1999) Annu. Rev. Biochem., 68, pp. 913-963; 
Svitkin Y.V., Pause A., Haghighat A., Pyronnet S., Witherell G., Belsham G.J., Sonenberg N., The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5′ secondary structure (2001) RNA, 7, pp. 382-394; 
Eberle J., Krasagakis K., Orfanos C.E., Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro (1997) Int. J. Cancer, 71, pp. 396-401; 
Eberle J., Fecker L.F., Bittner J.U., Orfanos C.E., Geilen C.C., Decreased proliferation of human melanoma cell lines caused by antisense RNA against translation factor eIF-4A1 (2002) Br. J. Cancer, 86, pp. 1957-1962; 
Shuda M., Kondoh N., Tanaka K., Ryo A., Wakatsuki T., Hada A., Goseki N., Yamamoto M., Enhanced expression of translation factor mRNAs in hepatocellular carcinoma (2000) Anticancer Res., 20, pp. 2489-2494; 
Wang W.B., Boing S., Zhou X.Q., Ji P., Dong Y., Yao Q., Muller-Tidow C., Identification of metastasis-associated genes in early stage non-small cell lung cancer by subtractive hybridization (2002) Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai), 34, pp. 273-278; 
Yang H.S., Jansen A.P., Nair R., Shibahara K., Verma A.K., Cmarik J.L., Colburn N.H., A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation (2001) Oncogene, 20, pp. 669-676; 
Yang H.S., Jansen A.P., Komar A.A., Zheng X., Merrick W.C., Costes S., Lockett S.J., Colburn N.H., The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation (2003) Mol. Cell. Biol., 23, pp. 26-37; 
Yang H.S., Knies J.L., Stark C., Colburn N.H., Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation (2003) Oncogene, 22, pp. 3712-3720; 
Lane D.P., Hoeffler W.K., SV40 large T shares an antigenic determinant with a cellular protein of molecular weight 68,000 (1980) Nature, 288, pp. 167-170; 
Ford M.J., Anton I.A., Lane D.P., Nuclear protein with sequence homology to translation initiation factor eIF-4A (1988) Nature, 332, pp. 736-738; 
Scheffner M., Knippers R., Stahl H., RNA unwinding activity of SV40 large T antigen (1989) Cell, 57, pp. 955-963; 
Hirling H., Scheffner M., Restle T., Stahl H., RNA helicase activity associated with the human p68 protein (1989) Nature, 339, pp. 562-564; 
Iggo R.D., Lane D.P., Nuclear protein p68 is an RNA-dependent ATPase (1989) EMBO J., 8, pp. 1827-1831; 
Iggo R.D., Jamieson D.J., MacNeill S.A., Southgate J., McPheat J., Lane D.P., P68 RNA helicase: Identification of a nucleolar form and cloning of related genes containing a conserved intron in yeasts (1991) Mol. Cell. Biol., 11, pp. 1326-1333; 
Huang Y., Liu Z.R., The ATPase, RNA unwinding, and RNA binding activities of recombinant p68 RNA helicase (2002) J. Biol. Chem., 277, pp. 12810-12815; 
Buelt M.K., Glidden B.J., Storm D.R., Regulation of p68 RNA helicase by calmodulin and protein kinase (1994) J. Biol. Chem., 269, pp. 29367-29370; 
Lemaire L., Heinlein U.A., High-level expression in male germ cells of murine P68 RNA helicase mRNA (1993) Life Sci., 52, pp. 917-926; 
Sandhu H., Lemaire L., Heinlein U.A., Male germ cell extracts contain proteins binding to the conserved 3′-end of mouse p68 RNA helicase mRNA (1995) Biochem. Biophys. Res. Commun., 214, pp. 632-638; 
Gingras M.C., Margolin J.F., Differential expression of multiple unexpected genes during U937 cell andmacrophage differentiation detected by suppressive subtractive hybridization (2000) Exp. Hematol., 28, pp. 65-76; 
Stevenson R.J., Hamilton S.J., MacCallum D.E., Hall P.A., Fuller-Pace F.V., Expression of the 'dead box' RNA helicase p68 is developmentally and growth regulated and correlates with organ differentiation/maturation in the fetus (1998) J. Pathol., 184, pp. 351-359; 
Seufert W., Kos R., Erickson C.A., Swalla B.J., P68, a DEAD-box RNA helicase, is expressed in chordate embryo neural and mesodermal tissues (2000) J. Exp. Zool., 288, pp. 193-204; 
Kitamura A., Nishizuka M., Tominaga K., Tsuchiya T., Nishihara T., Imagawa M., Expression of p68 RNA helicase is closely related to the early stage of adipocyte differentiation of mouse 3T3-L1 cells (2001) Biochem. Biophys. Res. Commun., 287, pp. 435-439; 
Liu Z.R., P68 RNA helicase is an essential human splicing factor that acts at the U1 snRNA-5′ splice site duplex (2002) Mol. Cell. Biol., 22, pp. 5443-5450; 
Guil S., Gattoni R., Carrascal M., Abian J., Stevenin J., Bach-Elias M., Roles of hnRNP A1, SR proteins, and p68 helicase in c-H-ras alternative splicing regulation (2003) Mol. Cell. Biol., 23, pp. 2927-2941; 
Endoh H., Maruyama K., Masuhiro Y., Kobayashi Y., Goto M., Tai H., Yanagisawa J., Kato S., Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha (1999) Mol. Cell. Biol., 19, pp. 5363-5372; 
Rossow K.L., Janknecht R., Synergism between p68 RNA helicase and the transcriptional coactivators CBP and p300 (2003) Oncogene, 22, pp. 151-156; 
Ogilvie V.C., Wilson B.J., Nicol S.M., Morrice N.A., Saunders L.R., Barber G.N., Fuller-Pace F.V., The highly related DEAD box RNA helicases p68 and p72 exist as heterodimers in cells (2003) Nucleic Acids Res., 31, pp. 1470-1480; 
Uhlmann-Schiffler H., Rossler O.G., Stahl H., The mRNA of DEAD box protein p72 is alternatively translated into an 82-kDa RNA helicase (2002) J. Biol. Chem., 277, pp. 1066-1075; 
Lamm G.M., Nicol S.M., Fuller-Pace F.V., Lamond A.I., P72: A human nuclear DEAD box protein highly related to p68 (1996) Nucleic Acids Res., 24, pp. 3739-3747; 
Lee C.G., RH70, a bidirectional RNA helicase, co-purifies with U1snRNP (2002) J. Biol. Chem., 277, pp. 39679-39683; 
Rossler O.G., Hloch P., Schutz N., Weitzenegger T., Stahl H., Structure and expression of the human p68 RNA helicase gene (2000) Nucleic Acids Res., 28, pp. 932-939; 
Honig A., Auboeuf D., Parker M.M., O'Malley B.W., Berget S.M., Regulation of alternative splicing by the ATP-dependent DEAD-box RNA helicase p72 (2002) Mol. Cell. Biol., 22, pp. 5698-5707; 
Jothy S., CD44 and its partners in metastasis (2003) Clin. Exp. Metastasis, 20, pp. 195-201; 
Dubey P., Hendrickson R.C., Meredith S.C., Siegel C.T., Shabanowitz J., Skipper J.C., Engelhard V.H., Schreiber H., The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68 (1997) J. Exp. Med., 185, pp. 695-705; 
Causevic M., Hislop R.G., Kernohan N.M., Carey F.A., Kay R.A., Steele R.J., Fuller-Pace F.V., Overexpression and poly-ubiquitylation of the DEAD-box RNA helicase p68 in colorectal tumours (2001) Oncogene, 20, pp. 7734-7743; 
Akao Y., Tsujimoto Y., Finan J., Nowell P.C., Croce C.M., Molecular characterization of a t(11;14)(q23;q32) chromosome translocation in a B-cell lymphoma (1990) Cancer Res., 50, pp. 4856-4859; 
Akao Y., Seto M., Takahashi T., Saito M., Utsumi K.R., Nakazawa S., Ueda R., Rearrangements on chromosome 11q23 in hematopoietic tumor-associated t(11;14) and t(11;19) translocations (1991) Cancer Res., 51, pp. 6708-6711; 
Akao Y., Seto M., Takahashi T., Kubonishi I., Miyoshi I., Nakazawa S., Tsujimoto Y., Ueda R., Molecular cloning of the chromosomal breakpoint of a B-cell lymphoma with the t(11;14)(q23;q32) translocation (1991) Cancer Res., 51, pp. 1574-1576; 
Akao Y., Seto M., Yamamoto K., Iida S., Nakazawa S., Inazawa J., Abe T., Ueda R., The RCK gene associated with t(11;14) translocation is distinct from the MLL/ALL-1 gene with t(4;11) and t(11;19) translocations (1992) Cancer Res., 52, pp. 6083-6087; 
Lu D., Yunis J.J., Cloning, expression and localization of an RNA helicase gene from a human lymphoid cell line with chromosomal breakpoint 11q23.3 (1992) Nucleic Acids Res., 20, pp. 1967-1972; 
Akao Y., Marukawa O., Morikawa H., Nakao K., Kamei M., Hachiya T., Tsujimoto Y., The rck/p54 candidate proto-oncogene product is a 54-kilodalton D-E-A-D box protein differentially expressed in human and mouse tissues (1995) Cancer Res., 55, pp. 3444-3449; 
Miyaji K., Nakagawa Y., Matsumoto K., Yoshida H., Morikawa H., Hongou Y., Arisaka Y., Akao Y., Overexpression of a DEAD box/RNA helicase protein, rck/p54, in human hepatocytes from patients with hepatitis C virus-related chronic hepatitis and its implication in hepatocellular carcinogenesis (2003) J. Viral Hepatitis, 10, pp. 241-248; 
Nakagawa Y., Morikawa H., Hirata I., Shiozaki M., Matsumoto A., Maemura K., Nishikawa T., Akao Y., Overexpression of rck/p54, a DEAD box protein, in human colorectal tumours (1999) Br. J. Cancer, 80, pp. 914-917; 
Hashimoto K., Nakagawa Y., Morikawa H., Niki M., Egashira Y., Hirata I., Katsu K., Akao Y., Co-overexpression of DEAD box protein rck/p54 and c-myc protein in human colorectal adenomas and the relevance of their expression in cultured cell lines (2001) Carcinogenesis, 22, pp. 1965-1970; 
Akao Y., Yoshida H., Matsumoto K., Matsui T., Hogetu K., Tanaka N., Usukura J., A tumour-associated DEAD-box protein, rck/p54 exhibits RNA unwinding activity toward c-myc RNAs in vitro (2003) Genes Cells, 8, pp. 671-676; 
Lee C.G., Hurwitz J., Human RNA helicase a is homologous to the maleless protein of Drosophila (1993) J. Biol. Chem., 268, pp. 16822-16830; 
Zhang S., Maacke H., Grosse F., Molecular cloning of the gene encoding nuclear DNA helicase II. A bovine homologue of human RNA helicase a and Drosophila Mle protein (1995) J. Biol. Chem., 270, pp. 16422-16427; 
Meller V.H., Initiation of dosage compensation in Drosophila embryos depends on expression of the roX RNAs (2003) Mech. Dev., 120, pp. 759-767; 
Richter L., Bone J.R., Kuroda M.I., RNA-dependent association of the Drosophila maleless protein with the male X chromosome (1996) Genes Cells., 1, pp. 325-336; 
Zhang S., Grosse F., Domain structure of human nuclear DNA helicase II (RNA helicase A) (1997) J. Biol. Chem., 272, pp. 11487-11494; 
Lee C.G., Chang K.A., Kuroda M.I., Hurwitz J., The NTPase/helicase activities of Drosophila maleless, an essential factor in dosage compensation (1997) EMBO J., 16, pp. 2671-2681; 
Lee C.G., Costa Soares Da V., Newberger C., Manova K., Lacy E., Hurwitz J., RNA helicase a is essential for normal gastrulation (1998) Proc. Natl. Acad. Sci. U. S. A., 95, pp. 13709-13713; 
Zhang S., Schlott B., Gorlach M., Grosse F., DNA-dependent protein kinase (DNA-PK) phosphorylates nuclear DNA helicase II/RNA helicase a and hnRNP proteins in an RNA-dependent manner (2004) Nucleic Acids Res., 32, pp. 1-10; 
Takeda Y., Caudell P., Grady G., Wang G., Suwa A., Sharp G.C., Dynan W.S., Hardin J.A., Human RNA helicase a is a lupus autoantigen that is cleaved during apoptosis (1999) J. Immunol., 163, pp. 6269-6274; 
Abdelhaleem M., The actinomycin D-induced apoptosis in BCR-ABL-positive K562 cells is associated with cytoplasmic translocation and cleavage of RNA helicase a (2003) Anticancer Res., 23, pp. 485-490; 
Gibson T.J., Thompson J.D., Detection of dsRNA-binding domains in RNA helicase a and Drosophila maleless: Implications for monomeric RNA helicases (1994) Nucleic Acids Res., 22, pp. 2552-2556; 
Hung M.L., Chao P., Chang K.Y., DsRBM1 and a proline-rich domain of RNA helicase a can form a composite binder to recognize a specific dsDNA (2003) Nucleic Acids Res., 31, pp. 5741-5753; 
Nakajima T., Uchida C., Anderson S.F., Lee C.G., Hurwitz J., Parvin J.D., Montminy M., RNA helicase a mediates association of CBP with RNA polymerase II (1997) Cell, 90, pp. 1107-1112; 
Aratani S., Fujii R., Oishi T., Fujita H., Amano T., Ohshima T., Hagiwara M., Nakajima T., Dual roles of RNA helicase a in CREB-dependent transcription (2001) Mol. Cell. Biol., 21, pp. 4460-4469; 
Aratani S., Fujii R., Fujita H., Fukamizu A., Nakajima T., Aromatic residues are required for RNA helicase a mediated transactivation (2003) Int. J. Mol. Med., 12, pp. 175-180; 
Anderson S.F., Schlegel B.P., Nakajima T., Wolpin E.S., Parvin J.D., BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase a (1998) Nat. Genet., 19, pp. 254-256; 
Schlegel P., Starita L.M., Parvin J.D., Overexpression of a protein fragment of RNA helicase a causes inhibition of endogenous BRCA1 function and defects in ploidy and cytokinesis in mammary epithelial cells (2003) Oncogene, 22, pp. 983-991; 
Zhou K., Choe K.T., Zaidi Z., Wang Q., Mathews M.B., Lee C.G., RNA helicase a interacts with dsDNA and topoisomerase IIalpha (2003) Nucleic Acids Res., 31, pp. 2253-2260; 
Fuchsova B., Novak P., Kafkova J., Hozak P., Nuclear DNA helicase II is recruited to IFN-alpha-activated transcription sites at PML nuclear bodies (2002) J. Cell Biol., 158, pp. 463-473; 
Myohanen S., Baylin S.B., Sequence-specific DNA binding activity of RNA helicase a to the p16INK4a promoter (2001) J. Biol. Chem., 276, pp. 1634-1642; 
Zhang S., Herrmann C., Grosse F., Pre-mRNA and mRNA binding of human nuclear DNA helicase II (RNA helicase A) (1999) J. Cell Sci., 112 (7 PART), pp. 1055-1064; 
Tang H., Gaietta G.M., Fischer W.H., Ellisman M.H., Wong-Staal F., A cellular cofactor for the constitutive transport element of type D retrovirus (1997) Science, 276, pp. 1412-1415; 
Li J., Tang H., Mullen T.M., Westberg C., Reddy T.R., Rose D.W., Wong-Staal F., A role for RNA helicase a in post-transcriptional regulation of HIV type 1 (1999) Proc. Natl. Acad. Sci. U. S. A., 96, pp. 709-714; 
Reddy T.R., Tang H., Xu W., Wong-Staal F., Sam68, RNA helicase a and Tap cooperate in the post-transcriptional regulation of human immunodeficiency virus and type D retroviral mRNA (2000) Oncogene, 19, pp. 3570-3575; 
Tang H., Wong-Staal F., Specific interaction between RNA helicase a and Tap, two cellular proteins that bind to the constitutive transport element of type D retrovirus (2000) J. Biol. Chem., 275, pp. 32694-32700; 
Tang H., McDonald D., Middlesworth T., Hope T.J., Wong-Staal F., The carboxyl terminus of RNA helicase a contains a bidirectional nuclear transport domain (1999) Mol. Cell. Biol., 19, pp. 3540-3550; 
Fujii R., Okamoto M., Aratani S., Oishi T., Ohshima T., Taira K., Baba M., Nakajima T., A role of RNA helicase a in cis-acting transactivation response element-mediated transcriptional regulation of human immunodeficiency virus type 1 (2001) J. Biol. Chem., 276, pp. 5445-5451; 
Wei X., Pacyna-Gengelbach M., Schluns K., An Q., Gao Y., Cheng S., Petersen I., Analysis of the RNA helicase a gene in human lung cancer (2004) Oncol. Rep., 11, pp. 253-258; 
Savitsky K., Ziv Y., Bar-Shira A., Gilad S., Tagle D.A., Smith S., Uziel T., Rotman G., A human gene (DDX10) encoding a putative DEAD-box RNA helicase at 11q22-q23 (1996) Genomics, 33, pp. 199-206; 
Arai Y., Hosoda F., Kobayashi H., Arai K., Hayashi Y., Kamada N., Kaneko Y., Ohki M., The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, NUP98, with the putative RNA helicase gene DDX10 (1997) Blood, 89, pp. 3936-3944; 
Ikeda T., Ikeda K., Sasaki K., Kawakami K., Takahara J., The inv(11)(p15q22) chromosome translocation of therapy-related myelodysplasia with NUP98-DDX10 and DDX10-NUP98 fusion transcripts (1999) Int. J. Hematol., 69, pp. 160-164; 
Nakao K., Nishino M., Takeuchi K., Iwata M., Kawano A., Arai Y., Ohki M., Fusion of the nucleoporin gene, NUP98, and the putative RNA helicase gene, DDX10, by inversion 11 (p15q22) chromosome translocation in a patient with etoposide-related myelodysplastic syndrome (2000) Intern. Med., 39, pp. 412-415; 
Griffis E.R., Xu S., Powers M.A., Nup98 localizes to both nuclear and cytoplasmic sides of the nuclear pore and binds to two distinct nucleoporin subcomplexes (2003) Mol. Biol. Cell, 14, pp. 600-610; 
Martin A., Schneider S., Schwer B., Prp43 is an essential RNA-dependent ATPase required for release of lariat-intron from the spliceosome (2002) J. Biol. Chem., 277, pp. 17743-17750; 
Meng X., Liu J., Shen Z., Genomic structure of the human BCCIP gene and its expression in cancer (2003) Gene, 302, pp. 139-146; 
Liu J., Yuan Y., Huan J., Shen Z., Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionarily conserved nuclear protein that interacts with BRCA2 (2001) Oncogene, 20, pp. 336-345; 
Martelange V., De Smet C., De Plaen E., Lurquin C., Boon T., Identification on a human sarcoma of two new genes with tumor-specific expression (2000) Cancer Res., 60, pp. 3848-3855; 
Doorbar J., Elston R.C., Napthine S., Raj K., Medcalf E., Jackson D., Coleman N., Dunlop J., The E1E4 protein of human papillomavirus type 16 associates with a putative RNA helicase through sequences in its C terminus (2000) J. Virol., 74, pp. 10081-10095; 
Holzmann K., Gerner C., Poltl A., Schafer R., Obrist P., Ensinger C., Grimm R., Sauermann G., A human common nuclear matrix protein homologous to eukaryotic translation initiation factor 4A (2000) Biochem. Biophys. Res. Commun., 267, pp. 339-344; 
Lee S., Baek M., Yang H., Bang Y.J., Kim W.H., Ha J.H., Kim D.K., Jeoung D.I., Identification of genes differentially expressed between gastric cancers and normal gastric mucosa with cDNA microarrays (2002) Cancer Lett., 184, pp. 197-206; 
Cho B., Lim Y., Lee D.Y., Park S.Y., Lee H., Kim W.H., Yang H., Jeoung D.I., Identification and characterization of a novel cancer/testis antigen gene CAGE (2002) Biochem. Biophys. Res. Commun., 292, pp. 715-726; 
Cho B., Lee H., Jeong S., Bang Y.J., Lee H.J., Hwang K.S., Kim H.Y., Jeoung D.I., Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma (2003) Biochem. Biophys. Res. Commun., 307, pp. 52-63; 
Xu Q., Lee C., Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences (2003) Nucleic Acids Res., 31, pp. 5635-5643; 
Jiang Z.H., Wu J.Y., Alternative splicing and programmed cell death (1999) Proc. Soc. Exp. Biol. Med., 220, pp. 64-72; 
Stickeler E., Kittrell F., Medina D., Berget S.M., Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis (1999) Oncogene, 18, pp. 3574-3582; 
Clemens M.J., Bommer U.A., Translational control: The cancer connection (1999) Int. J. Biochem. Cell Biol., 31, pp. 1-23; 
De Benedetti, Harris A.L., EIF4E expression in tumors: Its possible role in progression of malignancies (1999) Int. J. Biochem. Cell Biol., 31, pp. 59-72; 
Dua K., Williams T.M., Beretta L., Translational control of the proteome: Relevance to cancer (2001) Proteomics, 1, pp. 1191-1199; 
Watkins S.J., Norbury C.J., Translation initiation and its deregulation during tumorigenesis (2002) Br. J. Cancer, 86, pp. 1023-1027; 
Meric F., Hunt K.K., Translation initiation in cancer: A novel target for therapy (2002) Mol. Cancer Ther., 1, pp. 971-979; 
Calkhoven C.F., Muller C., Leutz A., Translational control of gene expression and disease (2002) Trends Mol. Med., 8, pp. 577-583; 
Ruggero D., Pandolfi P.P., Does the ribosome translate cancer? (2003) Nat. Rev., Cancer, 3, pp. 179-192; 
Graff J.R., Zimmer S.G., Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs (2003) Clin. Exp. Metastasis, 20, pp. 265-273; 
Stoneley M., Willis A.E., Aberrant regulation of translation initiation in tumorigenesis (2003) Curr. Mol. Med., 3, pp. 597-603
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-3042669445&partnerID=40&md5=4af369021a86ac76e260032e770f7208
ER  - 

TY  - JOUR
TI  - B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos
T2  - Oncogene
VL  - 19
IS  - 14
SP  - 1752
EP  - 1763
PY  - 2000
AU  - Echlin D.R.
AU  - Tae H.-J.
AU  - Mitin N.
AU  - Taparowsky E.J.
N1  - 施引文献 :50
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Angel P., Karin M., (1991) Biochim. Biophys. Acta, 1072, pp. 129-157; 
Aronheim A., Zandi E., Hennemann H.S., Elledge S.J., Karin M., (1997) Mol. Cell. Biol., 17, pp. 3094-3102; 
Bohmann D., Bos T.J., Admon A., Nishimura T., Vogt P.K., Tjian R., (1987) Science, 238, pp. 1386-1392; 
Bossy-Wetzel E., Bakiri L., Yaniv M., (1997) EMBO J., 16, pp. 1695-1709; 
Brown P.H., Chen T.K., Birrer M.J., (1994) Oncogene, 9, pp. 791-799; 
Brown P.H., Alani R., Preis L.H., Szabo E., Birrer M.J., (1993) Oncogene, 8, pp. 877-886; 
Carrozza M.L., Jacobs H., Acton D., Verma I., Berns A., (1997) Oncogene, 14, pp. 1083-1091; 
Chen B.P.C., Liang G., Whelan J., Hai T., (1994) J. Biol. Chem., 269, pp. 15819-15826; 
Colotta F., Polentarutti N., Sironi M., Mantovani A., (1992) J. Biol. Chem., 267, pp. 18278-18283; 
Dang C.V., Barrett J., Villa-Garcia M., Resar M.S., Kato G.J., Fearon E.R., (1991) Mol. Cell. Biol., 11, pp. 954-962; 
Davenport E.A., Taparowsky E.J., (1992) Exp. Cell Res., 202, pp. 532-540; 
Davis R.L., Weintraub H., Lassar A.B., (1987) Cell, 51, pp. 987-1000; 
Dorsey M.J., Tae H.-J., Sollenberger K.G., Mascarenhas N.T., Johansen L.M., Taparowsky E.J., (1995) Oncogene, 11, pp. 2255-2265; 
Foletta V.C., Segal D.H., Cohen D.R., (1998) J. Leuk. Biol., 63, pp. 139-152; 
Fujiwara K.T., Kataoka K., Nishizawa M., (1993) Oncogene, 8, pp. 2371-2380; 
Glover J.N.M., Harrison S.C., (1995) Nature, 373, pp. 257-261; 
Grigoriadis A.E., Schellander K., Wang Z.-Q., Wagner E.F., (1993) J. Cell Biol., 122, pp. 685-701; 
Hai T., Curran T., (1991) Proc. Natl. Acad. Sci. USA, 88, pp. 3720-3724; 
Ham J., Babij C., Whitfield J., Pfarr C.M., Lallemand D., Yaniv M., Rubin L.L., (1995) Neuron, 14, pp. 927-939; 
Hasegawa H., Utsunomiya Y., Kishimoto K., Tange Y., Yasukawa M., Fujita S., (1996) Biochem. Biophys. Res. Comm., 222, pp. 164-170; 
Hsu J.-C., Laz T., Mohn K.L., Taub R., (1991) Proc. Natl. Acad. Sci. USA, 88, pp. 3511-3515; 
Johnson R., Spiegelman B., Hanahan D., Wisdom R., (1996) Mol. Cell. Biol., 16, pp. 4504-4511; 
Johnson R.S., Van Lingen B., Papaioannou V.E., Spiegelman B.M., (1993) Genes Dev., 7, pp. 1309-1317; 
Karin M., Liu Z.-G., Zandi E., (1997) Curr. Opin. Cell Biol., 9, pp. 240-246; 
Kataoka K., Igarashi K., Itoh K., Fujiwara K.T., Noda M., Yamamoto M., Nishizawa M., (1995) Mol. Cell. Biol., 15, pp. 2180-2190; 
Kataoka K., Noda M., Nishizawa M., (1994) Mol. Cell. Biol., 14, pp. 700-712; 
Kerppola T.K., Curran T., (1991) Curr. Opin. Struct. Biol., 1, pp. 71-79; 
Kerppola T.K., Curran T., (1994) Oncogene, 9, pp. 675-684; 
Lemercier C., To R.Q., Swanson B.J., Lyons G.E., Konieczny S.F., (1997) Dev. Biol., 182, pp. 101-113; 
Lloyd A., Yancheva N., Wasylyk B., (1991) Nature, 352, pp. 635-638; 
Meyer N.P., Johansen L.M., Tae H.-J., Budde P.P., Williams K.L., Taparowsky E.J., (1998) Mammal. Genome, 9, pp. 849-852; 
Miller A.D., Verma I.M., Curran T., (1985) J. Virol., 55, pp. 521-526; 
Min S., Crider-Miller S.J., Taparowsky E.J., (1994) Cell Growth Differ., 5, pp. 563-573; 
Min S., Taparowsky E.J., (1992) Oncogene, 7, pp. 1531-1540; 
Nakabeppu Y., Nathans D., (1991) Cell, 64, pp. 751-759; 
Olive M., Krylov D., Echlin D.R., Gardner K., Taparowsky E.J., Vinson C., (1997) J. Biol. Chem., 272, pp. 18586-18594; 
Pfarr C.M., Mechta F., Spyrou G., Lallemand D., Carillo S., Yaniv M., (1994) Cell, 76, pp. 747-760; 
Ramocki M.B., Johnson S.E., White M.A., Ashendel C.L., Konieczny S.F., Taparowsky E.J., (1997) Mol. Cell. Biol., 17, pp. 3547-3555; 
Sambrook J., Fritsch E.F., Mainiatis T., (1989) Molecular Cloning: A Laboratory Manual, , Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY; 
Sassone-Corsi P., (1995) Ann. Rev. Cell Dev. Biol., 11, pp. 355-377; 
Schreiber M., Kolbus A., Piu F., Szabowski A., Möhle-Steinlein U., Tian J., Karin M., Wagner E.F., (1999) Genes Dev., 13, pp. 607-619; 
Smeal T., Binetruy B., Mercola D.A., Birrer M., Karin M., (1991) Nature, 354, pp. 494-496; 
Smeyne R.J., Vendrell M., Hayward M., Baker S.J., Miao G.G., Schilling L.M., Robertson L.M., Morgan J., (1993) Nature, 363, pp. 166-169; 
Taparowsky E.J., Suard Y., Fasano O., Shimizu K., Goldfarb M., Wigler M., (1982) Nature, 300, pp. 762-764; 
Teegarden D., Taparowsky E.J., Kent C., (1990) J. Biol. Chem., 265, pp. 6042-6047; 
Vandel L., Montreau N., Vial E., Pfarr C.M., Binetruy B., Castellazzi M., (1996) Mol. Cell. Biol., 16, pp. 1881-1888; 
Vogt P.K., Bos T.J., (1990) Adv. Cancer Res., 55, pp. 1-35; 
Wang C.-Y., Bassuk A.C., Boise L.H., Thompson C.B., Bravo R., Leiden J.M., (1994) Mol. Cell. Biol., 14, pp. 1153-1159; 
Wang H., Zirong X., Scott R.E., (1996) J. Cell Biol., 135, pp. 1151-1162; 
Wang X., Peters M.A., Utama F.E., Wang Y., Taparowsky E.J., (1999) Mol. Endocrinol., 13, pp. 254-267; 
Wick M., Lucibello F.C., Müller R., (1992) Oncogene, 7, pp. 859-867; 
Wisdom R., Johnson R.S., Moore C., (1999) EMBO J., 18, pp. 188-197; 
Xanthoudakis S., Curan T., (1996) Biological Reactive Intermediates V, , Snyder R et al. (eds), Plenum Press: New York
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-0000448132&partnerID=40&md5=a2e8877188929d572177756c86128cf7
ER  - 

TY  - JOUR
TI  - Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation
T2  - Molecular Cancer Research
VL  - 3
IS  - 6
SP  - 355
EP  - 363
PY  - 2005
DO  - 10.1158/1541-7786.MCR-05-0022
AU  - Yang L.
AU  - Lin C.
AU  - Liu Z.-R.
N1  - 施引文献 :44
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Crawford L., Leppard K., Lane D., Harlow E., Cellular proteins reactive with monoclonal antibodies directed against simian virus 40 T-antigen (1982) J Virol, 42, pp. 612-620; 
Lane D.P., Hoeffler W.K., SV40 large T shares an antigenic determinant with a cellular protein of molecular weight 68,000 (1980) Nature, 288, pp. 167-170; 
Iggo R.D., Lane D.P., Nuclear protein p68 is an RNA-dependent ATPase (1989) EMBO J, 8, pp. 1827-1831; 
Ford M.J., Anton I.A., Lane D.P., Nuclear protein with sequence homology to translation initiation factor cIF-4A (1988) Nature, 332, pp. 736-738; 
Hirling H., Scheffner M., Restle T., Stahl H., RNA helicase activity associated with the human p68 protein (1989) Nature, 339, pp. 562-564; 
Huang Y., Liu Z.R., The ATPase. RNA unwinding, and RNA binding activities of recombinant p68 RNA helicase (2002) J Biol Chem, 277, pp. 12810-12815; 
Rossler O.G., Straka A., Stahl H., Rearrangement of structured RNA via branch migration structures catalysed by the highly related DEAD-box proteins p68 and p72 (2001) Nucleic Acids Res, 29, pp. 2088-2096; 
Schmid S.R., Linder P., D-E-A-D protein family of putative RNA helicases (1992) Mol Microbiol, 6, pp. 283-291; 
Endoh H., Maruyama K., Masuhiro Y., Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor α (1999) Mol Cell Biol, 19, pp. 5363-5372; 
Fujita T., Kobayashi Y., Wada O., Full activation of estrogen receptor α activation function-1 induces proliferation of breast cancer cells (2003) J Biol Chem, 278, pp. 26704-26714; 
Watanabe M., Yanagisawa J., Kitagawa H., A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor α coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA (2001) EMBO J, 20, pp. 1341-1352; 
Rossow K.L., Janknecht R., Synergism between p68 RNA helicase and the transcriptional coactivators CBP and p300 (2003) Oncogene, 22, pp. 151-156; 
Bates G.J., Nicol S.M., Wilson B.J., The DEAD box protein p68: A novel transcriptional coactivator of the p53 tumour suppressor (2005) EMBO J, 24, pp. 543-553; 
Metivier R., Penot G., Hubner M.R., Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter (2003) Cell, 115, pp. 751-763; 
Jost J.P., Schwarz S., Hess D., A chicken embryo protein related to the mammalian DEAD box protein p68 is tightly associated with the highly purified protein-RNA complex of 5-MeC-DNA glycosylase (1999) Nucleic Acids Res, 27, pp. 3245-3252; 
Liu Z.R., P68 RNA Helicase Is an Essential Human Splicing Factor That Acts at the U1 snRNA-5′ Splice Site Duplex (2002) Mol Cell Biol, 22, pp. 5443-5450; 
Liu Z.R., Sargueil B., Smith C.W., Detection of a novel ATP-dependent crosslinked protein at the 5′ splice site-U1 small nuclear RNA duplex by methylene blue-mediated photo-cross-linking (1998) Mol Cell Biol, 18, pp. 6910-6920; 
Hartmuth K., Urlaub H., Vornlocher H.P., Protein composition of human prespliceosomes isolated by a tobramycin affinity-selection method (2002) Proc Natl Acad Sci U S A, 99, pp. 16719-16724; 
Honig A., Auboeuf D., Parker M.M., O'Malley B.W., Berget S.M., Regulation of alternative splicing by the ATP-dependent DEAD-box RNA helicase p72 (2002) Mol Cell Biol, 22, pp. 5698-5707; 
Guil S., Gattoni R., Carrascal M., Abian J., Stevenin J., Bach-Elias M., Roles of hnRNP A1, SR proteins, and p68 helicase in c-H-ras alternative splicing regulation (2003) Mol Cell Biol, 23, pp. 2927-2941; 
Jurica M.S., Licklider L.J., Gygi S.R., Grigorieff N., Moore M.J., Purification and characterization of native spliceosomes suitable for three-dimensional structural analysis (2002) RNA, 8, pp. 426-439; 
Heinlein U.A., Dead box for the living (1998) J Pathol, 184, pp. 345-347; 
Stevenson R.J., Hamilton S.J., MacCallum D.E., Hall P.A., Fuller-Pace F.V., Expression of the 'dead box' RNA helicase p68 is developmentally and growth regulated and correlates with organ differentiation/maturation in the fetus (1998) J Pathol, 184, pp. 351-359; 
Dubey P., Hendrickson R.C., Meredith S.C., The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68 (1997) J Exp Med, 185, pp. 695-705; 
Causevic M., Hislop R.G., Kernohan N.M., Overexpression and polyubiquitylation of the DEAD-box RNA heliease p68 in colorectal tumours (2001) Oncogene, 20, pp. 7734-7743; 
Wei Y., Hu M.H., The study of p68 RNA helicase on cell transformation (2001) Yi Chuan Xue Bao, 28, pp. 991-996; 
Yang L., Yang J., Huang Y., Liu Z.R., Phosphorylation of p68 RNA helicase regulates RNA binding by the C-terminal domain of the protein (2004) Biochem Biophys Res Commun, 314, pp. 622-630; 
Buelt M.K., Glidden B.J., Storm D.R., Regulation of p68 RNA helicase by calmodulin and protein kinase C (1994) J Biol Chem, 269, pp. 29367-29370; 
Akileswaran L., Taraska J.W., Sayer J.A., Gettemy J.M., Coghlan V.M., A-kinase-anchoring protein AKAP95 is targeted to the nuclear matrix and associates with p68 RNA helicase (2001) J Biol Chem, 276, pp. 17448-17454; 
Yang L., Lin C., Liu Z.-R., Signaling to the DEAD box-regulation of DEAD-box p68 RNA helicase by protein phosporylation (2005) Cell Signaling, , In press; 
Fitzpatrick D.R., Peroni D.J., Bielefeldt-Ohmann H., The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma (1995) Am J Respir Cell Mol Biol, 12, pp. 455-460; 
Heldin C.H., Structural and functional studies on platelet-derived growth factor (1992) EMBO J, 11, pp. 4251-4259; 
Gaur U., Aggarwal B.B., Regulation of proliferation, survival and apoptosis by members of the TNF superfamily (2003) Biochem Pharmacol, 66, pp. 1403-1408; 
Wong W.S., Leong K.P., Tyrosine kinase inhibitors: A new approach for asthma (2004) Biochim Biophys Acta, 1697, pp. 53-69; 
Ashikawa K., Majumdar S., Banerjee S., Bharti A.C., Shishodia S., Aggarwal B.B., Piceatannol inhibits TNF-induced NF-κB activation and NF-κB-mediated gene expression through suppression of IκBα kinase and p65 phosphorylation (2002) J Immunol, 169, pp. 6490-6497; 
Nakagami H., Cui T.X., Iwai M., Tumor necrosis factor-α inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells (2002) Arterioscler Thromb Vasc Biol, 22, pp. 238-242; 
Varfolomeev E.E., Ashkenazi A., Tumor necrosis factor: An apoptosis JuNKie? (2004) Cell, 116, pp. 491-497; 
Roskoski Jr. R., STI-571: An anticancer protein-tyrosine kinase inhibitor (2003) Biochem Biophys Res Commun, 309, pp. 709-717; 
Goldman J.M., Melo J.V., Chronic myeloid leukemia-advances in biology and new approaches to treatment (2003) N Engl J Med, 349, pp. 1451-1464; 
Hubbard S.R., Protein tyrosine kinases: Autoregulation and small-molecule inhibition (2002) Curr Opin Struct Biol, 12, pp. 735-741; 
Vlahovic G., Crawford J., Activation of tyrosine kinases in cancer (2003) Oncologist, 8, pp. 531-538; 
Liu Z.R., Laggerbauer B., Luhrmann R., Smith C.W., Cross-linking of the U5 snRNP-specific 116-kDa protein to RNA hairpins that block step 2 of splicing (1997) RNA, 3, pp. 1207-1219
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-21344459251&partnerID=40&md5=c304cd0e5a06f0f2ea75b50edb06f2d0
ER  - 

TY  - JOUR
TI  - Transcriptional factor FOXL2 interacts with DP103 and induces apoptosis
T2  - Biochemical and Biophysical Research Communications
VL  - 336
IS  - 3
SP  - 876
EP  - 881
PY  - 2005
DO  - 10.1016/j.bbrc.2005.08.184
AU  - Lee K.
AU  - Pisarska M.D.
AU  - Ko J.-J.
AU  - Kang Y.
AU  - Yoon S.
AU  - Ryou S.-M.
AU  - Cha K.-Y.
AU  - Bae J.
N1  - 施引文献 :42
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Coulam C.B., Premature gonadal failure (1982) Fertil. Steril., 38, pp. 645-655; 
Simpson J.L., Rajkovic A., Ovarian differentiation and gonadal failure (1999) Am. J. Med. Genet., 89, pp. 186-200; 
Santoro N., Research on the mechanisms of premature ovarian failure (2001) J. Soc. Gynecol. Investig., 8, pp. 10-S12; 
Schlessinger D., Herrera L., Crisponi L., Mumm S., Percesepe A., Pellegrini M., Pilia G., Forabosco A., Genes and translocations involved in POF (2002) Am. J. Med. Genet., 111, pp. 328-333; 
Laml T., Preyer O., Umek W., Hengstschlager M., Hanzal H., Genetic disorders in premature ovarian failure (2002) Hum. Reprod. Update, 8, pp. 483-491; 
Crisponi L., Deiana M., Loi A., Chiappe F., Uda M., Amati P., Bisceglia L., Pilia G., The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome (2001) Nat. Genet., 27, pp. 159-166; 
Prueitt R.L., Zinn A.R., A fork in the road to fertility (2001) Nat. Genet., 27, pp. 132-134; 
Nikic S., Vaiman D., Conserved patterns of gene expression in mice and goats in the vicinity of the Polled Intersex Syndrome (PIS) locus (2004) Chromosome Res., 12, pp. 465-474; 
Wang D., Kobayashi T., Zhou L., Nagahama Y., Molecular cloning and gene expression of Foxl2 in the Nile tilapia, Oreochromis niloticus (2004) Biochem. Biophys. Res. Commun., 320, pp. 83-89; 
Baron D., Houlgatte R., Fostier A., Guiguen Y., Large-scale temporal gene expression profiling during gonadal differentiation and early gametogenesis in Rainbow Trout (2005) Biol. Reprod.; 
Baron D., Batista F., Chaffaux S., Cocquet J., Cotinot C., Cribiu E., De Baeree E., Fellous M., Foxl2 gene and the development of the ovary: A story about goat, mouse, fish and woman (2005) Reprod. Nutr., pp. 377-382; 
Baumstark A., Hameister H., Hakhverdyan M., Bakloushinskaya I., Just W., Characterization of Pisrt1/Foxl2 in Ellobius lutescens and exclusion as sex-determining genes (2005) Mamm. Genome, 16, pp. 281-289; 
Adell T., Muller W.E., Isolation and characterization of five Fox (Forkhead) genes from the sponge Suberites domuncula (2004) Gene, 334, pp. 35-46; 
Baron D., Cocquet J., Xia X., Fellous M., Guiguen Y., Veitia R.A., An evolutionary and functional analysis of FoxL2 in rainbow trout gonad differentiation (2004) J. Mol. Endocrinol., 33, pp. 705-715; 
Pisarska M.D., Bae J., Klein C., Hsueh A.J., Forkhead l2 is expressed in the ovary and represses the promoter activity of the steroidogenic acute regulatory gene (2004) Endocrinology, 145, pp. 3424-3433; 
Uda M., Ottolenghi C., Crisponi L., Garcia J.E., Deiana M., Kimber W., Forabosco A., Pilia G., Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development (2004) Hum. Mol. Genet., 13, pp. 1171-1181; 
Schmidt D., Ovitt C.E., Anlag K., Fehsenfeld S., Gredsted L., Treier A.C., Treier M., The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance (2004) Development, 131, pp. 933-942; 
Baker T.G., Study of germ cells in human ovaries (1963) Proc. R. Soc. Lond. B. Biol. Sci., 158, pp. 417-433; 
Tilly J.L., Kowalski K.I., Johnson A.L., Hsueh A.J., Involvement of apoptosis in ovarian follicular atresia and postovulatory regression (1991) Endocrinology, 129, pp. 2799-2801; 
Hughes Jr. F.M., Gorospe W.C., Biochemical identification of apoptosis (programmed cell death) in granulosa cells: Evidence for a potential mechanism underlying follicular atresia (1991) Endocrinology, 129, pp. 2415-2422; 
Gosden R.G., Follicular status at the menopause (1987) Hum. Reprod., 2, pp. 617-621; 
Kaipia A., Hsueh A.J., Regulation of ovarian follicle atresia (1997) Annu. Rev. Physiol., 59, pp. 349-363; 
Hsu S.Y., Hsueh A.J., Intracellular mechanisms of ovarian cell apoptosis (1998) Mol. Cell. Endocrinol., 145, pp. 21-25; 
Grundhoff A.T., Kremmer E., Tureci O., Glieden A., Gindorf C., Atz J., Mueller-Lantzsch N., Grasser F.A., Characterization of DP103, a novel DEAD box protein that binds to the Epstein-Barr virus nuclear proteins EBNA2 and EBNA3C (1999) J. Biol. Chem., 274, pp. 19136-19144; 
Gillian A.L., Svaren J., The Ddx20/DP103 dead box protein represses transcriptional activation by Egr2/Krox-20 (2004) J. Biol. Chem., 279, pp. 9056-9093; 
Ou Q., Mouillet J.F., Yan X., Dorn C., Crawford P.A., Sadovsky Y., The DEAD box protein DP103 is a regulator of steroidogenic factor-1 (2001) Mol. Endocrinol., 15, pp. 69-79; 
Campbell L., Hunter K.M., Mohaghegh P., Tinsley J.M., Brasch M.A., Davies K.E., Direct interaction of Smn with dp103, a putative RNA helicase: A role for Smn in transcription regulation? (2000) Hum. Mol. Genet., 9, pp. 1093-1100; 
Lee M.B., Lebedeva L.A., Suzawa M., Wadekar S.A., Desclozeaux M., Ingraham H.A., The DEAD-box protein DP103 (Ddx20 or Gemin-3) represses orphan nuclear receptor activity via SUMO modification (2005) Mol. Cell. Biol., 25, pp. 1879-1890; 
Hsu S.Y., Kaipia A., Zhu L., Hsueh A.J., Interference of BAD (Bcl-xL/Bcl-2-associated death promoter)-induced apoptosis in mammalian cells by 14-3-3 isoforms and P11 (1997) Mol. Endocrinol., 11, pp. 1858-1867; 
Bae J., Donigian J.R., Hsueh A.J., Tankyrase 1 interacts with Mcl-1 proteins and inhibits their regulation of apoptosis (2003) J. Biol. Chem., 278, pp. 5195-5204; 
Xue D., Horvitz H.R., Inhibition of the Caenorhabditis elegans cell-death protease CED-3 by a CED-3 cleavage site in baculovirus p35 protein (1995) Nature, 377, pp. 248-251; 
Kaufmann E., Knochel W., Five years on the wings of fork head (1996) Mech. Dev., pp. 3-20; 
Kaestner K.H., Knochel W., Martinez D.E., Unified nomenclature for the winged helix/forkhead transcription factors (2000) Genes Dev., 14, pp. 142-146; 
Bernasconi M., Remppis A., Fredericks W.J., Rauscher III F.J., Schafer B.W., Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins (1996) Proc. Natl. Acad. Sci. USA, 93, pp. 13164-13169; 
Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Greenberg M.E., Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor (1999) Cell, 96, pp. 857-868; 
Blixt A., Mahlapuu M., Aitola M., Pelto-Huikko M., Enerback S., Carlsson P., A forkhead gene, FoxE3, is essential for lens epithelial proliferation and closure of the lens vesicle (2000) Genes Dev., 14, pp. 245-254; 
Nakamura N., Ramaswamy S., Vazquez F., Signoretti S., Loda M., Sellers W.R., Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN (2000) Mol. Cell. Biol., 20, pp. 8969-8982; 
Tang T.T., Dowbenko D., Jackson A., Toney L., Lewin D.A., Dent A.L., Lasky L.A., The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor (2002) J. Biol. Chem., 277, pp. 14255-14265; 
Kops G.J., Medema R.H., Glassford J., Essers M.A., Dijkers P.F., Coffer P.J., Lam E.W., Burgering B.M., Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors (2002) Mol. Cell. Biol., 22, pp. 2025-2036; 
Kops G.J., Dansen T.B., Polderman P.E., Saarloos I., Wirtz K.W., Coffer P.J., Huang T.T., Burgering B.M., Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress (2002) Nature, 419, pp. 316-321; 
Kops G.J., De Ruiter N.D., De Vries-Smits A.M., Powell D.R., Bos J.L., Burgering B.M., Direct control of the Forkhead transcription factor AFX by protein kinase B (1999) Nature, 398, pp. 630-634; 
Tang E.D., Nunez G., Barr F.G., Guan K.L., Negative regulation of the forkhead transcription factor FKHR by Akt (1999) J. Biol. Chem., 274, pp. 16741-16746; 
Morris J.B., Kenney B., Huynh H., Woodcock E.A., Regulation of the pro-apoptotic factor FOXO1 (FKHR) in cardiomyocytes by growth factors and {alpha}1-adrenergic agonists (2005) Endocrinology; 
Gilley J., Coffer P.J., Ham J., FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons (2003) J. Cell. Biol., 162, pp. 613-622; 
Urbich C., Knau A., Fichtlscherer S., Walter D.H., Bruhl T., Potente M., Hofmann W.K., Dimmeler S., FOXO-dependent expression of the proapoptotic protein Bim: Pivotal role for apoptosis signaling in endothelial progenitor cells (2005) FASEB J., 19, pp. 974-976; 
Stahl M., Dijkers P.F., Kops G.J., Lens S.M., Coffer P.J., Burgering B.M., Medema R.H., The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2 (2002) J. Immunol., 168, pp. 5024-5031; 
Bakke M., Zhao L., Hanley N.A., Parker K.L., SF-1: A critical mediator of steroidogenesis (2001) Mol. Cell. Endocrinol., 171, pp. 5-7
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-25144456097&partnerID=40&md5=f69271cf050fafd09fd6ba204cc3caba
ER  - 

TY  - JOUR
TI  - Candidate functional promoter variant in the FOXD3 melanoblast developmental regulator gene in autosomal dominant vitiligo [4]
T2  - Journal of Investigative Dermatology
VL  - 125
IS  - 2
SP  - 388
EP  - 391
PY  - 2005
DO  - 10.1111/j.0022-202X.2005.23822.x
AU  - Alkhateeb A.
AU  - Fain P.R.
AU  - Spritz R.A.
N1  - 施引文献 :40
N1  - Export Date: 2 January 2016
TY  - Letter
DB  - Scopus
N1  - 参考文献: Alkhateeb A., Fain P.R., Thody T., Bennett D.C., Spritz R.A., Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families (2003) Pigment Cell Res, 16, pp. 208-214; 
Alkhateeb A., Stetler G.L., Old W., Mapping of an autoimmunity susceptibility locus (AISI) to chromosome 1p31.3-p32.2 (2002) Hum Mol Genet, 11, pp. 661-667; 
Dottori M., Gross M.K., Labosky P., Goulding M., The winged-helix transcription factor Foxd3 suppresses interneuron differentiation and promotes neural crest cell fate (2001) Development, 128, pp. 4127-4138; 
Guo Y., Costa R., Ramsey H., The embryonic stem cell transcription factors Oct-4 and FoxD3 interact to regulate endodermal-specific promoter expression (2002) Proc Natl Acad Sci USA, 99, pp. 3663-3667; 
Hahn S.-K., Nordlund J.J., (2000) Vitiligo, , Oxford: Blackwell Science; 
Hromas R., Ye H., Spinella M., Dmitrovsky E., Xu D., Costa R.H., Genesis, a Winged Helix transcriptional repressor, has embryonic expression limited to the neural crest, and stimulates proliferation in vitro in a neural development model (1999) Cell Tissue Res, 297, pp. 371-382; 
Kos R., Reedy M.V., Johnson R.L., Erickson C.A., The winged-helix transcription factor FoxD3 is important for establishing the neural crest lineage and repressing melanogenesis in avian embryos (2001) Development, 128, pp. 1467-1479; 
Sutton J., Costa R., Klug M., Genesis, a winged helix transcriptional represser with expression restricted to embryonic stem cells (1996) J Biol Chem, 271, pp. 23126-23133
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-24344441593&partnerID=40&md5=d99e51d046e094da221529e024f9c71d
ER  - 

TY  - JOUR
TI  - Thyroid cancer susceptibility polymorphisms: Confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24
T2  - Journal of Medical Genetics
VL  - 49
IS  - 3
SP  - 158
EP  - 163
PY  - 2012
DO  - 10.1136/jmedgenet-2011-100586
AU  - Jones A.M.
AU  - Howarth K.M.
AU  - Martin L.
AU  - Gorman M.
AU  - Mihai R.
AU  - Moss L.
AU  - Auton A.
AU  - Lemon C.
AU  - Mehanna H.
AU  - Mohan H.
AU  - Clarke S.E.M.
AU  - Wadsley J.
AU  - Macias E.
AU  - Coatesworth A.
AU  - Beasley M.
AU  - Roques T.
AU  - Martin C.
AU  - Ryan P.
AU  - Gerrard G.
AU  - Power D.
AU  - Bremmer C.
AU  - Tomlinson I.
AU  - Carvajal-Carmona L.G.
AU  - Scrase C.
AU  - Goodman A.
AU  - Gildersleve J.
AU  - Robinson A.
AU  - Brammer C.
AU  - Mohan H.K.
AU  - Clarke S.E.
AU  - Goodchild K.
AU  - Hamid A.
AU  - Sharp J.
AU  - Coatsworth M.A.
AU  - Courtney H.
AU  - Whitaker S.
AU  - Wood K.
AU  - McCaul J.
AU  - Ashford C.
AU  - Loo V.
AU  - Marshall J.
AU  - Roy A.
AU  - Simpson J.
AU  - Rowell N.
AU  - Babu M.E.
AU  - Srihari N.
AU  - Ellenbogen M.S.
AU  - Jamil A.
N1  - 施引文献 :35
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Kondo T., Ezzat S., Asa S.L., Pathogenetic mechanisms in thyroid follicular-cell neoplasia (2006) Nat Rev Cancer, 6, pp. 292-306; 
Goldgar D.E., Easton D.F., Cannon-Albright L.A., Skolnick M.H., Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands (1994) J Natl Cancer Inst, 86, pp. 1600-1608; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Jonasson J.G., Sigurdsson A., Bergthorsson J.T., He H., Stefansson K., Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations (2009) Nat Genet, 41, pp. 460-464; 
Jazdzewski K., Liyanarachchi S., Swierniak M., Pachucki J., Ringel M.D., Jarzab B., de la Chapelle A., Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer (2009) Proc Natl Acad Sci U S A, 106, pp. 1502-1505; 
Ruiz-Llorente S., Montero-Conde C., Milne R.L., Moya C.M., Cebrian A., Leton R., Cascon A., Robledo M., Association study of 69 genes in the ret pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma (2007) Cancer Res, 67, pp. 9561-9567; 
Wokolorczyk D., Gliniewicz B., Sikorski A., Zlowocka E., Masojc B., Debniak T., Matyjasik J., Cybulski C., A range of cancers is associated with the rs6983267 marker on chromosome 8 (2008) Cancer Res, 68, pp. 9982-9986; 
Klonisch T., Hoang-Vu C., Hombach-Klonisch S., Thyroid stem cells and cancer (2009) Thyroid, 19, pp. 1303-1315; 
Craddock N., Hurles M.E., Cardin N., Pearson R.D., Plagnol V., Robson S., Vukcevic D., Donnelly P., Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls (2010) Nature, 464, pp. 713-720. , Wellcome Trust Case Control Consortium; 
Tomlinson I., Webb E., Carvajal-Carmona L., Broderick P., Kemp Z., Spain S., Penegar S., Houlston R., A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21 (2007) Nat Genet, 39, pp. 984-988; 
Howie B.N., Donnelly P., Marchini J., A flexible and accurate genotype imputation method for the next generation of genome-wide association studies (2009) PLoS Genet, 5, pp. e1000529; 
Carvajal-Carmona L.G., Cazier J.B., Jones A.M., Howarth K., Broderick P., Pittman A., Dobbins S., Tomlinson I., Fine-mapping of colorectal cancer susceptibility loci at 8q23.3, 16q22.1 and 19q13.11: refinement of association signals and use of in silico analysis to suggest functional variation and unexpected candidate target genes (2011) Hum Mol Genet, 20, pp. 2879-2888; 
Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sham P.C., PLINK: a tool set for whole-genome association and population-based linkage analyses (2007) Am J Hum Genet, 81, pp. 559-575; 
Marchini J., Howie B., Myers S., McVean G., Donnelly P., A new multipoint method for genome-wide association studies by imputation of genotypes (2007) Nat Genet, 39, pp. 906-913; 
Barrett J.C., Fry B., Maller J., Haploview: analysis and visualization of LD and haplotype maps (2005) Bioinformatics, 21, pp. 263-265; 
Houlston R.S., Webb E., Broderick P., Pittman A.M., Di Bernardo M.C., Lubbe S., Chandler I., Dunlop M.G., Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer (2008) Nat Genet, 40, pp. 1426-1435; 
Carvajal-Carmona L.G., Challenges in the identification and use of rare diseaseassociated predisposition variants (2010) Curr Opin Genet Dev, 20, p. 5; 
Tuupanen S., Turunen M., Lehtonen R., Hallikas O., Vanharanta S., Kivioja T., Bjorklund M., Aaltonen L.A., The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling (2009) Nat Genet, 41, pp. 885-890; 
He H., Jazdzewski K., Li W., Liyanarachchi S., Nagy R., Volinia S., Calin G.A., de la Chapelle A., The role of microRNA genes in papillary thyroid carcinoma (2005) Proc Natl Acad Sci U S A, 102, pp. 19075-19080
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-84860306298&partnerID=40&md5=91d94ef74c76c21a8f6ca10dae2d56f5
ER  - 

TY  - JOUR
TI  - Replication of breast cancer GWAS susceptibility loci in the women's health initiative African American SHARe study
T2  - Cancer Epidemiology Biomarkers and Prevention
VL  - 20
IS  - 9
SP  - 1950
EP  - 1959
PY  - 2011
DO  - 10.1158/1055-9965.EPI-11-0524
AU  - Hutter C.M.
AU  - Young A.M.
AU  - Ochs-Balcom H.M.
AU  - Carty C.L.
AU  - Wang T.
AU  - Chen C.T.L.
AU  - Rohan T.E.
AU  - Kooperberg C.
AU  - Peters U.
N1  - 施引文献 :35
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Jemal A., Siegel R., Xu J.Q., Ward E., Cancer statistics, 2010 (2010) CA Cancer J Clin, 60, pp. 277-300; 
Chlebowski R.T., Chen Z., Anderson G.L., Rohan T., Aragaki A., Lane D., Ethnicity and breast cancer: Factors influencing differences in incidence and outcome (2005) J Natl Cancer Inst, 97, pp. 439-448; 
Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease (2001) Lancet, 358, pp. 1389-1399. , Collaborative Group on Hormonal Factors in Breast Cancer; 
Stratton M.R., Rahman N., The emerging landscape of breast cancer susceptibility (2008) Nat Genet, 40, pp. 17-22; 
Hindorff L.A., Sethupathy P., Junkins H.A., Ramos E.M., Mehta J.P., Collins F.S., Potential etiologic and functional implications of genome-wide association loci for human diseases and traits (2009) Proc Natl Acad Sci U S A, 106, pp. 9362-9367; 
Manolio T.A., Genomewide association studies and assessment of the risk of disease (2010) N Engl J Med, 363, pp. 166-176; 
Ahmed S., Thomas G., Ghoussaini M., Healey C.S., Humphreys M.K., Platte R., Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 (2009) Nat Genet, 41, pp. 585-590; 
Easton D.F., Pooley K.A., Dunning A.M., Pharoah P.D.P., Thompson D., Ballinger D.G., Genome-wide association study identifies novel breast cancer susceptibility loci (2007) Nature, 447, pp. 1087-1087; 
Gold B., Kirchhoff T., Stefanov S., Lautenberger J., Viale A., Garber J., Friedman E., Offit K., Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33 (2008) Proceedings of the National Academy of Sciences of the United States of America, 105 (11), pp. 4340-4345. , http://www.pnas.org/cgi/reprint/105/11/4340, DOI 10.1073/pnas.0800441105; 
Hunter D.J., Kraft P., Jacobs K.B., Cox D.G., Yeager M., Hankinson S.E., Wacholder S., Chanock S.J., A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer (2007) Nature Genetics, 39 (7), pp. 870-874. , DOI 10.1038/ng2075, PII NG2075; 
Long J.R., Cai Q.Y., Shu X.O., Qu S.M., Li C., Zheng Y., Identification of a functional genetic variant at 16q12.1 for breast cancer risk: Results from the Asia Breast Cancer Consortium (2010) PLoS Genet, 6, pp. e1001002; 
Stacey S.N., Manolescu A., Sulem P., Rafnar T., Gudmundsson J., Gudjonsson S.A., Masson G., Stefansson K., Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer (2007) Nature Genetics, 39 (7), pp. 865-869. , DOI 10.1038/ng2064, PII NG2064; 
Stacey S.N., Manolescu A., Sulem P., Thorlacius S., Gudjonsson S.A., Jonsson G.F., Jakobsdottir M., Stefansson K., Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer (2008) Nature Genetics, 40 (6), pp. 703-706. , DOI 10.1038/ng.131, PII NG131; 
Thomas G., Jacobs K.B., Kraft P., Yeager M., Wacholder S., Cox D.G., A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) (2009) Nat Genet, 41, pp. 579-584; 
Turnbull C., Ahmed S., Morrison J., Pernet D., Renwick A., Maranian M., Genome-wide association study identifies five new breast cancer susceptibility loci (2010) Nat Genet, 42, pp. 504-547; 
Zheng W., Long J.R., Gao Y.T., Li C., Zheng Y., Xiang Y.B., Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1 (2009) Nat Genet, 41, pp. 324-328; 
Long J.R., Shu X.O., Cai Q.Y., Gao Y.T., Zheng Y., Li G.L., Evaluation of breast cancer susceptibility loci in Chinese women (2010) Cancer Epidemiol Biomarkers Prev, 19, pp. 2357-2365; 
Slattery M.L., Baumgartner K.B., Giuliano A.R., Byers T., Herrick J.S., Wolff R.K., Replication of five GWAS-identified loci and breast cancer risk among Hispanic and non-Hispanic white women living in the Southwestern United States (2011) Breast Cancer Res Treat, , Epub 2011 April 5. PubMed PMID: 21475998; 
Barnholtz-Sloan J.S., Shetty P.B., Guan X.W., Nyante S.J., Luo J.C., Brennan D.J., FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women (2010) Carcinogenesis, 31, pp. 1417-1423; 
Chen F., Stram D.O., Le Marchand L., Monroe K.R., Kolonel L.N., Henderson B.E., Caution in generalizing known genetic risk markers for breast cancer across all ethnic/racial populations (2011) Eur J Hum Genet, 19, pp. 243-245; 
Ruiz-Narvaez E.A., Rosenberg L., Rotimi C.N., Cupples L.A., Boggs D.A., Adeyemo A., Genetic variants on chromosome 5p12 are associated with risk of breast cancer in African American women: The Black Women's Health Study (2010) Breast Cancer Res Treat, 123, pp. 525-530; 
Ruiz-Narvaez E.A., Rosenberg L., Cozier Y.C., Cupples L.A., Adams-Campbell L.L., Palmer J.R., Polymorphisms in the TOX3/LOC643714 locus and risk of breast cancer in African-American women (2010) Cancer Epidemiol Biomarkers Prev, 19, pp. 1320-1327; 
Udler M.S., Meyer K.B., Pooley K.A., Karlins E., Struewing J.P., Zhang J., FGFR2 variants and breast cancer risk: Fine-scale mapping using African American studies and analysis of chromatin conformation (2009) Hum Mol Genet, 18, pp. 1692-1703; 
Zheng W., Cai Q.Y., Signorello L.B., Long J.R., Hargreaves M.K., Deming S.L., Evaluation of 11 breast cancer susceptibility loci in African-American women (2009) Cancer Epidemiol Biomarkers Prev, 18, pp. 2761-2764; 
Anderson G., Cummings S., Freedman L.S., Furberg C., Henderson M., Johnson S.R., Kuller L., Clark A., Design of the Women's Health Initiative clinical trial and observational study (1998) Controlled Clinical Trials, 19 (1), pp. 61-109. , DOI 10.1016/S0197-2456(97)00078-0, PII S0197245697000780; 
Hays J., Hunt J.R., Hubbell F.A., Anderson G.L., Limacher M., Allen C., Rossouw J.E., The Women's Health Initiative recruitment methods and results (2003) Annals of Epidemiology, 13 (9 SUPPL.), pp. S18-S77. , DOI 10.1016/S1047-2797(03)00042-5; 
Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., Rodabough R.J., McTiernan A., Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial (2003) Journal of the American Medical Association, 289 (24), pp. 3243-3253. , DOI 10.1001/jama.289.24.3243; 
Curb J.D., Mctiernan A., Heckbert S.R., Kooperberg C., Stanford J., Nevitt M., Johnson K.C., Daugherty S., Outcomes ascertainment and adjudication methods in the women's health initiative (2003) Annals of Epidemiology, 13 (9 SUPPL.), pp. S122-S128. , DOI 10.1016/S1047-2797(03)00048-6; 
Li Y., Willer C.J., Ding J., Scheet P., Abecasis G.R., MaCH: Using sequence and genotype data to estimate haplotypes and unobserved genotypes (2010) Genet Epidemiol, 34, pp. 816-834; 
Price A.L., Patterson N.J., Plenge R.M., Weinblatt M.E., Shadick N.A., Reich D., Principal components analysis corrects for stratification in genome-wide association studies (2006) Nature Genetics, 38 (8), pp. 904-909. , DOI 10.1038/ng1847, PII NG1847; 
Tang H., Peng J., Wang P., Risch N.J., Estimation of individual admixture: Analytical and study design considerations (2005) Genetic Epidemiology, 28 (4), pp. 289-301. , DOI 10.1002/gepi.20064; 
Hindorff L.A., Junkins H.A., Hall P.N., Mehta J.P., Manolio T.A., A Catalog of Published Genome-Wide Association Studies, , http://www.genome.gov/gwastudies, [Internet; accessed 2011 March 1]. Available from; 
(2010) Batch Genome Variation Server, , http://gvsbatch.gs.washington.edu/GVSBatch, Internet; updated June 27; cited 2011 March 1. Available from; 
Saxena R., Voight B.F., Lyssenko V., Burtt N.P., De Bakker P.I.W., Chen H., Roix J.J., Altshuler D., Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels (2007) Science, 316 (5829), pp. 1331-1336. , DOI 10.1126/science.1142358; 
Yuan S.H., Qiu Z.L., Ghosh A., TOX3 regulates calcium-dependent transcription in neurons (2009) Proc Natl Acad Sci U S A, 106, pp. 2909-2914; 
Dittmer S., Kovacs Z., Yuan S.H., Siszler G., Kogl M., Summer H., TOX3 is a neuronal survival factor that induces transcription depending on the presence of CITED1 or phosphorylated CREB in the transcriptionally active complex (2011) J Cell Sci, 124, pp. 252-260; 
Udler M.S., Ahmed S., Healey C.S., Meyer K., Struewing J., Maranian M., Fine scale mapping of the breast cancer 16q12 locus (2010) Hum Mol Genet, 19, pp. 2507-2515; 
Bryc K., Auton A., Nelson M.R., Oksenberg J.R., Hauser S.L., Williams S., Genome-wide patterns of population structure and admixture in West Africans and African Americans (2010) Proc Natl Acad Sci U S A, 107, pp. 786-791; 
Tishkoff S.A., Reed F.A., Friedlaender F.R., Ehret C., Ranciaro A., Froment A., The Genetic structure and history of Africans and African Americans (2009) Science, 324, pp. 1035-1044; 
Eswarakumar V.P., Lax I., Schlessinger J., Cellular signaling by fibroblast growth factor receptors (2005) Cytokine and Growth Factor Reviews, 16 (2 SPEC. ISS.), pp. 139-149. , DOI 10.1016/j.cytogfr.2005.01.001; 
Lu P.F., Ewald A.J., Martin G.R., Werb Z., Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis (2008) Dev Biol, 321, pp. 77-87; 
Parsa S., Ramasamy S.K., De Langhe S., Gupte V.V., Haigh J.J., Medina D., Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signaling (2008) Dev Biol, 317, pp. 121-131; 
Martin A.J., Grant A., Ashfield A.M., Palmer C.N., Baker L., Quinlan P.R., FGFR2 protein expression in breast cancer: Nuclear localisation and correlation with patient genotype (2011) BMC Res Notes, 4, p. 72; 
Travis R.C., Reeves G.K., Green J., Bull D., Tipper S.J., Baker K., Gene-environment interactions in 7610 women with breast cancer: Prospective evidence from the Million Women Study (2010) Lancet, 375, pp. 2143-2151; 
Antoniou A.C., Wang X.S., Fredericksen Z.S., McGuffog L., Tarrell R., Sinilnikova O.M., A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population (2010) Nat Genet, 42, pp. 885-892; 
Li C.I., Malone K.E., Daling J.R., Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older (2002) Cancer Epidemiology Biomarkers and Prevention, 11 (7), pp. 601-607; 
Hao K., Chudin E., McElwee J., Schadt E.E., Accuracy of genome-wide imputation of untyped markers and impacts on statistical power for association studies (2009) BMC Genet, 10, p. 27; 
Price A.L., Zaitlen N.A., Reich D., Patterson N.J., New approaches to population stratification in genome-wide association studies (2010) Nat Rev Genet, 11, pp. 459-463; 
Chang B.L., Spangler E., Gallagher S., Haiman C.A., Henderson B.E., Isaacs W., Validation of genome-wide prostate cancer associations in men of African descent (2011) Cancer Epidemiol Biomarkers Prev, 20, pp. 23-32; 
He J., Wilkens L.R., Stram D.O., Kolonel L.K., Henderson B.E., Wu A.H., Generalizability and epidemiologic characterization of eleven colorectal cancer GWAS hits in multiple populations (2011) Cancer Epidemiol Biomarkers Prev, 20, pp. 70-81
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-80052533624&partnerID=40&md5=51efb71dfdc6ee5bf35be10543e704b1
ER  - 

TY  - JOUR
TI  - FOXD3 is a mutant B-RAF-regulated inhibitor of G1-S progression in melanoma cells
T2  - Cancer Research
VL  - 70
IS  - 7
SP  - 2891
EP  - 2900
PY  - 2010
DO  - 10.1158/0008-5472.CAN-09-3139
AU  - Abel E.V.
AU  - Aplin A.E.
N1  - 施引文献 :35
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Wijchers P.J., Burbach J.P., Smidt M.P., In control of biology: Of mice, men and Foxes (2006) Biochem J, 397, pp. 233-246; 
Myatt S.S., Lam E.W., The emerging roles of forkhead box (Fox) proteins in cancer (2007) Nat Rev Cancer, 7, pp. 847-859; 
Sutton J., Costa R., Klug M., Genesis, a winged helix transcriptional repressor with expression restricted to embryonic stem cells (1996) J Biol Chem, 271, pp. 23126-23133; 
Thomas A.J., Erickson C.A., The making of a melanocyte: The specification of melanoblasts from the neural crest (2008) Pigment Cell Melanoma Res, 21, pp. 598-610; 
Hanna L.A., Foreman R.K., Tarasenko I.A., Kessler D.S., Labosky P.A., Requirement for Foxd3 in maintaining pluripotent cells of the early mouse embryo (2002) Genes Dev, 16, pp. 2650-2661; 
Tompers D.M., Foreman R.K., Wang Q., Kumanova M., Labosky P.A., Foxd3 is required in the trophoblast progenitor cell lineage of the mouse embryo (2005) Dev Biol, 285, pp. 126-137; 
Teng L., Mundell N.A., Frist A.Y., Wang Q., Labosky P.A., Requirement for Foxd3 in the maintenance of neural crest progenitors (2008) Development, 135, pp. 1615-1624; 
Liu Y., Labosky P.A., Regulation of embryonic stem cell self-renewal and pluripotency by Foxd3 (2008) Stem Cells, 26, pp. 2475-2484; 
Kos R., Reedy M.V., Johnson R.L., Erickson C.A., The winged-helix transcription factor FoxD3 is important for establishing the neural crest lineage and repressing melanogenesis in avian embryos (2001) Development, 128, pp. 1467-1479; 
Real C., Glavieux-Pardanaud C., Le Douarin N.M., Dupin E., Clonally cultured differentiated pigment cells can dedifferentiate and generate multipotert progenitors with self-renewing potential (2006) Dev Biol, 300, pp. 656-669; 
Davies H., Bignell G.R., Cox C., Mutations of the BRAF gene in human cancer (2002) Nature, 417, pp. 949-954; 
Satyamoorthy K., Li G., Gerrero M.R., Constitutive mitogenactivated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation (2003) Cancer Res, 63, pp. 756-759; 
Marin Y.E., Namkoong J., Cohen-Solal K., Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCε (2005) Cell Signal, 18, pp. 1279-1286; 
Fecher L.A., Amaravadi R., Schuchter L.M., Effectively targeting BRAF in melanoma: A formidable challenge (2008) Pigment Cell Melanoma Res, 21, pp. 410-411; 
Ignatius M.S., Moose H.E., El-Hodiri H.M., Henion P.D., Colgate/hdac1 repression of foxd3 expression is required to permit mitfa-dependent melanogenesis (2008) Dev Biol, 313, pp. 568-583; 
Thomas A.J., Erickson C.A., FOXD3 regulates the lineage switch between neural crest-derived glial cells and pigment cells by repressing MITF through a non-canonical mechanism (2009) Development, 136, pp. 1849-1858; 
Wellbrock C., Rana S., Paterson H., Pickersgill H., Brummelkamp T., Marais R., Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF (2008) PLoS One, 3, pp. e2734; 
Garraway L.A., Widlund H.R., Rubin M.A., Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma (2005) Nature, 436, pp. 117-122; 
Conner S.R., Scott G., Aplin A.E., Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells (2003) J Biol Chem, 278, pp. 34548-34554; 
Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A., High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma (2003) Cancer Res, 63, pp. 1454-1457; 
Davies B.R., Logie A., McKay J.S., AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signalregulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models (2007) Mol Cancer Ther, 6, pp. 2209-2219; 
Spofford L.S., Abel E.V., Boisvert-Adamo K., Aplin A.E., Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent PI-3 kinase signaling and contributes to G1-S progression (2006) J Biol Chem, 281, pp. 25644-25651; 
Boisvert-Adamo K., Aplin A.E., Mutant B-RAF mediates resistance to anoikis via Bad and Bim (2008) Oncogene, 27, pp. 3301-3312; 
Pfaffl M.W., A new mathematical model for relative quantification in real-time RT-PCR (2001) Nucleic Acids Res, 29, pp. e45; 
Boisvert-Adamo K., Aplin A.E., B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis (2006) Oncogene, 25, pp. 4848-4856; 
Bhatt K.V., Hu R., Spofford L.S., Aplin A.E., Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27(Kip1) in human melanoma cells (2007) Oncogene, 26, pp. 1056-1066; 
Montagut C., Settleman J., Targeting the RAF-MEK-ERK pathway in cancer therapy (2009) Cancer Lett, 283, pp. 125-134; 
Favata M.F., Horiuchi K.Y., Manos E.J., Identification of a novel inhibitor of mitogen-activated protein kinase kinase (1998) J Biol Chem, 273, pp. 18623-18632; 
Cheng M., Olivier P., Diehl J.A., The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts (1999) EMBO J, 18, pp. 1571-1583; 
Bhatt K.V., Spofford L.S., Aram G., McMullen M., Pumiglia K., Aplin A.E., Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling (2005) Oncogene, 12, pp. 3459-3471; 
Solit D.B., Garraway L.A., Pratilas C.A., BRAF mutation predicts sensitivity to MEK inhibition (2006) Nature, 439, pp. 358-362; 
El-Deiry W.S., Tokino T., Velculescu V.E., WAF1, a potential mediator of p53 tumor suppression (1993) Cell, 75, pp. 817-825; 
Volkenandt M., Schlegel U., Nanus D.M., Albino A.P., Mutational analysis of the human p53 gene in malignant melanoma (1991) Pigment Cell Res, 4, pp. 35-40; 
Smalley K.S., Contractor R.S., Haass N.K., An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells (2007) Cancer Res, 67, pp. 1-9; 
Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A., Suppression of BRAF(V599E) in human melanoma abrogates transformation (2003) Cancer Res, 63, pp. 5198-5202; 
Michaloglou C., Vredeveld L.C., Mooi W.J., Peeper D.S., BRAF(E600) in benign and malignant human tumours (2008) Oncogene, 27, pp. 877-895; 
Yang J.Y., Zong C.S., Xia W., ERK promotes tumorigenesis by inhibiting FOX03a via MDM2-mediated degradation (2008) Nat Cell Biol, 10, pp. 138-148; 
Rym M., Tong T.H.K., Cheung A.M.S., Tsang A.C.C., Leung W.Y., Yao K.-M., Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXMIc (2005) J Cell Sci, 118, pp. 795-806; 
Weinmann A.S., Yan P.S., Oberley M.J., Huang T.H., Farnham P.J., Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis (2002) Genes Dev, 16, pp. 235-244; 
Goodall J., Wellbrock C., Dexter T.J., Roberts K., Marais R., Goding C.R., The Bm-2 transcription factor links activated BRAF to melanoma proliferation (2004) Mol Cell Biol, 24, pp. 2923-2931; 
Kruse J.P., Gu W., Snapshot: P53 posttranslational modifications (2008) Cell, 133, pp. 930-930. , e1; 
Pani L., Horal M., Loeken M.R., Rescue of neural tube defects in Pax-3deficient embryos by p53 loss of function: Implications for Pax-3dependent development and tumorigenesis (2002) Genes Dev, 16, pp. 676-680; 
Underwood T.J., Amin J., Lillycrop K.A., Blaydes J.P., Dissection of the functional interaction between p53 and the embryonic proto-oncoprotein PAX3 (2007) FEBS Lett, 581, pp. 5831-5835; 
Quintana E., Shackleton M., Sabei M.S., Fullen D.R., Johnson T.M., Morrison S.J., Efficient tumour formation by single human melanoma cells (2008) Nature, 456, pp. 593-598; 
Pan G., Li J., Zhou Y., Zheng H., Pei D., A negative feedback loop of transcription factors that controls stem cell pluripotency and self-renewal (2006) FASEB J, 20, pp. 1730-1732
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-77950847051&partnerID=40&md5=a0410b7402214edbb5a782b97c126a95
ER  - 

TY  - JOUR
TI  - The FOXE1 and NKX2-1 loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population
T2  - Journal of Medical Genetics
VL  - 48
IS  - 9
SP  - 645
EP  - 648
PY  - 2011
DO  - 10.1136/jmedgenet-2011-100063
AU  - Matsuse M.
AU  - Takahashi M.
AU  - Mitsutake N.
AU  - Nishihara E.
AU  - Hirokawa M.
AU  - Kawaguchi T.
AU  - Rogounovitch T.
AU  - Saenko V.
AU  - Bychkov A.
AU  - Suzuki K.
AU  - Matsuo K.
AU  - Tajima K.
AU  - Miyauchi A.
AU  - Yamada R.
AU  - Matsuda F.
AU  - Yamashita S.
N1  - 施引文献 :32
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Adjadj E., Schlumberger M., de Vathaire F., Germ-line DNA polymorphisms and susceptibility to differentiated thyroid cancer (2009) Lancet Oncol, 10, pp. 181-190; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Jonasson J.G., Sigurdsson A., Bergthorsson J.T., He H., Stefansson K., Common variants on 9q22.33 and 14q13. 3 predispose to thyroid cancer in European populations (2009) Nat Genet, 41, pp. 460-464; 
Takahashi M., Saenko V.A., Rogounovitch T.I., Kawaguchi T., Drozd V.M., Takigawa-Imamura H., Akulevich N.M., Yamashita S., The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl (2010) Hum Mol Genet, 19, pp. 2516-2523; 
Kumagai A., Namba H., Akanov Z., Saenko V.A., Meirmanov S., Ohtsuru A., Yano H., Yamashita S., Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer (2007) Endocr J, 54, pp. 399-405; 
Nakayama H., Yoshida A., Nakamura Y., Hayashi H., Miyagi Y., Wada N., Rino Y., Imada T., Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas (2007) Anticancer Res, 27, pp. 3645-3649; 
Watanabe R., Hayashi Y., Sassa M., Kikumori T., Imai T., Kiuchi T., Murata Y., Possible involvement of BRAFV600E in altered gene expression in papillary thyroid cancer (2009) Endocr J, 56, pp. 407-414; 
Zuo H., Nakamura Y., Yasuoka H., Zhang P., Nakamura M., Mori I., Miyauchi A., Kakudo K., Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma (2007) Pathol Int, 57, pp. 12-20; 
Xing M., BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications (2007) Endocr Rev, 28, pp. 742-762; 
Kim S.W., Lee J.I., Kim J.W., Ki C.S., Oh Y.L., Choi Y.L., Shin J.H., Chung J.H., BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population (2010) J Clin Endocrinol Metab, 95, pp. 3693-3700; 
Feldt-Rasmussen U., Iodine and cancer (2001) Thyroid, 11, pp. 483-486; 
Williams E.D., Abrosimov A., Bogdanova T., Demidchik E.P., Ito M., LiVolsi V., Lushnikov E., Thomas G.A., Morphologic characteristics of Chernobyl-related childhood papillary thyroid carcinomas are independent of radiation exposure but vary with iodine intake (2008) Thyroid, 18, pp. 847-852; 
Guan H., Ji M., Bao R., Yu H., Wang Y., Hou P., Zhang Y., Xing M., Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer (2009) J Clin Endocrinol Metab, 94, pp. 1612-1617; 
Yamada R., Okada Y., An optimal dose-effect mode trend test for SNP genotype tables (2009) Genet Epidemiol, 33, pp. 114-127; 
Breslow N.E., Day N.E., Statistical methods in cancer research. Volume IdThe analysis of case-control studies (1980) IARC Sci Publ, 32, pp. 5-338; 
Zhao H., Nettleton D., Dekkers J.C., Evaluation of linkage disequilibrium measures between multi-allelic markers as predictors of linkage disequilibrium between single nucleotide polymorphisms (2007) Genet Res, 89, pp. 1-6; 
Landa I., Ruiz-Llorente S., Montero-Conde C., Inglada-Perez L., Schiavi F., Leskela S., Pita G., Robledo M., The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors (2009) PLoS Genet, 5, pp. e1000637; 
De Felice M., Ovitt C., Biffali E., Rodriguez-Mallon A., Arra C., Anastassiadis K., Macchia P.E., Di Lauro R., A mouse model for hereditary thyroid dysgenesis and cleft palate (1998) Nat Genet, 19, pp. 395-398; 
Kimura S., Hara Y., Pineau T., Fernandez-Salguero P., Fox C.H., Ward J.M., Gonzalez F.J., The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary (1996) Genes Dev, 10, pp. 60-69
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-80052570272&partnerID=40&md5=ef668b7879821588f4145f0fd743702a
ER  - 

TY  - JOUR
TI  - Association studies in thyroid cancer susceptibility: are we on the right track?
T2  - Journal of molecular endocrinology
VL  - 47
IS  - 1
SP  - R43
EP  - 58
PY  - 2011
DO  - 10.1530/JME-11-0005
AU  - Landa I.
AU  - Robledo M.
N1  - 施引文献 :28
N1  - Export Date: 2 January 2016
TY  - Review
DB  - Scopus
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-80054122603&partnerID=40&md5=4074129d716cde45b1be4260a9ffcd32
ER  - 

TY  - JOUR
TI  - FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility
T2  - Clinical Endocrinology
VL  - 77
IS  - 6
SP  - 926
EP  - 933
PY  - 2012
DO  - 10.1111/j.1365-2265.2012.04505.x
AU  - Tomaz R.A.
AU  - Sousa I.
AU  - Silva J.G.
AU  - Santos C.
AU  - Teixeira M.R.
AU  - Leite V.
AU  - Cavaco B.M.
N1  - 施引文献 :23
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Farid N.R., Shi Y., Zou M., Molecular basis of thyroid cancer (1994) Endocrine Reviews, 15 (2), pp. 202-232. , DOI 10.1210/er.15.2.202; 
Schlumberger M.J., Papillary and follicular thyroid carcinoma (1998) New England Journal of Medicine, 338 (5), pp. 297-306. , DOI 10.1056/NEJM199801293380506; 
Loh K.C., Familial nonmedullary thyroid carcinoma: A meta-review of case series (1997) Thyroid, 7, pp. 107-113; 
Uchino S., Noguchi S., Kawamoto H., Yamashita H., Watanabe S., Yamashita H., Shuto S., Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population (2002) World Journal of Surgery, 26 (8), pp. 897-902. , DOI 10.1007/s00268-002-6615-y; 
Malchoff C.D., Malchoff D.M., Familial nonmedullary thyroid carcinoma (2006) Cancer Control, 13, pp. 106-110; 
Musholt T.J., Musholt P.B., Petrich T., Familial papillary thyroid carcinoma: Genetics, criteria for diagnosis, clinical features, and surgical treatment (2000) World Journal of Surgery, 24, pp. 1409-1417; 
Sippel R.S., Caron N.R., Clark O.H., An evidence-based approach to familial nonmedullary thyroid cancer: Screening, clinical management, and follow-up (2007) World Journal of Surgery, 31 (5), pp. 924-933. , DOI 10.1007/s00268-006-0847-1; 
Bignell G.R., Canzian F., Shayeghi M., Stark M., Shugart Y.Y., Biggs P., Mangion J., Foulkes W.D., Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer (1997) American Journal of Human Genetics, 61 (5), pp. 1123-1130. , DOI 10.1086/301610; 
Malchoff C.D., Sarfarazi M., Tendler B., Forouhar F., Whalen G., Joshi V., Arnold A., Malchoff D.M., Papillary thyroid carcinoma associated with papillary renal neoplasia: Genetic linkage analysis of a distinct heritable tumor syndrome (2000) Journal of Clinical Endocrinology and Metabolism, 85 (5), pp. 1758-1764. , DOI 10.1210/jc.85.5.1758; 
Canzian F., Amati P., Ruben Harach H., Kraimps J.-L., Lesueur F., Barbier J., Levillain P., Bonneau D., A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2 (1998) American Journal of Human Genetics, 63 (6), pp. 1743-1748. , DOI 10.1086/302164; 
McKay J.D., Lesueur F., Jonard L., Pastore A., Williamson J., Hoffman L., Burgess J., Romeo G., Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21 (2001) American Journal of Human Genetics, 69 (2), pp. 440-446. , DOI 10.1086/321979; 
Cavaco B.M., Batista P.F., Sobrinho L.G., Leite V., Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis (2008) Journal of Clinical Endocrinology and Metabolism, 93 (11), pp. 4426-4430. , http://jcem.endojournals.org/cgi/reprint/93/11/4426, DOI 10.1210/jc.2008-0449; 
He H., Nagy R., Liyanarachchi S., A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24 (2009) Cancer Research, 69, pp. 625-631; 
Suh I., Filetti S., Vriens M.R., Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: A SNP array-based linkage analysis of 38 families (2009) Surgery, 146, pp. 1073-1080; 
Rio Frio T., Bahubeshi A., Kanellopoulou C., DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors (2011) JAMA: The Journal of the American Medical Association, 305, pp. 68-77; 
Ngan E.S., Lang B.H., Liu T., A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma (2009) Journal of the National Cancer Institute, 101, pp. 162-175; 
Cantara S., Capuano S., Formichi C., Lack of germline A339V mutation in thyroid transcription factor (TITF-1/NKX2.1) gene in familial papillary thyroid cancer (2010) Thyroid Research, 3, p. 4; 
Parlato R., Rosica A., Rodriguez-Mallon A., Affuso A., Postiglione M.P., Arra C., Mansouri A., De Felice M., An integrated regulatory network controlling survival and migration in thyroid organogenesis (2004) Developmental Biology, 276 (2), pp. 464-475. , DOI 10.1016/j.ydbio.2004.08.048, PII S0012160604006190; 
Fagman H., Nilsson M., Morphogenetics of early thyroid development (2011) Journal of Molecular Endocrinology, 46, pp. R33-R42; 
MacChia P.E., Mattei M.G., Lapi P., Cloning, chromosomal localization and identification of polymorphisms in the human thyroid transcription factor 2 gene (TITF2) (1999) Biochimie, 81, pp. 433-440; 
Hishinuma A., Ohyama Y., Kuribayashi T., Nagakubo N., Namatame T., Shibayama K., Arisaka O., Ieiri T., Polymorphism of the polyalanine tract of thyroid transcription factor-2 gene in patients with thyroid dysgenesis (2001) European Journal of Endocrinology, 145 (4), pp. 385-389; 
Tonacchera M., Banco M., Lapi P., Di Cosmo C., Perri A., Montanelli L., Moschini L., Pinchera A., Genetic analysis of TTF-2 gene in children with congenital hypothyroidism and cleft palate, congenital hypothyroidism, or isolated cleft palate (2004) Thyroid, 14 (8), pp. 584-588. , DOI 10.1089/1050725041692864; 
Carre A., Castanet M., Sura-Trueba S., Szinnai G., Vliet G., Trochet D., Amiel J., Polak M., Polymorphic length of FOXE1 alanine stretch: Evidence for genetic susceptibility to thyroid dysgenesis (2007) Human Genetics, 122 (5), pp. 467-476. , DOI 10.1007/s00439-007-0420-5; 
Santarpia L., Valenzise M., Di Pasquale G., Arrigo T., San Martino G., Ciccio M.P., Trimarchi F., Benvenga S., TTF-2/FOXE1 gene polymorphisms in Sicilian patients with permanent primary congenital hypothyroidism (2007) Journal of Endocrinological Investigation, 30 (1), pp. 13-19; 
Szczepanek E., Ruchala M., Szaflarski W., FOXE1 polyalanine tract length polymorphism in patients with thyroid hemiagenesis and subjects with normal thyroid (2011) Hormone Research in Paediatrics, 75, pp. 329-334; 
Zannini M., Avantaggiato V., Biffali E., Arnone M.I., Sato K., Pischetola M., Taylor B.A., Di Lauro R., TTF-2, a new forkhead protein, shows a temporal expression in the developing thyroid which is consistent with a role in controlling the onset of differentiation (1997) EMBO Journal, 16 (11), pp. 3185-3197. , DOI 10.1093/emboj/16.11.3185; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations (2009) Nature Genetics, 41, pp. 460-464; 
Matsuse M., Takahashi M., Mitsutake N., The FOXE1 and NKX2-1 loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population (2011) Journal of Medical Genetics, 48, pp. 645-648; 
Landa I., Ruiz-Llorente S., Montero-Conde C., The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors (2009) PLoS Genetics, 5, pp. e1000637; 
Takahashi M., Saenko V.A., Rogounovitch T.I., The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl (2010) Human Molecular Genetica, 19, pp. 2516-2523; 
Kallel R., Belguith-Maalej S., Akdi A., Genetic investigation of FOXE1 polyalanine tract in thyroid diseases: New insight on the role of FOXE1 in thyroid carcinoma (2010) Cancer Biomarkers, 8, pp. 43-51; 
Bullock M., Duncan E.L., O'Neill C., Association of FOXE1 polyalanine repeat region with papillary thyroid cancer (2012) Journal of Clinical Endocrinology and Metabolism, , [Epub ahead of print]; 
DeLellis R.A., Lloyd R.V., Heitz P.U., (2004) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs, pp. 50-105. , IARC Press, Lyon; 
Shi Y.Y., He L., SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci (2005) Cell Research, 15 (2), pp. 97-98. , DOI 10.1038/sj.cr.7290272; 
Barrett J.C., Fry B., Maller J., Daly M.J., Haploview: Analysis and visualization of LD and haplotype maps (2005) Bioinformatics, 21 (2), pp. 263-265. , DOI 10.1093/bioinformatics/bth457
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-84869040208&partnerID=40&md5=0e41c28d18f7bdfe50eee150e8f897f4
ER  - 

TY  - JOUR
TI  - Confirmation of papillary thyroid cancer susceptibility loci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35 and 8p12 in a Chinese population
T2  - Journal of Medical Genetics
VL  - 50
IS  - 10
SP  - 689
EP  - 695
PY  - 2013
DO  - 10.1136/jmedgenet-2013-101687
AU  - Wang Y.-L.
AU  - Feng S.-H.
AU  - Guo S.-C.
AU  - Wei W.-J.
AU  - Li D.-S.
AU  - Wang Y.
AU  - Wang X.
AU  - Wang Z.-Y.
AU  - Ma Y.-Y.
AU  - Jin L.
AU  - Ji Q.-H.
AU  - Wang J.-C.
N1  - 施引文献 :18
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Siegel R., Naishadham D., Jemal A., Cancer statistics (2013) 2013. CA Cancer J Clin, 63, pp. 11-30; 
Kondo T., Ezzat S., Asa S.L., Pathogenetic mechanisms in thyroid follicular-cell neoplasia (2006) Nat Rev Cancer, 6, pp. 292-306; 
Fallah M., Pukkala E., Tryggvadottir L., Olsen J.H., Tretli S., Sundquist K., Hemminki K., Risk of thyroid cancer in first-degree relatives of patients with non-medullary thyroid cancer by histology type and age at diagnosis: a joint study from five Nordic countries (2013) J Med Genet, 50, pp. 373-382; 
Vriens M.R., Suh I., Moses W., Kebebew E., Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer (2009) Thyroid, 19, pp. 1343-1349; 
Bevan S., Pal T., Greenberg C.R., Green H., Wixey J., Bignell G., Narod S.A., Houlston R.S., A comprehensive analysis of MNG1, TCO1, fPTC, PTEN,TSHR, and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCO1 (2001) J Clin Endocrinol Metab, 86, pp. 3701-3704; 
He H., Nagy R., Liyanarachchi S., Jiao H., Li W., Suster S., Kere J., de la Chapelle A., A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24 (2009) Cancer Res, 69, pp. 625-631; 
Lesueur F., Stark M., Tocco T., Ayadi H., Delisle M.J., Goldgar D.E., Schlumberger M., Canzian F., Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium (1999) J Clin Endocrinol Metab, 84, pp. 2157-2162; 
Ngan E.S., Lang B.H., Liu T., Shum C.K., So M.T., Lau D.K., Leon T.Y., Garcia-Barcelo M.M., A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2 1) in patients with multinodular goiter and papillary thyroid carcinoma (2009) J Natl Cancer Inst, 101, pp. 162-175; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Jonasson J.G., Sigurdsson A., Bergthorsson J.T., He H., Stefansson K., Common variants on 9q22 33 and 14q13. 3 predispose to thyroid cancer in European populations (2009) Nat Genet, 41, pp. 460-464; 
Takahashi M., Saenko V.A., Rogounovitch T.I., Kawaguchi T., Drozd V.M., Takigawa-Imamura H., Akulevich N.M., Yamashita S., The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl (2010) Hum Mol Genet, 19, pp. 2516-2523; 
Jones A.M., Howarth K.M., Martin L., Gorman M., Mihai R., Moss L., Auton A., Carvajal-Carmona L.G., Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24 (2012) J Med Genet, 49, pp. 158-163; 
Matsuse M., Takahashi M., Mitsutake N., Nishihara E., Hirokawa M., Kawaguchi T., Rogounovitch T., Yamashita S., The FOXE1 and NKX2-1 loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population (2012) J Med Genet, 48, pp. 645-648; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Jonasson J.G., Masson G., He H., Jonasdottir A., Stefansson K., Discovery of common variants associated with low TSH levels and thyroid cancer risk (2012) Nat Genet, 44, pp. 319-322; 
Wokolorczyk D., Gliniewicz B., Sikorski A., Zlowocka E., Masojc B., Debniak T., Matyjasik J., Cybulski C., A range of cancers is associated with the rs6983267 marker on chromosome 8 (2008) Cancer Res, 68, pp. 9982-9986; 
Wang X., Lu M., Qian J., Yang Y., Li S., Lu D., Yu S., Jin L., Rationales, design and recruitment of the Taizhou Longitudinal Study (2009) BMC Public Health, 9, p. 223; 
Wang Y.L., Wang J.C., Wu Y., Zhang L., Huang C.P., Shen Q., Zhu Y.X., Ji Q.H., Incidentally simultaneous occurrence of RET/PTC H4-PTEN and BRAF mutation in papillary thyroid carcinoma (2008) Cancer Lett, 263, pp. 44-52; 
Wang Y.L., Zhang R.M., Luo Z.W., Wu Y., Du X., Wang Z.Y., Zhu Y.X., Ji Q.H., High frequency of level II-V lymph node involvement in RET/PTC positive papillary thyroid carcinoma (2008) Eur J Surg Oncol, 34, pp. 77-81; 
Jiang X.Y., Zhang Q., Chen P., Li S.Y., Zhang N.N., Chen X.D., Wang G.C., Lu M., CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin (2012) J Clin Pharm Ther, 37, pp. 719-723; 
Gonzalez J.R., Armengol L., Sole X., Guino E., Mercader J.M., Estivill X., Moreno V., SNPassoc: an R package to perform whole genome association studies (2007) Bioinformatics, 23, pp. 644-645; 
Abecasis G.R., Auton A., Brooks L.D., DePristo M.A., Durbin R.M., Handsaker R.E., Kang H.M., McVean G.A., An integrated map of genetic variation from 1 (2012) 092 human genomes. Nature, 491, pp. 56-65; 
The, ENCODE., (ENCyclopedia Of, DNA., Elements), Project (2004) Science, 306, pp. 636-640. , ENCODE Project Consortium; 
Goldman M., Craft B., Swatloski T., Ellrott K., Cline M., Diekhans M., Ma S., Zhu J., The UCSC Cancer Genomics Browser: update 2013 (2013) Nucleic Acids Res, 41, pp. D949-D954; 
Quinlan A.R., Hall I.M., BEDTools: a flexible suite of utilities for comparing genomic features (2010) Bioinformatics, 26, pp. 841-842; 
Barrett J.C., Fry B., Maller J., Daly M.J., Haploview: analysis and visualization of LD and haplotype maps (2005) Bioinformatics, 21, pp. 263-265; 
Purcell S., Cherny S.S., Sham P.C., Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits (2003) Bioinformatics, 19, pp. 149-150; 
Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., Mazzaferri E.L., Tuttle R.M., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer (2009) Thyroid, 19, pp. 1167-1214; 
Sastre L., Clinical implications of the ENCODE project (2012) Clin Transl Oncol, 14, pp. 801-802; 
Landa I., Ruiz-Llorente S., Montero-Conde C., Inglada-Perez L., Schiavi F., Leskela S., Pita G., Robledo M., The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors (2009) PLoS Genet, 5, pp. e1000637; 
Tomaz R.A., Sousa I., Silva J.G., Santos C., Teixeira M.R., Leite V., Cavaco B.M., FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility (2012) Clin Endocrinol (Oxf), 77, pp. 926-933; 
Jendrzejewski J., He H., Radomska H.S., Li W., Tomsic J., Liyanarachchi S., Davuluri R.V., de la Chapelle A., The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type (2012) Proc Natl Acad Sci USA, 109, pp. 8646-8651; 
Bodmer D., Schepens M., Eleveld M.J., Schoenmakers E.F., Geurts van Kessel A., Disruption of a novel gene, DIRC3, and expression of DIRC3-HSPBAP1 fusion transcripts in a case of familial renal cell cancer and t(2; 3)(q35; q21) (2003) Genes Chromosomes Cancer, 38, pp. 107-116; 
Garcia-Barcelo M.M., Tang C.S., Ngan E.S., Lui V.C., Chen Y., So M.T., Leon T.Y., Tam P.K., Genome-wide association study identifies NRG1 as a susceptibility locus for Hirschsprung's disease (2009) Proc Natl Acad Sci USA, 106, pp. 2694-2699; 
Gardner M., Gonzalez-Neira A., Lao O., Calafell F., Bertranpetit J., Comas D., Extreme population differences across Neuregulin 1 gene, with implications for association studies (2006) Mol Psychiatry, 11, pp. 66-75; 
Burke L.J., Zhang R., Lutz M., Renkawitz R., The thyroid hormone receptor and the insulator protein CTCF: two different factors with overlapping functions (2002) J Steroid Biochem Mol Biol, 83, pp. 49-57; 
Phillips J.E., Corces V.G., CTCF: master weaver of the genome (2009) Cell, 137, pp. 1194-1211; 
Onay V.U., Briollais L., Knight J.A., Shi E., Wang Y., Wells S., Li H., Ozcelik H., SNP-SNP interactions in breast cancer susceptibility (2006) BMC Cancer, 6, p. 114
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-84890218140&partnerID=40&md5=ff2ec33da0a738bdf2f45c084fa0fe76
ER  - 

TY  - JOUR
TI  - Genome-wide association study on differentiated thyroid cancer
T2  - Journal of Clinical Endocrinology and Metabolism
VL  - 98
IS  - 10
SP  - E1674
EP  - E1681
PY  - 2013
DO  - 10.1210/jc.2013-1941
AU  - Köhler A.
AU  - Chen B.
AU  - Gemignani F.
AU  - Elisei R.
AU  - Romei C.
AU  - Figlioli G.
AU  - Cipollini M.
AU  - Cristaudo A.
AU  - Bambi F.
AU  - Hoffmann P.
AU  - Herms S.
AU  - Kalemba M.
AU  - Kula D.
AU  - Harris S.
AU  - Broderick P.
AU  - Houlston R.
AU  - Pastor S.
AU  - Marcos R.
AU  - Velázquez A.
AU  - Jarzab B.
AU  - Hemminki K.
AU  - Landi S.
AU  - Försti A.
N1  - 施引文献 :17
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Agate L., Lorusso L., Elisei R., New and old knowledge on differentiated thyroid cancer epidemiology and risk factors (2012) J Endocrinol Invest, 35, pp. 3-9; 
Leenhardt L., Grosclaude P., Chérié-Challine L., Increased incidence of thyroid carcinoma in France: A true epidemic or thyroid nodule management effects? Report from the french thyroid cancer committee (2004) Thyroid, 14, pp. 1056-1060. , Thyroid Cancer Committee; 
Li N., Du X.L., Reitzel L.R., Xu L., Sturgis E.M., Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: Reviewofincidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008 (2013) Thyroid, 23, pp. 103-110; 
DeLellis R.A., Pathology and genetics of thyroid carcinoma (2006) J Surg Oncol., 94, pp. 662-669; 
Cardis E., Kesminiene A., Ivanov V., Risk of thyroid cancer after exposure to 131I in childhood (2005) J Natl Cancer Inst, 97, pp. 724-732; 
Hemminki K., Eng C., Chen B., Familial risks for nonmedullary thyroid cancer (2005) J Clin Endocrinol Metab., 90, pp. 5747-5753; 
Hemminki K., Sundquist J., Lorenzo Bermejo J., Familial risks for cancer as the basis for evidence-based clinical referral and counseling (2008) Oncologist, 13, pp. 239-247; 
Nosé V., Familial non-medullary thyroid carcinoma: An update (2008) Endocr Pathol, 19, pp. 226-240; 
Bonora E., Tallini G., Romeo G., Genetic predisposition to familial nonmedullary thyroid cancer: An update of molecular findings and state-of-the-art studies (2010) J Oncol., 2010, p. 385206; 
Canzian F., Amati P., Harach H.R., A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2 (1998) Am J Hum Genet, 63, pp. 1743-1748; 
Malchoff C.D., Sarfarazi M., Tendler B., Papillary thyroid carcinoma associated with papillary renal neoplasia: Genetic linkage analysis of a distinct heritable tumor syndrome (2000) J Clin Endocrinol Metab., 85, pp. 1758-1764; 
McKay J.D., Lesueur F., Jonard L., Localization of asusceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21 (2001) Am J Hum Genet, 69, pp. 440-446; 
He H., Nagy R., Liyanarachchi S., A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24 (2009) Cancer Res., 69, pp. 625-631; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Commonvariants on 9q22.33 and 14q13.3 predispose to thyroid cancer in european populations (2009) Nat Genet, 41, pp. 460-464; 
Takahashi M., Saenko V.A., Rogounovitch T.I., The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in chernobyl (2010) Hum Mol Genet, 19, pp. 2516-2523; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Discovery of common variants associated with low TSH levels and thyroid cancer risk (2012) Nat Genet, 44, pp. 319-322; 
Penegar S., Wood W., Lubbe S., National study of colorectal cancer genetics (2007) Br J Cancer, 97, pp. 1305-1309; 
Bodmer D., Schepens M., Eleveld M.J., Schoenmakers E.F., Geurts van kessel A. Disruption of a novel gene, DIRC3, and expression of DIRC3-HSPBAP1 fusion transcripts in a case of familial renal cell cancer and t(2; 3)(q35;q21) (2003) Genes Chromosomes Cancer, 38, pp. 107-116; 
Petek E., Windpassinger C., Vincent J.B., Disruption of a novel gene (IMMP2L) by a breakpoint in 7q31 associated with tourette syndrome (2001) Am J Hum Genet, 68, pp. 848-858; 
Maestrini E., Pagnamenta A.T., Lamb J.A., 2010High-density SNP association study and copy number variation analysis of the AUTS1 and AUTS5loci implicate the IMMP2L-DOCK4 gene region in autism susceptibility Mol Psychiatry, 15, pp. 954-968. , IMGSAC; 
Bertin J., Guo Y., Wang L., CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B (2000) J Biol Chem, 275, pp. 41082-41086; 
Nakamura S., Nakamura S., Matsumoto T., Overexpression of caspase recruitment domain (CARD) membrane-associated guany-late kinase 1 (CARMA1) and CARD9 in primary gastric B-cell lymphoma (2005) Cancer, 104, pp. 1885-1893; 
Repplinger D., Bargren A., Zhang Y.W., Adler J.T., Haymart M., Chen H., Is hashimoto's thyroiditis a risk factor for papillary thyroid cancer? (2008) J Surg Res., 150, pp. 49-52; 
Lopez Herraez D., Bauchet M., Genetic variation and recent positive selection in worldwide human populations: Evidence from nearly 1 million SNPs (2009) PloS One, 4, pp. e7888; 
McEvoy B.P., Montgomery G.W., McRae A.F., Geographical structure and differential natural selection among north european populations (2009) Genome Res., 19, pp. 804-814; 
Novembre J., Johnson T., Bryc K., Genes mirror geography within europe (2008) Nature, 456, pp. 98-101; 
Nagpal S., Patel S., Asano A.T., Johnson A.T., Duvic M., Chandraratna R.A., Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin (1996) J Invest Dermatol, 106, pp. 269-274; 
Jing C., El-Ghany M.A., Beesley C., Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity (2002) J Natl Cancer Inst, 94, pp. 482-490; 
Zhang J., Liu L., Pfeifer G.P., Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene (2004) Oncogene, 23, pp. 2241-2249
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-84885235141&partnerID=40&md5=f2b63ed19c2f9b0f050023cdf5c320f5
ER  - 

TY  - JOUR
TI  - Thyroid cancer: Molecular aspects and new therapeutic strategies
T2  - Journal of Thyroid Research
VL  - 2012
PY  - 2012
DO  - 10.1155/2012/847108
AU  - Grande E.
AU  - Díez J.J.
AU  - Zafon C.
AU  - Capdevila J.
N1  - 施引文献 :16
N1  - Export Date: 2 January 2016
TY  - Review
DB  - Scopus
C7  - 847108
N1  - 参考文献: Asioli S., Erickson L.A., Righi A., Jin L., Volante M., Jenkins S., Papotti M., Lloyd R.V., Poorly differentiated carcinoma of the thyroid: Validation of the Turin proposal and analysis of IMP3 expression (2010) Modern Pathology, 23 (9), pp. 1269-1278. , 2-s2.0-77956294580 10.1038/modpathol.2010.117; 
Chen A.Y., Jemal A., Ward E.M., Increasing incidence of differentiated thyroid cancer in the United States, 19882005 (2009) Cancer, 115 (16), pp. 3801-3807. , 2-s2.0-68549099879 10.1002/cncr.24416; 
Enewold L., Zhu K., Ron E., Marrogi A.J., Stojadinovic A., Peoples G.E., Devesa S.S., Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 19802005 (2009) Cancer Epidemiology Biomarkers and Prevention, 18 (3), pp. 784-791. , 2-s2.0-64549114616 10.1158/1055-9965.EPI-08-0960; 
Shimaoka K., Schoenfeld D.A., DeWys W.D., A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma (1985) Cancer, 56 (9), pp. 2155-2160. , DOI 10.1002/1097-0142(19851101)56: 9<2155::AID-CNCR2820560903>3.0. CO;2-E; 
Kondo T., Ezzat S., Asa S.L., Pathogenetic mechanisms in thyroid follicular-cell neoplasia (2006) Nature Reviews Cancer, 6 (4), pp. 292-306. , 2-s2.0-33645307434 10.1038/nrc1836; 
Sipos J.A., Shah M.H., Thyroid cancer: Emerging role for targeted therapies (2010) Therapeutic Advances in Medical Oncology, 2 (1), pp. 3-16. , 2-s2.0-77953368220 10.1177/1758834009352667; 
Soh E.Y., Eigelberger M.S., Kim K.J., Wong M.G., Young D.M., Clark O.H., Duh Q.Y., Roeher H.D., Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo (2000) Surgery, 128 (6), pp. 1059-1066. , 2-s2.0-0033671622; 
Yu X.-M., Lo C.-Y., Chan W.-F., Lam K.-Y., Leung P., Luk J.M., Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases (2005) Clinical Cancer Research, 11 (22), pp. 8063-8069. , DOI 10.1158/1078-0432.CCR-05-0646; 
Haq M.S., McCready R.V., Harmer C.L., Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy (2004) Nuclear Medicine Communications, 25 (8), pp. 799-805. , DOI 10.1097/01.mnm.0000136693.94761.5c; 
Schlumberge M., Sherman S., Approach to the patient with advanced differentiated thyroid cancer (2011) European Journal of Endocrinology, 166 (1), pp. 5-11; 
Matuszczyk A., Petersenn S., Bockisch A., Gorges R., Sheu S.Y., Veit P., Mann K., Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium (2008) Hormone and Metabolic Research, 40 (3), pp. 210-213. , DOI 10.1055/s-2008-1046781; 
Licitra L., Locati L.D., Greco A., Granata R., Bossi P., Multikinase inhibitors in thyroid cancer (2010) European Journal of Cancer, 46 (6), pp. 1012-1018. , 2-s2.0-77949539631 10.1016/j.ejca.2010.01.010; 
De Souza E.C.L., Ferreira A.C., De Carvalho D.P., The mTOR protein as a target in thyroid cancer (2011) Expert Opinion on Therapeutic Targets, 15 (9), pp. 1099-1112. , 10.1517/14728222.2011.594044; 
Marotta V., Guerra A., Sapio M.R., Vitale M., RET/PTC rearrangement in benign and malignant thyroid diseases: A clinical standpoint (2011) European Journal of Endocrinology, 165 (4), pp. 499-507. , 10.1530/EJE-11-0499; 
Bounacer A., Schlumberger M., Wicker R., Du-Villard J.A., Caillou B., Sarasin A., Suarez H.G., Search for NTRK1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation (2000) British Journal of Cancer, 82 (2), pp. 308-314; 
Gupta-Abramson V., Troxel A.B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., Mandel S.J., Brose M.S., Phase II trial of sorafenib in advanced thyroid cancer (2008) Journal of Clinical Oncology, 26 (29), pp. 4714-4719. , 2-s2.0-50649095250 10.1200/JCO.2008.16.3279; 
Kloos R.T., Ringel M.D., Knopp M.V., Hall N.C., King M., Stevens R., Liang J., Grever M., Phase II trial of sorafenib in metastatic thyroid cancer (2009) Journal of Clinical Oncology, 27 (10), pp. 1675-1684. , 2-s2.0-63849265332 10.1200/JCO.2008.18.2717; 
Ahmed M., Barbachano Y., Riddell A., Hickey J., Newbold K.L., Viros A., Harrington K.J., Nutting C.M., Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: A phase II study in a UK based population (2011) European Journal of Endocrinology, 165 (2), pp. 315-322. , 2-s2.0-79960179069 10.1530/EJE-11-0129; 
Hoftijzer H., Heemstra K.A., Morreau H., Stokkel M.P., Corssmit E.P., Gelderblom H., Weijers K., Smit J.W., Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma (2009) European Journal of Endocrinology, 161 (6), pp. 923-931. , 2-s2.0-72949106263 10.1530/EJE-09-0702; 
Capdevila J., Iglesias L., Halperin I., Segura Á., Martínez-Trufero J., Vaz M.Á., Corral J., Tabernero J., Sorafenib in metastatic thyroid cancer (2012) Endocrine-Related Cancer, 19 (2), pp. 209-216. , 10.1530/ERC-11-0351; 
Leboulleux S., Bastholt L., Krause T.M., Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular; DTC): A randomized, double-blind phase II trial Proceedings of the 4th International Thyroid Congress 2010 Paris, France Abstract OC-023; 
Cohen E.E.W., Rosen L.S., Vokes E.E., Kies M.S., Forastiere A.A., Worden F.P., Kane M.A., Cohen R.B., Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study (2008) Journal of Clinical Oncology, 26 (29), pp. 4708-4713. , 2-s2.0-50649095801 10.1200/JCO.2007.15.9566; 
Carr L.L., Mankoff D.A., Goulart B.H., Eaton K.D., Capell P.T., Kell E.M., Bauman J.E., Martins R.G., Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation (2010) Clinical Cancer Research, 16 (21), pp. 5260-5268. , 2-s2.0-78049462514 10.1158/1078-0432.CCR-10-0994; 
Cohen E.E., Needles B.M., Cullen K.J., Phase 2 study of sunitinib in refractory thyroid cancer (2008) Journal of Clinical Oncology, 26. , supplement, abstract 6025; 
Sherman S.I., Jarzab B., Cabanillas M.E., A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) (2011) Journal of Clinical Oncology, 29. , supplement, abstract 5503; 
Sherman S.I., Wirth L.J., Droz J.-P., Hofmann M., Bastholt L., Martins R.G., Licitra L., Schlumberger M.J., Motesanib diphosphate in progressive differentiated thyroid cancer (2008) New England Journal of Medicine, 359 (1), pp. 31-42. , http://content.nejm.org/cgi/reprint/359/1/31.pdf, DOI 10.1056/NEJMoa075853; 
Bible K.C., Suman V.J., Molina J.R., Smallridge R.C., Maples W.J., Menefee M.E., Rubin J., Erlichman C., Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study (2010) The Lancet Oncology, 11 (10), pp. 962-972. , 2-s2.0-77957359933 10.1016/S1470-2045(10)70203-5; 
Wells Jr. S.A., Robinson B.G., Gagel R.F., Dralle H., Fagin J.A., Santoro M., Baudin E., Schlumberger M.J., Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial (2012) Journal of Clinical Oncology, 30 (2), pp. 134-141. , 10.1200/JCO.2011.35.5040; 
Kurzrock R., Sherman S.I., Ball D.W., Forastiere A.A., Cohen R.B., Mehra R., Pfister D.G., Salgia R., Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer (2011) Journal of Clinical Oncology, 29 (19), pp. 2660-2666. , 2-s2.0-79959936054 10.1200/JCO.2010.32.4145; 
Lam E.T., Ringel M.D., Kloos R.T., Prior T.W., Knopp M.V., Liang J., Sammet S., Shah M.H., Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer (2010) Journal of Clinical Oncology, 28 (14), pp. 2323-2330. , 2-s2.0-77952468875 10.1200/JCO.2009.25.0068; 
Schlumberger M.J., Elisei R., Bastholt L., Wirth L.J., Martins R.G., Locati L.D., Jarzab B., Sherman S.I., Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer (2009) Journal of Clinical Oncology, 27 (23), pp. 3794-3801. , 2-s2.0-68949108390 10.1200/JCO.2008.18.7815; 
De Souza J.A., Busaidy N., Zimrin A., Phase II trial of sunitinib in medullary thyroid cancer (MTC) (2010) Journal of Clinical Oncology, 28 (15 S). , supplement, abstract 5504; 
Santarpia L., Myers J.N., Sherman S.I., Trimarchi F., Clayman G.L., El-Naggar A.K., Genetic alterations in the Ras/Raf/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma (2010) Cancer, 116 (12), pp. 2974-2983. , 2-s2.0-77954022714 10.1002/cncr.25061; 
Grande-Pulido E., Castelo B., Fonseca P.J., Efficacy and tolerability of sunitinib in patients with advanced thyroid cancer out of a trial: A Spanish multicenter cohort (2011) Journal of Clinical Oncology, 29. , supplement, abstract e16024; 
Cakir M., Grossman A.B., Medullary thyroid cancer: Molecular biology and novel molecular therapies (2009) Neuroendocrinology, 90 (4), pp. 323-348. , 2-s2.0-71849111319 10.1159/000220827; 
Pacini F., Castagna M.G., Cipri C., Schlumberger M., Medullary thyroid carcinoma (2010) Clinical Oncology, 22 (6), pp. 475-485. , 2-s2.0-77954757206 10.1016/j.clon.2010.05.002; 
Phay J.E., Shah M.H., Targeting RET receptor tyrosine kinase activation in cancer (2010) Clinical Cancer Research, 16 (24), pp. 5936-5941. , 2-s2.0-78650412305 10.1158/1078-0432.CCR-09-0786; 
Perri F., Lorenzo G.D., Scarpati G.D., Buonerba C.C., Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options (2011) World Journal of Clinical Oncology, 2 (3), pp. 150-157; 
Nagaiah G., Fu P., Wasman J.K., CTRU Research Nurses. Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (2009) Journal of Clinical Oncology, 27 (15 S). , supplement, abstract 6058; 
Sosa J.A., Elisei R., Jarzab B., A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial (2011) Journal of Clinical Oncology, 29. , supplement, abstract 5502
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-84869019637&partnerID=40&md5=95f5b544142bce087af14163191ab375
ER  - 

TY  - JOUR
TI  - Genome-wide association studies of cancer: Principles and potential utility
T2  - ONCOLOGY
VL  - 24
IS  - 7
PY  - 2010
AU  - Stadler Z.K.
AU  - Gallagher D.J.
AU  - Thom P.
AU  - Offit K.
N1  - 施引文献 :16
N1  - Export Date: 2 January 2016
TY  - Review
DB  - Scopus
N1  - 参考文献: Manolio T.A., Brooks L.D., Collins F.S., A HapMap harvest of insights into the genetics of common disease (2008) J Clin Invest, 118, pp. 1590-1605; 
Lichtenstein P., Holm N.V., Verkasalo P.K., Environmental and heritable factors in the causation of cancer - Analyses of cohorts of twins from Sweden, Denmark, and Finland (2000) N Engl J Med, 343, pp. 78-85; 
Goldgar D.E., Easton D.F., Cannon-Albright L.A., Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands (1994) J Natl Cancer Inst, 86, pp. 1600-1608; 
Athma P., Rappaport R., Swift M., Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer (1996) Cancer Genetics and Cytogenetics, 92 (2), pp. 130-134. , DOI 10.1016/S0165-4608(96)00328-7, PII S0165460896003287; 
Bernstein J.L., Bernstein L., Thompson W.D., ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer (2003) Br J Cancer, 89, pp. 1513-1516; 
Bretsky P., Haiman C.A., Gilad S., The relationship between twenty missense ATM variants and breast cancer risk: The Multiethnic Cohort (2003) Cancer Epidemiol Biomarkers Prev, 12, pp. 733-738; 
CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies (2004) Am J Hum Genet, 74, pp. 1175-1182. , CHEK2 Breast Cancer Case-Control Consorrtium; 
Meijers-Heijboer H., Van Den Ouweland A., Klijn J., Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations (2002) Nat Genet, 31, pp. 55-59; 
Thompson D., Seal S., Schutte M., A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers (2006) Cancer Epidemiol Biomarkers Prev, 15, pp. 2542-2545; 
Seal S., Thompson D., Renwick A., Elliott A., Kelly P., Barfoot R., Chagtai T., Rahman N., Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles (2006) Nature Genetics, 38 (11), pp. 1239-1241. , DOI 10.1038/ng1902, PII NG1902; 
Rahman N., Seal S., Thompson D., Kelly P., Renwick A., Elliott A., Reid S., Stratton M.R., PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene (2007) Nature Genetics, 39 (2), pp. 165-167. , DOI 10.1038/ng1959, PII NG1959; 
Easton D.F., How many more breast cancer predisposition genes are there? (1999) Breast Cancer Res, 1, pp. 14-147; 
Lander E.S., The new genomics: Global views of biology (1996) Science, 274, pp. 536-539; 
Xiong M., Guo S.W., Fine-scale genetic mapping based on linkage disequilibrium: Theory and applications (1997) Am J Hum Genet, 60, pp. 1513-1531; 
Frazer K.A., Ballinger D.G., Cox D.R., A second generation human haplotype map of over 3.1 million SNPs (2007) Nature, 449, pp. 851-8561; 
Kruglyak L., The road to genome-wide association studies (2008) Nat Rev Genet, 9, pp. 314-318; 
Satagopan J.M., Elston R.C., Optimal two-stage genotyping in population-based association studies (2003) Genet Epidemiol, 25, pp. 149-157; 
Wang W.Y., Barratt B.J., Clayton D.G., Genome-wide association studies: Theoretical and practical concerns (2005) Nat Rev Genet, 6, pp. 109-6118; 
Garcia-Closas M., Chanock S., Genetic susceptibility loci for breast cancer by estrogen receptor status (2008) Clin Cancer Res, 14, pp. 8000-8009. , p〉; 
Ardlie K.G., Lunetta K.L., Seielstad M., Testing for population subdivision and association in four case-control studies (2002) Am J Hum Genet, 71, pp. 304-311; 
Wacholder S., Rothman N., Caporaso N., Counterpoint: Bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer (2002) Cancer Epidemiology Biomarkers and Prevention, 11 (6), pp. 513-520; 
Marchini J., Cardon L.R., Phillips M.S., Donnelly P., The effects of human population structure on large genetic association studies (2004) Nature Genetics, 36 (5), pp. 512-517. , DOI 10.1038/ng1337; 
Freedman M.L., Reich D., Penney K.L., Assessing the impact of population stratification on genetic association studies (2004) Nat Genet, 36, pp. 388-393; 
Price A.L., Patterson N.J., Plenge R.M., Principal components analysis corrects for stratification in genome-wide association studies (2006) Nat Genet, 38, pp. 904-909; 
Easton D.F., Pooley K.A., Dunning A.M., Pharoah P.D.P., Thompson D., Ballinger D.G., Struewing J.P., Hartikainen J., Genome-wide association study identifies novel breast cancer susceptibility loci (2007) Nature, 447 (7148), pp. 1087-1093. , DOI 10.1038/nature05887, PII NATURE05887; 
Garcia-Closas M., Hall P., Nevanlinna H., Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics (2008) PLoS Genet, 4, pp. e1000054; 
Ahmed S., Thomas G., Ghoussaini M., Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 (2009) Nat Genet, 41, pp. 585-590; 
Hunter D.J., Kraft P., Jacobs K.B., Cox D.G., Yeager M., Hankinson S.E., Wacholder S., Chanock S.J., A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer (2007) Nature Genetics, 39 (7), pp. 870-874. , DOI 10.1038/ng2075, PII NG2075; 
Thomas G., Jacobs K.B., Kraft P., A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) (2009) Nat Genet, 41, pp. 579-584; 
Stacey S.N., Manolescu A., Sulem P., Rafnar T., Gudmundsson J., Gudjonsson S.A., Masson G., Stefansson K., Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer (2007) Nature Genetics, 39 (7), pp. 865-869. , DOI 10.1038/ng2064, PII NG2064; 
Stacey S.N., Manolescu A., Sulem P., Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer (2008) Nat Genet, 40, pp. 703-706; 
Gold B., Kirchhoff T., Stefanov S., Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33 (2008) Proc Natl Acad Sci U S A, 105, pp. 4340-4345; 
Zheng W., Long J., Gao Y.T., Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1 (2009) Nat Genet, 41, pp. 324-328; 
Eeles R.A., Kote-Jarai Z., Giles G.G., Olama A.A.A., Guy M., Jugurnauth S.K., Mulholland S., Easton D.F., Multiple newly identified loci associated with prostate cancer susceptibility (2008) Nature Genetics, 40 (3), pp. 316-321. , DOI 10.1038/ng.90, PII NG90; 
Thomas G., Jacobs K.B., Yeager M., Kraft P., Wacholder S., Orr N., Yu K., Chanock S.J., Multiple loci identified in a genome-wide association study of prostate cancer (2008) Nature Genetics, 40 (3), pp. 310-315. , DOI 10.1038/ng.91, PII NG91; 
Yeager M., Orr N., Hayes R.B., Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 (2007) Nat Genet, 39, pp. 645-649; 
Yeager M., Chatterjee N., Ciampa J., Identification of a new prostate cancer susceptibility locus on chromosome 8q24 (2009) Nat Genet, 41, pp. 1055-1057; 
Eeles R.A., Kote-Jarai Z., Al Olama A.A., Identification of seven new prostate cancer susceptibility loci through a genome-wide association study (2009) Nat Genet, 41, pp. 1116-1121; 
Gudmundsson J., Sulem P., Manolescu A., Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 (2007) Nat Genet, 39, pp. 631-637; 
Gudmundsson J., Sulem P., Rafnar T., Bergthorsson J.T., Manolescu A., Gudbjartsson D., Agnarsson B.A., Stefansson K., Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer (2008) Nature Genetics, 40 (3), pp. 281-283. , DOI 10.1038/ng.89, PII NG89; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility (2009) Nat Genet, 41, pp. 1122-1126; 
Amundadottir L.T., Sulem P., Gudmundsson J., Helgason A., Baker A., Agnarsson B.A., Sigurdsson A., Stefansson K., A common variant associated with prostate cancer in European and African populations (2006) Nature Genetics, 38 (6), pp. 652-658. , DOI 10.1038/ng1808, PII N1808; 
Freedman M.L., Haiman C.A., Patterson N., Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men (2006) Proc Natl Acad Sci U S A, 103, pp. 14068-14073; 
Al Olama A.A., Kote-Jarai Z., Giles G.G., Multiple loci on 8q24 associated with prostate cancer susceptibility (2009) Nat Genet, 41, pp. 1058-1060; 
Sun J., Zheng S.L., Wiklund F., Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12 (2008) Nat Genet, 40, pp. 1153-2115; 
Tomlinson I., Webb E., Carvajal-Carmona L., A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21 Nat Genet, 39, pp. 984-988; 
Zanke B.W., Greenwood C.M., Rangrej J., Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24 (2007) Nat Genet, 39, pp. 989-994; 
Tomlinson I.P.M., Webb E., Carvajal-Carmona L., Broderick P., Howarth K., Pittman A.M., Spain S., Houlston R.S., A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3 (2008) Nature Genetics, 40 (5), pp. 623-630. , DOI 10.1038/ng.111, PII NG111; 
Houlston R.S., Webb E., Broderick P., Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer (2008) Nat Genet, 40, pp. 1426-1435; 
Tenesa A., Farrington S.M., Prendergast J.G., Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21 (2007) Nat Genet, 40, pp. 631-637; 
Jaeger E., Webb E., Howarth K., Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk (2008) Nat Genet, 40, pp. 26-28; 
Broderick P., Carvajal-Carmona L., Pittman A.M., Webb E., Howarth K., Rowan A., Lubbe S., Houlston R.S., A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk (2007) Nature Genetics, 39 (11), pp. 1315-1317. , DOI 10.1038/ng.2007.18, PII NG200718; 
Wang Y., Broderick P., Webb E., Common 5p15.33 and 6p21.33 variants influence lung cancer risk (2008) Nat Genet, 40, pp. 1407-1409; 
McKay J.D., Hung R.J., Gaborieau V., Lung cancer susceptibility locus at 5p15.33 (2008) Nat Genet, 40, pp. 1404-1406; 
Amos C.I., Wu X., Broderick P., Gorlov I.P., Gu J., Eisen T., Dong Q., Houlston R.S., Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 (2008) Nature Genetics, 40 (5), pp. 616-622. , DOI 10.1038/ng.109, PII NG109; 
Hung R.J., McKay J.D., Gaborieau V., Boffetta P., Hashibe M., Zaridze D., Mukeria A., Brennan P., A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 (2008) Nature, 452 (7187), pp. 633-637. , DOI 10.1038/nature06885, PII NATURE06885; 
Liu P., Vikis H.G., Wang D., Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer (2008) J Natl Cancer Inst, 100, pp. 1326-1330; 
Petersen G.M., Amundadottir L., Fuchs C.S., A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33 (2010) Nat Genet, 42, pp. 224-228; 
Amundadottir L., Kraft P., Stolzenberg-Solomon R.Z., Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer (2009) Nat Genet, 41, pp. 986-990; 
Sakamoto H., Yoshimura K., Saeki N., Katai H., Shimoda T., Matsuno Y., Saito D., Hirohashi S., Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer (2008) Nature Genetics, 40 (6), pp. 730-740. , DOI 10.1038/ng.152, PII NG152; 
Cui R., Kamatani Y., Takahashi A., Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk (2009) Gastroenterology, 137, pp. 1768-1775; 
Kiemeney L.A., Thorlacius S., Sulem P., Sequence variant on 8q24 confers susceptibility to urinary bladder cancer (2008) Nat Genet, 40, pp. 1307-1312; 
Wu X., Ye Y., Kiemeney L.A., Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer (2009) Nat Genet, 41, pp. 991-995; 
Rapley E.A., Turnbull C., Al Olama A.A., A genome-wide association study of testicular germ cell tumor (2009) Nat Genet, 41, pp. 807-810; 
Kanetsky P.A., Mitra N., Vardhanabhuti S., Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer (2009) Nat Genet, 41, pp. 811-815; 
Song H., Ramus S.J., Tyrer J., A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2 (2009) Nat Genet, 41, pp. 996-1000; 
Stacey S.N., Sulem P., Masson G., New common variants affecting susceptibility to basal cell carcinoma (2009) Nat Genet, 41, pp. 909-914; 
Stacey S.N., Gudbjartsson D.F., Sulem P., Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits (2008) Nat Genet, 40, pp. 1313-1318; 
Bishop D.T., Demenais F., Iles M.M., Genome-wide association study identifies three loci associated with melanoma risk (2009) Nat Genet, 41, pp. 920-925; 
Gudbjartsson D.F., Sulem P., Stacey S.N., Goldstein A.M., Rafnar T., Sigurgeirsson B., Benediktsdottir K.R., Stefansson K., ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma (2008) Nature Genetics, 40 (7), pp. 886-891. , DOI 10.1038/ng.161, PII NG161; 
Brown K.M., MacGregor S., Montgomery G.W., Craig D.W., Zhao Z.Z., Iyadurai K., K Henders A., Hayward N.K., Common sequence variants on 20q11.22 confer melanoma susceptibility (2008) Nature Genetics, 40 (7), pp. 838-840. , DOI 10.1038/ng.163, PII NG163; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations (2009) Nat Genet, 41, pp. 460-464; 
Capasso M., Devoto M., Hou C., Common variations in BARD1 influence susceptibility to high-risk neuroblastoma (2009) Nat Genet, 41, pp. 718-723; 
Maris J.M., Mosse Y.P., Bradfield J.P., Chromosome 6p22 locus associated with clinically aggressive neuroblastoma (2008) N Engl J Med, 358, pp. 2585-2593; 
Shete S., Hosking F.J., Robertson L.B., Genome-wide association study identifies five susceptibility loci for glioma (2009) Nat Genet, 41, pp. 899-904; 
Wrensch M., Jenkins R.B., Chang J.S., Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility (2009) Nat Genet, 41, pp. 905-908; 
Papaemmanuil E., Hosking F.J., Vijayakrishnan J., Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia (2009) Nat Genet, 41, pp. 1006-1010; 
Trevino L.R., Yang W., French D., Germline genomic variants associated with childhood acute lymphoblastic leukemia (2009) Nat Genet, 41, pp. 1001-1005; 
Di Bernardo M.C., Crowther-Swanepoel D., Broderick P., A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia (2008) Nat Genet, 40, pp. 1204-1210; 
Skibola C.F., Bracci P.M., Halperin E., Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma (2009) Nat Genet, 41, pp. 873-875; 
Kilpivaara O., Mukherjee S., Schram A.M., A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms (2009) Nat Genet, 41, pp. 455-459; 
Sole X., Hernandez P., De Heredia M.L., Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility (2008) BMC Genomics, 9, p. 12; 
Pomerantz M.M., Ahmadiyeh N., Jia L., The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer (2009) Nat Genet, 41, pp. 882-884; 
Tuupanen S., Turunen M., Lehtonen R., The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling (2009) Nat Genet, 41, pp. 885-890; 
Rafnar T., Sulem P., Stacey S.N., Sequence variants at the TERT-CLPTM1L locus associate with many cancer types (2009) Nat Genet, 41, pp. 221-227; 
Xu J., Kibel A.S., Hu J.J., Prostate cancer risk associated loci in African Americans (2009) Cancer Epidemiol Biomarkers Prev, 18, pp. 2145-2149; 
Marcus D.M., The ABO and Lewis blood-group system. Immunochemistry, genetics and relation to human disease (1969) N Engl J Med, 280, pp. 994-1006; 
Mahakali Zama A., Hudson III F.P., Bedell M.A., Analysis of hypomorphic KitlSl mutants suggests different requirements for KITL in proliferation and migration of mouse primordial germ cells (2005) Biol Reprod, 73, pp. 639-647; 
Han J., Kraft P., Nan H., A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation (2008) PLoS Genet, 4, pp. e1000074; 
Janssens A.C., Gwinn M., Bradley L.A., A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions (2008) Am J Hum Genet, 82, pp. 593-599; 
Grosse S.D., Khoury M.J., What is the clinical utility of genetic testing? (2006) Genet Med, 8, pp. 448-450; 
Burke W., Clinical validity and clinical utility of genetic tests (2009) Curr Protoc Hum Genet, , Chapter 9:Unit 9 15, Jan; 
Gail M.H., Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model (2009) J Natl Cancer Inst, 101, pp. 959-963; 
Fitzgerald L.M., Kwon E.M., Koopmeiners J.S., Analysis of recently identified prostate cancer susceptibility loci in a population-based study: Associations with family history and clinical features (2009) Clin Cancer Res, 15, pp. 3231-3237; 
Penney K.L., Salinas C.A., Pomerantz M., Evaluation of 8q24 and 17q risk loci and prostate cancer mortality (2009) Clin Cancer Res, 15, pp. 3223-3230; 
Wiklund F.E., Adami H.O., Zheng S.L., Established prostate cancer susceptibility variants are not associated with disease outcome (2009) Cancer Epidemiol Biomarkers Prev, 18, pp. 1659-1662; 
Fong P.C., Boss D.S., Yap T.A., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers (2009) N Engl J Med, 361, pp. 123-134; 
Andriole G.L., Crawford E.D., Grubb III R.L., Mortality results from a randomized prostate-cancer screening trial (2009) N Engl J Med, 360, pp. 1310-1319; 
Schroder F.H., Hugosson J., Roobol M.J., Screening and prostate-cancer mortality in a randomized European study (2009) N Engl J Med, 360, pp. 1320-1328; 
Kramer B.S., Hagerty K.L., Justman S., Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline (2009) J Clin Oncol, 27, pp. 1502-1516; 
Robson M.E., Storm C.D., Weitzel J., American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility (2010) J Clin Oncol, 28, pp. 893-901; 
(2009) The Integration of Genetic Technologies into Health Care and Public Health: A Progress Report and Future Directions of the Secretarys Advisory Committee on Genetics, Health, and Society, , http://oba.od.nih.gov/SACGHS/sacghs_documents.html, January Available at: Accessed December May 25, 2010; 
Offit K., Thom P., Ethical and Legal Aspects of Cancer Genetic Testing (2007) Seminars in Oncology, 34 (5), pp. 435-443. , DOI 10.1053/j.seminoncol.2007.07.007, PII S0093775407001443, Breast and Colorectal Cancer Genetics for Practicing Oncologists
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-77958034604&partnerID=40&md5=d2cad93c82442f1a210182e7fc7e133b
ER  - 

TY  - JOUR
TI  - Risk of thyroid cancer in first-degree relatives of patients with non-medullary thyroid cancer by histology type and age at diagnosis: A joint study from five nordic countries
T2  - Journal of Medical Genetics
VL  - 50
IS  - 6
SP  - 373
EP  - 382
PY  - 2013
DO  - 10.1136/jmedgenet-2012-101412
AU  - Fallah M.
AU  - Pukkala E.
AU  - Tryggvadottir L.
AU  - Olsen J.H.
AU  - Tretli S.
AU  - Sundquist K.
AU  - Hemminki K.
N1  - 施引文献 :14
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M., GLOBOCAN 2008 v2.0, cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet] (2010), Lyon, France: International Agency for Research on CancerKhan A., Smellie J., Nutting C., Harrington K., Newbold K., Familial nonmedullary thyroid cancer: a review of the genetics (2010) Thyroid, 20, pp. 795-801; 
Howlader N., Noone A., Krapcho M., Neyman N., Aminou R., Waldron W., Altekruse S., Edwards B., SEER Cancer Statistics Review, 1975-2008 (2011), Bethesda, MD: National Cancer InstitutePacini F., Castagna M.G., Cipri C., Schlumberger M., Medullary thyroid carcinoma (2010) Clin Oncol (R Coll Radiol), 22, pp. 475-485; 
Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R., A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. (1998) Cancer, 83, pp. 2638-2648; 
Boyle P., Levin B., (2008) World Cancer Report 2008, , Lyon: International Agency for Research on Cancer (IARC); 
Goldgar D.E., Easton D.F., Cannon-Albright L.A., Skolnick M.H., Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands (1994) J Natl Cancer Inst, 86, pp. 1600-1608; 
Amundadottir L.T., Thorvaldsson S., Gudbjartsson D.F., Sulem P., Kristjansson K., Arnason S., Gulcher J.R., Stefansson K., Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family (2004) PLoS Med, 1, pp. e65; 
Negri E., Ron E., Franceschi S., La Vecchia C., Preston-Martin S., Kolonel L., Kleinerman R.A., Fraumeni Jr. J.F., Risk factors for medullary thyroid carcinoma: a pooled analysis (2002) Cancer Causes Control, 13, pp. 365-372; 
Hemminki K., Dong C., Population-based study of familial medullary thyroid cancer (2001) Fam Cancer, 1, pp. 45-49; 
Hemminki K., Dong C., Familial relationships in thyroid cancer by histo-pathological type (2000) Int J Cancer, 85, pp. 201-205; 
Mazeh H., Benavidez J., Poehls J.L., Youngwirth L., Chen H., Sippel R.S., In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease (2012) Thyroid, 22, pp. 3-8; 
Nose V., Familial follicular cell tumors: classification and morphological characteristics (2010) Endocr Pathol, 21, pp. 219-226; 
Hanief M.R., Igali L., Grama D., Hurthle cell carcinoma: diagnostic and therapeutic implications (2004) World J Surg Oncol, 2, p. 27; 
Chiacchio S., Lorenzoni A., Boni G., Rubello D., Elisei R., Mariani G., Anaplastic thyroid cancer: prevalence, diagnosis and treatment (2008) Minerva Endocrinol, 33, pp. 341-357; 
Nagaiah G., Hossain A., Mooney C.J., Parmentier J., Remick S.C., Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment (2011) J Oncol, 2011, p. 542358; 
Giuffrida D., Gharib H., Anaplastic thyroid carcinoma: current diagnosis and treatment (2000) Ann Oncol, 11, pp. 1083-1089; 
Syed M.I., Stewart M., Syed S., Dahill S., Adams C., McLellan D.R., Clark L.J., Squamous cell carcinoma of the thyroid gland: primary or secondary disease? (2011) J Laryngol Otol, 125, pp. 3-9; 
Hemminki K., Eng C., Chen B., Familial risks for nonmedullary thyroid cancer (2005) J Clin Endocrinol Metab, 90, pp. 5747-5753; 
Frich L., Glattre E., Akslen L.A., Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway (2001) Cancer Epidemiol Biomarkers Prev, 10, pp. 113-117; 
Galanti M.R., Ekbom A., Grimelius L., Yuen J., Parental cancer and risk of papillary and follicular thyroid carcinoma (1997) Br J Cancer, 75, pp. 451-456; 
Brindel P., Doyon F., Bourgain C., Rachedi F., Boissin J.L., Sebbag J., Shan L., de Vathaire F., Family history of thyroid cancer and the risk of differentiated thyroid cancer in French polynesia (2010) Thyroid, 20, pp. 393-400; 
Mack W.J., Preston-Martin S., Bernstein L., Qian D., Lifestyle and other risk factors for thyroid cancer in Los Angeles County females (2002) Ann Epidemiol, 12, pp. 395-401; 
Memon A., Berrington De Gonzalez A., Luqmani Y., Suresh A., Family history of benign thyroid disease and cancer and risk of thyroid cancer (2004) Eur J Cancer, 40, pp. 754-760; 
Pal T., Vogl F.D., Chappuis P.O., Tsang R., Brierley J., Renard H., Sanders K., Foulkes W.D., Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study (2001) J Clin Endocrinol Metab, 86, pp. 5307-5312; 
Ron E., Kleinerman R.A., Boice J.D., LiVolsi V.A., Flannery J.T., Fraumeni Jr. J.F., A population-based case-control study of thyroid cancer. (1987) J Natl Cancer Inst, 79, pp. 1-12; 
Xu L., Li G., Wei Q., El-Naggar A.K., Sturgis E.M., Family history of cancer and risk of sporadic differentiated thyroid carcinoma (2012) Cancer, 118, pp. 1228-35; 
Vlajinac H.D., Adanja B.J., Zivaljevic V.R., Jankovic R.R., Dzodic R.R., Jovanovic D.D., Malignant tumors in families of thyroid cancer patients (1997) Acta Oncol, 36, pp. 477-481; 
Storm H.H., Survey of Nordic Cancer Registries (2000) Copenhagen: Danish Cancer Society; 
Lund E.M., Clemmensen I.H., Storm H.H., Engholm G., Survey of the Nordic Cancer Registries (2000) Danish Cancer Society, Copenhagen; 
Lappalainen T., Hannelius U., Salmela E., von Dobeln U., Lindgren C.M., Huoponen K., Savontaus M.L., Lahermo P., Population structure in contemporary Sweden-a Y-chromosomal and mitochondrial DNA analysis (2009) Ann Hum Genet, 73, pp. 61-73; 
Lao O., Lu T.T., Nothnagel M., Junge O., Freitag-Wolf S., Caliebe A., Balascakova M., Kayser M., Correlation between genetic and geographic structure in Europe (2008) Curr Biol, 18, pp. 1241-1248; 
Nelis M., Esko T., Magi R., Zimprich F., Zimprich A., Toncheva D., Karachanak S., Metspalu A., Genetic structure of Europeans: a view from the North-East (2009) PLoS One, 4, pp. e5472; 
Kharazmi E., Fallah M., Sundquist K., Hemminki K., Familial risk of early and late onset cancer: nationwide prospective cohort study (2012) BMJ, 345, pp. e8076; 
Rosario P.W., Mineiro Filho A.F., Prates B.S., Silva L.C., Lacerda R.X., Calsolari M.R., Ultrasonographic screening for thyroid cancer in siblings of patients with apparently sporadic papillary carcinoma (2012) Thyroid, 22, pp. 805-808; 
Nose V., Familial thyroid cancer: a review (2011) Mod Pathol, 24 (2 SUPPL.), pp. S19-33; 
Na K.Y., Kim R.M., Song E.M., Lee J.H., Lee J., Soh E.Y., Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer (2012) J Surg Oncol, 105, pp. 10-14; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Jonasson J.G., Sigurdsson A., Bergthorsson J.T., He H., Stefansson K., Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations (2009) Nat Genet, 41, pp. 460-464; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Jonasson J.G., Masson G., He H., Jonasdottir A., Stefansson K., Discovery of common variants associated with low TSH levels and thyroid cancer risk (2012) Nat Genet, 44, pp. 319-322; 
He H., Nagy R., Liyanarachchi S., Jiao H., Li W., Suster S., Kere J., de la Chapelle A., A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24 (2009) Cancer Res, 69, pp. 625-631; 
Fusco A., Viglietto G., Santoro M., Point mutation in GRIM-19: a new genetic lesion in Hurthle cell thyroid carcinomas (2005) Br J Cancer, 92, pp. 1817-1818; 
Maximo V., Botelho T., Capela J., Soares P., Lima J., Taveira A., Amaro T., Sobrinho-Simoes M., Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid (2005) Br J Cancer, 92, pp. 1892-1898; 
Fagin J.A., Mitsiades N., Molecular pathology of thyroid cancer: diagnostic and clinical implications (2008) Best Pract Res Clin Endocrinol Metab, 22, pp. 955-69; 
Weires M., Bermejo J.L., Sundquist J., Hemminki K., Clustering of concordant and discordant cancer types in Swedish couples is rare (2011) Eur J Cancer, 47, pp. 98-106
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-84878871240&partnerID=40&md5=6a65a689107fb8415465f16012b0124a
ER  - 

TY  - JOUR
TI  - Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma
T2  - Thyroid
VL  - 23
IS  - 12
SP  - 1532
EP  - 1540
PY  - 2013
DO  - 10.1089/thy.2013.0102
AU  - Liyanarachchi S.
AU  - Wojcicka A.
AU  - Li W.
AU  - Czetwertynska M.
AU  - Stachlewska E.
AU  - Nagy R.
AU  - Hoag K.
AU  - Wen B.
AU  - Ploski R.
AU  - Ringel M.D.
AU  - Kozłowicz-Gudzinska I.
AU  - Gierlikowski W.
AU  - Jazdzewski K.
AU  - He H.
AU  - De La Chapelle A.
N1  - 施引文献 :13
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Goldgar D.E., Easton D.F., Cannon-Albright L.A., Skolnick M.H., Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands (1994) Journal of the National Cancer Institute, 86 (21), pp. 1600-1608; 
Dong C., Hemminki K., Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families (2001) International Journal of Cancer, 92 (1), pp. 144-150; 
Risch N., The genetic epidemiology of cancer: Interpreting family and twin studies and their implications for molecular genetic approaches (2001) Cancer Epidemiology Biomarkers and Prevention, 10 (7), pp. 733-741; 
Albright F., Teerlink C., Werner T., Cannon-Albright L., Significant evidence for a heritable contribution to cancer predisposition: A review of cancer familiality by site (2012) BMC Cancer, 12, pp. 138-144; 
De La Chapelle A., Jazdzewski K., MicroRNAs in thyroid cancer (2011) J Clin Endocrinol Metab, 96, pp. 3326-3336; 
Bonora E., Tallini G., Romeo G., Genetic predisposition to familial nonmedullary thyroid cancer: An update of molecular findings and state-of-The-art studies (2010) J Oncol, 2010, pp. 1-7; 
Jendrzejewski J., He H., Radomska H.S., Li W., Tomsic J., Liyanarachchi S., Davuluri R.V., De La Chapelle A., The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type (2012) Proc Natl Acad Sci USA, 109, pp. 8646-8651; 
Jazdzewski K., Murray E.L., Franssila K., Jarzab B., Schoenberg D.R., De La Chapelle A., Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma (2008) Proceedings of the National Academy of Sciences of the United States of America, 105 (20), pp. 7269-7274. , http://www.pnas.org/cgi/reprint/105/20/7269, DOI 10.1073/pnas.0802682105; 
Jazdzewski K., Liyanarachchi S., Swierniak M., Pachucki J., Ringel M.D., Jarzab B., De La Chapelle A., Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer (2009) Proc Natl Acad Sci USA, 106, pp. 1502-1505; 
Sueta A., Ito H., Kawase T., Hirose K., Hosono S., Yatabe Y., Tajima K., Matsuo K., A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population (2012) Breast Cancer Res Treat, 132, pp. 711-721; 
Dai J., Hu Z., Jiang Y., Shen H., Dong J., Ma H., Shen H., Breast cancer risk assessment with five independent genetic variants and two risk factors in Chinese women (2012) Breast Cancer Res, 14, pp. 17-28; 
Dunlop M.G., Dobbins S.E., Farrington S.M., Jones A.M., Palles C., Whiffin N., Tenesa A., Houlston R.S., Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk (2012) Nat Genet, 44, pp. 770-776; 
De Haan H.G., Bezemer I.D., Doggen C.J.M., Le Cessie S., Reitsma P.H., Arellano A.R., Tong C.H., Vossen C.Y., Multiple SNP testing improves risk prediction of first venous thrombosis (2012) Blood, 120, pp. 656-663; 
Go M.J., Hwang J.Y., Kim D.J., Lee H.J., Jang H.B., Park K.H., Song J., Lee J.Y., Effect of genetic predisposition on blood lipid traits using cumulative risk assessment in the Korean population (2012) Genomics Inform, 10, pp. 99-105; 
Lango H., Palmer C.N.A., Morris A.D., Zeggini E., Hattersley A.T., McCarthy M.I., Frayling T.M., Weedon M.N., Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk (2008) Diabetes, 57, pp. 3129-3135; 
Meigs J.B., Shrader P., Sullivan L.M., McAteer J.B., Fox C.S., Dupuis J., Manning A.K., Cupples L.A., Genotype score in addition to common risk factors for prediction of type 2 diabetes (2008) N Engl J Med, 359, pp. 2208-2219; 
Li S., Zhao J.H., Ja L., Luben R.N., Rodwell S.A., Khaw K.-T., Ong K.K., Loos R.J., Cumulative effects and predictive value of common obesity-susceptibility variants identified by genome-wide association studies (2010) Am J Clin Nutr, 91, pp. 184-190; 
Witte J.S., Genome-wide association studies and beyond (2010) Annual Review of Public Health. Vol. 31. Annual Reviews, pp. 9-20. , Fielding JE, Brownson RC, Green LW (eds), Palo Alto, CA; 
Nam R.K., Zhang W.W., Trachtenberg J., Seth A., Klotz L.H., Stanimirovic A., Punnen S., Narod S.A., Utility of incorporating genetic variants for the early detection of prostate cancer (2009) Clin Cancer Res, 15, pp. 1787-1793; 
Park J.-H., Gail M.H., Greene M.H., Chatterjee N., Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: An evaluation of seven common cancers (2012) J Clin Oncol, 30, pp. 2157-2162; 
Wu C., Walsh K., Dewan A., Hoh J., Wang Z., Disease risk prediction with rare and common variants (2011) BMC Proc, 5 (SUPPL. 9), pp. 61-65; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Jonasson J.G., Sigurdsson A., Bergthorsson J.T., He H., Stefansson K., Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations (2009) Nat Genet, 41, pp. 460-464; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Jonasson J.G., Masson G., He H., Jonasdottir A., Stefansson K., Discovery of common variants associated with low TSH levels and thyroid cancer risk (2012) Nat Genet, 44, pp. 319-322; 
He H., Olesnanik K., Nagy R., Liyanarachchi S., Prasad M.L., Stratakis C.A., Kloos R.T., De La Chapelle A., Allelic variation in gene expression in thyroid tissue (2005) Thyroid, 15 (7), pp. 660-667. , DOI 10.1089/thy.2005.15.660; 
Lin X., Song K., Lim N., Yuan X., Johnson T., Abderrahmani A., Vollenweider P., Mooser V., Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score - The CoLaus Study (2009) Diabetologia, 52, pp. 600-608; 
Houlston R.S., Ford D., Genetics of coeliac disease (1996) QJM - Monthly Journal of the Association of Physicians, 89 (10), pp. 737-743; 
Broderick P., Chubb D., Johnson D.C., Weinhold N., Forsti A., Lloyd A., Olver B., Houlston R.S., Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk (2012) Nat Genet, 44, pp. 58-61; 
Cox A., Dunning A.M., Garcia-Closas M., Balasubramanian S., Reed M.W.R., Pooley K.A., Scollen S., Easton D.F., A common coding variant in CASP8 is associated with breast cancer risk (2007) Nature Genetics, 39 (3), pp. 352-358. , DOI 10.1038/ng1981, PII NG1981; 
Amundadottir L.T., Thorvaldsson S., Gudbjartsson D.F., Sulem P., Kristjansson K., Arnason S., Gulcher J.R., Stefansson K., Cancer as a complex phenotype: Pattern of cancer distribution within and beyond the nuclear family (2004) PLoS Medicine, 1 (3), pp. 229-236. , http://medicine.plosjournals.org/archive/1549-1676/1/3/pdf/10. 1371_journal.pmed.0010065-L.pdf, DOI 10.1371/journal.pmed.0010065, e65; 
Czene K., Lichtenstein P., Hemminki K., Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database (2002) International Journal of Cancer, 99 (2), pp. 260-266. , DOI 10.1002/ijc.10332; 
Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., Pukkala E., Hemminki K., Environmental and heritable factors in the causation of cancer: Analyses of cohorts of twins from Sweden, Denmark, and Finland (2000) New England Journal of Medicine, 343 (2), pp. 78-85. , DOI 10.1056/NEJM200007133430201; 
Albores-Saavedra J., Henson D.E., Glazer E., Schwartz A.M., Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype - Papillary, follicular, and anaplastic: A morphological and epidemiological study (2007) Endocrine Pathology, 18 (1), pp. 1-7. , DOI 10.1007/s12022-007-0002-z; 
Yu G.P., Li J.C., Branovan D., McCormick S., Schantz S.P., Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ ethnicity groups (2010) Thyroid, 20, pp. 465-473; 
Malchoff C.D., Sarfarazi M., Tendler B., Forouhar F., Whalen G., Joshi V., Arnold A., Malchoff D.M., Papillary thyroid carcinoma associated with papillary renal neoplasia: Genetic linkage analysis of a distinct heritable tumor syndrome (2000) Journal of Clinical Endocrinology and Metabolism, 85 (5), pp. 1758-1764. , DOI 10.1210/jc.85.5.1758; 
McKay J.D., Lesueur F., Jonard L., Pastore A., Williamson J., Hoffman L., Burgess J., Romeo G., Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21 (2001) American Journal of Human Genetics, 69 (2), pp. 440-446. , DOI 10.1086/321979; 
Cavaco B.M., Batista P.F., Sobrinho L.G., Leite V., Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis (2008) Journal of Clinical Endocrinology and Metabolism, 93 (11), pp. 4426-4430. , http://jcem.endojournals.org/cgi/reprint/93/11/4426, DOI 10.1210/jc.2008-0449; 
He H., Nagy R., Liyanarachchi S., Jiao H., Li W., Suster S., Kere J., De La Chapelle A., A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24 (2009) Cancer Res, 69, pp. 625-631; 
Suh I., Filetti S., Vriens M.R., Guerrero M.A., Tumino S., Wong M., Shen W.T., Clark O.H., Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: A SNP array-based linkage analysis of 38 families (2009) Surgery, 146, pp. 1073-1080; 
Canzian F., Amati P., Ruben Harach H., Kraimps J.-L., Lesueur F., Barbier J., Levillain P., Bonneau D., A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2 (1998) American Journal of Human Genetics, 63 (6), pp. 1743-1748. , DOI 10.1086/302164
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-84890372228&partnerID=40&md5=b507f4822a84ed1679d937ccb75aa25a
ER  - 

TY  - JOUR
TI  - Batf promotes growth arrest and terminal differentiation of mouse myeloid leukemia cells
T2  - Molecular Cancer Research
VL  - 9
IS  - 3
SP  - 350
EP  - 363
PY  - 2011
DO  - 10.1158/1541-7786.MCR-10-0375
AU  - Liao J.
AU  - Humphrey S.E.
AU  - Poston S.
AU  - Taparowsky E.J.
N1  - 施引文献 :10
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Hess J., Angel P., Schorpp-Kistner M., AP-1 subunits: Quarrel and harmony among siblings (2004) J Cell Sci, 117, pp. 5965-5973; 
Shaulian E., AP-1 - The Jun proteins: Oncogenes or tumor suppressors in disguise? (2010) Cell Signal, 22, pp. 894-899; 
Dorsey M.J., Tae H.J., Sollenberger K.G., Mascarenhas N.T., Johansen L.M., Taparowsky E.J., B-ATF: A novel human bZIP protein that associates with members of the AP-1 transcription factor family (1995) Oncogene, 11, pp. 2255-2265; 
Meyer N.P., Johansen L.M., Tae H.J., Budde P.P., Williams K.L., Taparowsky E.J., Genomic organization of human B-ATF, a target for regulation by EBV and HTLV-1 (1998) Mamm Genome, 9, pp. 849-852; 
Echlin D.R., Tae H.J., Mitin N., Taparowsky E.J., B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos (2000) Oncogene, 19, pp. 1752-1763; 
Williams K.L., Nanda I., Lyons G.E., Kuo C.T., Schmid M., Leiden J.M., Characterization of murine BATF: A negative regulator of activator protein-1 activity in the thymus (2001) Eur J Immunol, 31, pp. 1620-1627; 
Senga T., Iwamoto T., Humphrey S.E., Yokota T., Taparowsky E.J., Hamaguchi M., Stat3-dependent induction of BATF in M1 mouse myeloid leukemia cells (2002) Oncogene, 21, pp. 8186-8191; 
Lang R., Patel D., Morris J.J., Rutschman R.L., Murray P.J., Shaping gene expression in activated and resting primary macrophages by IL-10 (2002) J Immunol, 169, pp. 2253-2263; 
Johansen L.M., Deppmann C.D., Erickson K.D., Coffin III W.F., Thornton T.M., Humphrey S.E., EBNA2 and activated Notch induce expression of BATF (2003) J Virol, 77, pp. 6029-6040; 
Iacobelli M., Wachsman W., McGuire K.L., Repression of IL-2 promoter activity by the novel basic leucine zipper p21SNFT protein (2000) J Immunol, 165, pp. 860-868; 
Su Z.Z., Lee S.G., Emdad L., Lebdeva I.V., Gupta P., Valerie K., Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN) (2008) Proc Natl Acad Sci USA, 105, pp. 20906-20911; 
Williams K.L., Zullo A.J., Kaplan M.H., Brutkiewicz R.R., Deppmann C.D., Vinson C., BATF transgenic mice reveal a role for activator protein-1 in NKT cell development (2003) J Immunol, 170, pp. 2417-2426; 
Thornton T.M., Zullo A.J., Williams K.L., Taparowsky E.J., Direct manipulation of activator protein-1 controls thymocyte proliferation in vitro (2006) Eur J Immunol, 36, pp. 160-169; 
Schraml B.U., Hildner K., Ise W., Lee W.L., Smith W.A., Solomon B., The AP-1 transcription factor Batf controls T(H)17 differentiation (2009) Nature, 460, pp. 405-409; 
Betz B.C., Jordan-Williams K.L., Wang C., Kang S.G., Liao J., Logan M.R., Batf coordinates multiple aspects of B and T cell function required for normal antibody responses (2010) J Exp Med, 207, pp. 933-942; 
Ichikawa Y., Differentiation of a cell line of myeloid leukemia (1969) J Cell Phys, 74, pp. 223-234; 
Chiu C.P., Lee F., IL-6 is a differentiation factor for M1 and WEHI-3B myeloid leukemic cells (1989) J Immunol, 142, pp. 1909-1915; 
Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F., Principles of interleukin (IL)-6-type cytokine signalling and its regulation (2003) Biochem J, 374, pp. 1-20; 
Taga T., Kishimoto T., Gp130 and the interleukin-6 family of cytokines (1997) Annu Rev Immunol, 15, pp. 797-819; 
Liebermann D.A., Hoffman B., MyD genes in negative growth control (1998) Oncogene, 17, pp. 3319-3329; 
Nakajima K., Yamanaka Y., Nakae K., Kojima H., Ichiba M., Kiuchi N., A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells (1996) EMBO J, 15, pp. 3651-3658; 
Minami M., Inoue M., Wei S., Takeda K., Matsumoto M., Kishimoto T., STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line (1996) Proc Natl Acad Sci USA, 93, pp. 3963-3966; 
Liebermann D.A., Hoffman B., Myeloid differentiation (MyD) primary response genes in hematopoiesis (2002) Oncogene, 21, pp. 3391-3402; 
Lord K.A., Abdollahi A., Hoffman-Liebermann B., Liebermann D.A., Proto-oncogenes of the fos/jun family of transcription factors are positive regulators of myeloid differentiation (1993) Mol Cell Biol, 13, pp. 841-851; 
Ramsay R.G., Gonda T.J., MYB function in normal and cancer cells (2008) Nature Rev, 8, pp. 523-534; 
Hoffman-Liebermann B., Liebermann D.A., Suppression of c-myc and c-myb is tightly linked to terminal differentiation induced by IL6 or LIF and not growth inhibition in myeloid leukemia cells (1991) Oncogene, 6, pp. 903-909; 
Selvakumaran M., Liebermann D.A., Hoffman-Liebermann B., Deregulated c-myb disrupts interleukin-6- Or leukemia inhibitory factorinduced myeloid differentiation prior to c-myc: Role in leukemogenesis (1992) Mol Cell Biol, 12, pp. 2493-2500; 
Schmidt M., Koller R., Haviernik P., Bies J., Maciag K., Wolff L., Deregulated c-Myb expression in murine myeloid leukemias prevents the upregulation of p15(INK4b) normally associated with differentiation (2001) Oncogene, 20, pp. 6205-6214; 
Ramocki M.B., Johnson S.E., White M.A., Ashendel C.L., Konieczny S.F., Taparowsky E.J., Signaling through mitogen-activated protein kinase and Rac/Rho does not duplicate the effects of activated Ras on skeletal myogenesis (1997) Mol Cell Biol, 17, pp. 3547-3555; 
Zullo A.J., Benlagha K., Bendelac A., Taparowsky E.J., Sensitivity of NK1.1-negative NKT cells to transgenic BATF defines a role for activator protein-1 in the expansion and maturation of immature NKT cells in the thymus (2007) J Immunol, 178, pp. 58-66; 
Deppmann C.D., Thornton T.M., Utama F.E., Taparowsky E.J., Phosphorylation of BATF regulates DNA binding: A novel mechanism for AP-1 (activator protein-1) regulation (2003) Biochem J, 374, pp. 423-431; 
Pin C.L., Bonvissuto A.C., Konieczny S.F., Mist1 expression is a common link among serous exocrine cells exhibiting regulated exocytosis (2000) Anat Record, 259, pp. 157-167; 
Meydan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor (1996) Nature, 379, pp. 645-648; 
Levitzki A., Mishani E., Tyrphostins and other tyrosine kinase inhibitors (2006) Annu Rev Biochem, 75, pp. 93-109; 
Kawashima T., Murata K., Akira S., Tonozuka Y., Minoshima Y., Feng S., STAT5 induces macrophage differentiation of M1 leukemia cells through activation of IL-6 production mediated by NF-kappaB p65 (2001) J Immunol, 167, pp. 3652-3660; 
Bender T.P., Kremer C.S., Kraus M., Buch T., Rajewsky K., Critical functions for c-Myb at three checkpoints during thymocyte development (2004) Nature Immunol, 5, pp. 721-729; 
Thomas M.D., Kremer C.S., Ravichandran K.S., Rajewsky K., Bender T.P., C-Myb is critical for B cell development and maintenance of follicular B cells (2005) Immunity, 23, pp. 275-286; 
Sakamoto H., Dai G., Tsujino K., Hashimoto K., Huang X., Fujimoto T., Proper levels of c-Myb are discretely defined at distinct steps of hematopoietic cell development (2006) Blood, 108, pp. 896-903; 
Todokoro K., Watson R.J., Higo H., Amanuma H., Kuramochi S., Yanagisawa H., Down-regulation of c-myb gene expression is a prerequisite for erythropoietin-induced erythroid differentiation (1988) Proc Natl Acad Sci USA, 85, pp. 8900-8904; 
Bender T.P., Thompson C.B., Kuehl W.M., Differential expression of cmyb mRNA in murine B lymphomas by a block to transcription elongation (1987) Science, 237, pp. 1473-1476; 
Suhasini M., Reddy C.D., Reddy E.P., DiDonato J.A., Pilz R.B., cAMP-induced NF-kappaB (p50/relB) binding to a c-myb intronic enhancer correlates with c-myb up-regulation and inhibition of erythroleukemia cell differentiation (1997) Oncogene, 15, pp. 1859-1870; 
Lord K.A., Hoffman-Liebermann B., Liebermann D.A., Complexity of the immediate early response of myeloid cells to terminal differentiation and growth arrest includes ICAM-1, Jun-B and histone variants (1990) Oncogene, 5, pp. 387-396; 
Shafarenko M., Amanullah A., Gregory B., Liebermann D.A., Hoffman B., Fos modulates myeloid cell survival and differentiation and partially abrogates the c-Myc block in terminal myeloid differentiation (2004) Blood, 103, pp. 4259-4267; 
Perkel J.M., Simon M.C., Rao A., Identification of a c-myb attenuator-binding factor (2002) Leukemia Res, 26, pp. 179-190; 
Gibbs J.D., Liebermann D.A., Hoffman B., Leukemia suppressor function of Egr-1 is dependent on transforming oncogene (2008) Leukemia, 22, pp. 1909-1916; 
Shafarenko M., Liebermann D.A., Hoffman B., Egr-1 abrogates the block imparted by c-Myc on terminal M1 myeloid differentiation (2005) Blood, 106, pp. 871-878; 
Krishnaraju K., Hoffman B., Liebermann D.A., The zinc finger transcription factor Egr-1 activates macrophage differentiation in M1 myeloblastic leukemia cells (1998) Blood, 92, pp. 1957-1966
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-79952829918&partnerID=40&md5=ef248aa53dc8b9d44c414b513f5475a7
ER  - 

TY  - JOUR
TI  - BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer
T2  - Clinical Epigenetics
VL  - 5
IS  - 1
PY  - 2013
DO  - 10.1186/1868-7083-5-2
AU  - Van Roon E.H.
AU  - Boot A.
AU  - Dihal A.A.
AU  - Ernst R.F.
AU  - Van Wezel T.
AU  - Morreau H.
AU  - Boer J.M.
N1  - 施引文献 :8
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
C7  - 2
N1  - 参考文献: Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., Issa J.-P.J., CpG island methylator phenotype in colorectal cancer (1999) Proceedings of the National Academy of Sciences of the United States of America, 96 (15), pp. 8681-8686. , DOI 10.1073/pnas.96.15.8681; 
Hinoue T., Weisenberger D.J., Pan F., Campan M., Kim M., Young J., Whitehall V.L., Laird P.W., Analysis of the association between CIMP and BRAFV600E in colorectal cancer by DNA methylation profiling (2009) PLoS One, 4, pp. e8357; 
Kambara T., Simms L.A., Whitehall V.L.J., Spring K.J., Wynter C.V.A., Walsh M.D., Barker M.A., Leggett B.A., BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum (2004) Gut, 53 (8), pp. 1137-1144. , DOI 10.1136/gut.2003.037671; 
Minoo P., Moyer M.P., Jass J.R., Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis (2007) Journal of Pathology, 212 (2), pp. 124-133. , DOI 10.1002/path.2160; 
Nagasaka T., Koi M., Kloor M., Gebert J., Vilkin A., Nishida N., Shin S.K., Goel A., Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer (1960) Gastroenterology, 2008 (134), pp. 1950-1960; 
Shen L., Toyota M., Kondo Y., Lin E., Zhang L., Guo Y., Hernandez N.S., Issa J.-P.J., Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer (2007) Proceedings of the National Academy of Sciences of the United States of America, 104 (47), pp. 18654-18659. , http://www.pnas.org/cgi/reprint/104/47/18654, DOI 10.1073/pnas.0704652104; 
Velho S., Moutinho C., Cirnes L., Albuquerque C., Hamelin R., Schmitt F., Carneiro F., Seruca R., BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis? (2008) BMC Cancer, 8, p. 255; 
Weisenberger D.J., Siegmund K.D., Campan M., Young J., Long T.I., Faasse M.A., Kang G.H., Laird P.W., CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer (2006) Nature Genetics, 38 (7), pp. 787-793. , DOI 10.1038/ng1834, PII N1834; 
Boland C.R., Goel A., Microsatellite instability in colorectal cancer (2010) Gastroenterology, 138, pp. 2073-2087; 
Niv Y., Microsatellite instability and MLH1 promoter hypermethylation in colorectal cancer (2007) World J Gastroenterol, 13, pp. 1767-1769; 
Irizarry R.A., Ladd-Acosta C., Wen B., Wu Z., Montano C., Onyango P., Cui H., Feinberg A.P., The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores (2009) Nat Genet, 41, pp. 178-186; 
Yamauchi M., Morikawa T., Kuchiba A., Imamura Y., Qian Z.R., Nishihara R., Liao X., Ogino S., Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum (2012) Gut, 61, pp. 847-854; 
Yamauchi M., Lochhead P., Morikawa T., Huttenhower C., Chan A.T., Giovannucci E., Fuchs C., Ogino S., Colorectal cancer: A tale of two sides or a continuum? (2012) Gut, 61, pp. 794-797; 
Parsons M.T., Buchanan D.D., Thompson B., Young J.P., Spurdle A.B., Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: A literature review assessing utility of tumour features for MMR variant classification (2012) J Med Genet, 49, pp. 151-157; 
Samowitz W.S., Albertsen H., Herrick J., Levin T.R., Sweeney C., Murtaugh M.A., Wolff R.K., Slattery M.L., Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer (2005) Gastroenterology, 129 (3), pp. 837-845. , DOI 10.1053/j.gastro.2005.06.020, PII S0016508505011224; 
Ohm J.E., McGarvey K.M., Yu X., Cheng L., Schuebel K.E., Cope L., Mohammad H.P., Baylin S.B., A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing (2007) Nat Genet, 39, pp. 237-242; 
Rada-Iglesias A., Enroth S., Andersson R., Wanders A., Pahlman L., Komorowski J., Wadelius C., Histone H3 lysine 27 trimethylation in adult differentiated colon associated to cancer DNA hypermethylation (2009) Epigenetics, 4, pp. 107-113; 
Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., Eden E., Cedar H., Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer (2007) Nature Genetics, 39 (2), pp. 232-236. , DOI 10.1038/ng1950, PII NG1950; 
Kondo Y., Epigenetic cross-talk between DNA methylation and histone modifications in human cancers (2009) Yonsei Med J, 50, pp. 455-463; 
Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., Weisenberger D.J., Laird P.W., Epigenetic stem cell signature in cancer (2007) Nature Genetics, 39 (2), pp. 157-158. , DOI 10.1038/ng1941, PII NG1941; 
Simon J.A., Kingston R.E., Mechanisms of polycomb gene silencing: Knowns and unknowns (2009) Nat Rev Mol Cell Biol, 10, pp. 697-708; 
Nelms B.L., Labosky P.A., A predicted hairpin cluster correlates with barriers to PCR, sequencing and possibly BAC recombineering (2011) Sci Rep, 1, p. 106; 
Lin J., Lai M., Huang Q., Ma Y., Cui J., Ruan W., Methylation patterns of IGFBP7 in colon cancer cell lines are associated with levels of gene expression (2007) Journal of Pathology, 212 (1), pp. 83-90. , DOI 10.1002/path.2144; 
Carmona F.J., Esteller M., Epigenomics of human colon cancer (2010) Mutat Res, 693, pp. 53-60; 
Yan P.S., Chen C.-M., Shi H., Rahmatpanah F., Wei S.H., Caldwell C.W., Huang T.H.-M., Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays (2001) Cancer Research, 61 (23), pp. 8375-8380; 
Abel E.V., Aplin A.E., FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells (2010) Cancer Res, 70, pp. 2891-2900; 
De Keizer P.L., Packer L.M., Szypowska A.A., Riedl-Polderman P.E., Van Den Broek N.J., De Bruin A., Dansen T.B., Burgering B.M., Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence (2010) Cancer Res, 70, pp. 8526-8536; 
Muggerud A.A., Ronneberg J.A., Warnberg F., Botling J., Busato F., Jovanovic J., Solvang H., Tost J., Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer (2010) Breast Cancer Res, 12, pp. R3; 
Lo P.K., Lee J.S., Liang X., Han L., Mori T., Fackler M.J., Sadik H., Sukumar S., Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer (2010) Cancer Res, 70, pp. 6047-6058; 
Nakshatri H., Badve S., FOXA1 in breast cancer (2009) Expert Rev Mol Med, 11, pp. e8; 
Xu X., Quiros R.M., Gattuso P., Ain K.B., Prinz R.A., High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines (2003) Cancer Research, 63 (15), pp. 4561-4567; 
Wettenhall J.M., Smyth G.K., limmaGUI: A graphical user interface for linear modeling of microarray data (2004) Bioinformatics, 20 (18), pp. 3705-3706. , DOI 10.1093/bioinformatics/bth449; 
(2008) R: A Language and Environment for Statistical Computing, , Core Team RD: Vienna; 
Margaritis T., Lijnzaad P., Van Leenen D., Bouwmeester D., Kemmeren P., Van Hooff S.R., Holstege F.C., Adaptable gene-specific dye bias correction for two-channel DNA microarrays (2009) Mol Syst Biol, 5, p. 266; 
Benjamini Y., Hochberg Y., Controlling the false discovery rate - A practical and powerful approach to multiple testing (1995) J Roy Stat Soc B Met, 57, pp. 289-300; 
Deng G., Chen A., Hong J., Chae H.S., Kim Y.S., Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression (1999) Cancer Research, 59 (9), pp. 2029-2033; 
Xiong Z., Laird P.W., COBRA: A sensitive and quantitative DNA methylation assay (1997) Nucleic Acids Research, 25 (12), pp. 2532-2534. , DOI 10.1093/nar/25.12.2532; 
Van Roon E.H., Van Puijenbroek M., Middeldorp A., Van Eijk R., De Meijer E.J., Erasmus D., Wouters K.A., Morreau H., Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? (2010) BMC Cancer, 10, p. 180; 
Li L.C., Dahiya R., MethPrimer: Designing primers for methylation PCRs (2002) Bioinformatics, 18, pp. 1427-1431; 
Lewin J., Schmitt A.O., Adorjan P., Hildmann T., Piepenbrock C., Quantitative DNA methylation analysis based on four-dye trace data from direct sequencing of PCR amplificates (2004) Bioinformatics, 20 (17), pp. 3005-3012. , DOI 10.1093/bioinformatics/bth346; 
Van Wezel T., Lombaerts M., Van Roon E.H., Philippo K., Baelde H.J., Szuhai K., Cornelisse C.J., Cleton-Jansen A.M., Expression analysis of candidate breast tumour suppressor genes on chromosome 16q (2005) Breast Cancer Res, 7, pp. R998-R1004; 
Celniker S.E., Dillon L.A., Gerstein M.B., Gunsalus K.C., Henikoff S., Karpen G.H., Kellis M., Waterston R.H., Unlocking the secrets of the genome (2009) Nature, 459, pp. 927-930; 
Lee T.I., Jenner R.G., Boyer L.A., Guenther M.G., Levine S.S., Kumar R.M., Chevalier B., Young R.A., Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells (2006) Cell, 125 (2), pp. 301-313. , DOI 10.1016/j.cell.2006.02.043, PII S0092867406003849; 
Zhao X.D., Han X., Chew J.L., Liu J., Chiu K.P., Choo A., Orlov Y.L., Wei C.-L., Whole-Genome Mapping of Histone H3 Lys4 and 27 Trimethylations Reveals Distinct Genomic Compartments in Human Embryonic Stem Cells (2007) Cell Stem Cell, 1 (3), pp. 286-298. , DOI 10.1016/j.stem.2007.08.004, PII S1934590907001233; 
Thomas P.D., Campbell M.J., Kejariwal A., Mi H., Karlak B., Daverman R., Diemer K., Narechania A., PANTHER: A library of protein families and subfamilies indexed by function (2003) Genome Research, 13 (9), pp. 2129-2141. , DOI 10.1101/gr.772403
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-84876929302&partnerID=40&md5=eeeea54ba9b6110ef0b9bc07f185efd7
ER  - 

TY  - JOUR
TI  - Evaluation of reported prostate cancer risk-associated SNPs from genome-wide association studies of various racial populations in Chinese men
T2  - Prostate
VL  - 73
IS  - 15
SP  - 1623
EP  - 1635
PY  - 2013
DO  - 10.1002/pros.22629
AU  - Na R.
AU  - Liu F.
AU  - Zhang P.
AU  - Ye D.
AU  - Xu C.
AU  - Shao Q.
AU  - Qi J.
AU  - Wang X.
AU  - Chen Z.
AU  - Wang M.
AU  - He D.
AU  - Wang Z.
AU  - Zhou F.
AU  - Yuan J.
AU  - Gao X.
AU  - Wei Q.
AU  - Yang J.
AU  - Jiao Y.
AU  - Ou-Yang J.
AU  - Zhu Y.
AU  - Wu Q.
AU  - Chen H.
AU  - Lu D.
AU  - Shi R.
AU  - Lin X.
AU  - Jiang H.
AU  - Jiang D.
AU  - Sun J.
AU  - Zheng S.L.
AU  - Ding Q.
AU  - Mo Z.
AU  - Sun Y.
AU  - Xu J.
N1  - 施引文献 :7
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 (2010) Int J Cancer, 127 (12), pp. 2893-2917; 
Hsing A.W., Tsao L., Devesa S.S., International trends and patterns of prostate cancer incidence and mortality (2000) Int J Cancer, 85 (1), pp. 60-67; 
Ye D.W., Li C.L., Epidemiological trends of prostate cancer: Retrospect and prospect (2007) China Oncol, 17, pp. 177-180; 
Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., Pukkala E., Hemminki K., Environmental and heritable factors in the causation of cancer - Analyses of cohorts of twins from Sweden, Denmark, and Finland (2000) N Engl J Med, 343 (2), pp. 78-85; 
Amundadottir L.T., Sulem P., Gudmundsson J., Helgason A., Baker A., Agnarsson B.A., Sigurdsson A., Stefansson K., A common variant associated with prostate cancer in European and African populations (2006) Nat Genet, 38, pp. 652-658; 
Gudmundsson J., Sulem P., Manolescu A., Amundadottir L.T., Gudbjartsson D., Helgason A., Rafnar T., Stefansson K., Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 (2007) Nat Genet, 39, pp. 631-637; 
Yeager M., Orr N., Hayes R.B., Jacobs K.B., Kraft P., Wacholder S., Minichiello M.J., Thomas G., Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 (2007) Nat Genet, 39, pp. 645-649; 
Gudmundsson J., Sulem P., Steinthorsdottir V., Bergthorsson J.T., Thorleifsson G., Manolescu A., Rafnar T., Stefansson K., Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes (2007) Nat Genet, 39, pp. 977-983; 
Duggan D., Zheng S.L., Knowlton M., Benitez D., Dimitrov L., Wiklund F., Robbins C., Carpten J.D., Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP (2007) J Natl Cancer Inst, 99, pp. 1836-1844; 
Thomas G., Jacobs K.B., Yeager M., Kraft P., Wacholder S., Orr N., Yu K., Chanock S.J., Multiple loci identified in a genome-wide association study of prostate cancer (2008) Nat Genet, 40, pp. 310-315; 
Gudmundsson J., Sulem P., Rafnar T., Bergthorsson J.T., Manolescu A., Gudbjartsson D., Agnarsson B.A., Stefansson K., Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer (2008) Nat Genet, 40, pp. 281-283; 
Eeles R.A., Kote-Jarai Z., Giles G.G., Olama A.A., Guy M., Jugurnauth S.K., Mulholland S., Easton D.F., Multiple newly identified loci associated with prostate cancer susceptibility (2008) Nat Genet, 40, pp. 316-321. , UK Genetic Prostate Cancer Study Collaborators, British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; 
Yeager M., Chatterjee N., Ciampa J., Jacobs K.B., Gonzalez-Bosquet J., Hayes R.B., Kraft P., Chanock S.J., Identification of a new prostate cancer susceptibility locus on chromosome 8q24 (2009) Nat Genet, 41, pp. 1055-1057; 
Gudmundsson J., Sulem P., Gudbjartsson D.F., Blondal T., Gylfason A., Agnarsson B.A., Benediktsdottir K.R., Stefansson K., Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility (2009) Nat Genet, 41, pp. 1122-1126; 
Eeles R.A., Kote-Jarai Z., Al Olama A.A., Giles G.G., Guy M., Severi G., Muir K., Mitkova A., Identification of seven new prostate cancer susceptibility loci through a genome-wide association study (2009) Nat Genet, 41, pp. 1116-1121. , UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators; PRACTICAL Consortium; 
Kote-Jarai Z., Olama A.A., Giles G.G., Severi G., Schleutker J., Weischer M., Campa D., Fitzgerald L., Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study (2011) Nat Genet, 43, pp. 785-791; 
Duggan D., Zheng S.L., Knowlton M., Benitez D., Dimitrov L., Wiklund F., Robbins C., Carpten J.D., Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP (2007) J Natl Cancer Inst, 99 (24), pp. 1836-1844; 
Zheng S.L., Stevens V.L., Wiklund F., Isaacs S.D., Sun J., Smith S., Pruett K., Xu J., Two independent prostate cancer risk-associated Loci at 11q13 (2009) Cancer Epidemiol Biomarkers Prev, 18 (6), pp. 1815-1820; 
Hsu F.C., Sun J., Wiklund F., Isaacs S.D., Wiley K.E., Purcell L.D., Gao Z., Zheng S.L., A novel prostate cancer susceptibility locus at 19q13 (2009) Cancer Res, 69 (7), pp. 2720-2723; 
Sun J., Zheng S.L., Wiklund F., Isaacs S.D., Li G., Wiley K.E., Kim S.T., Chang B.L., Sequence variants at 22q13 are associated with prostate cancer risk (2009) Cancer Res, 69 (1), pp. 10-15; 
Xu J., Zheng S.L., Isaacs S.D., Wiley K.E., Wiklund F., Sun J., Kader A.K., Isaacs W.B., Inherited genetic variant predisposes to aggressive but not indolent prostate cancer (2010) Proc Natl Acad Sci USA, 107 (5), pp. 2136-2140; 
Amin Al Olama A., Kote-Jarai Z., Schumacher F.R., Wiklund F., Berndt S.I., Benlloch S., Giles G.G., Xu J., A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease (2012) Hum Mol Genet, , The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; The UK ProtecT Study Collaborators; The Australian Prostate Cancer Bioresource; The PRACTICAL Consortium;, doi:10.1093/hmg/dds425; 
Haiman C.A., Chen G.K., Blot W.J., Strom S.S., Berndt S.I., Kittles R.A., Rybicki B.A., Henderson B.E., Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21 (2011) Nat Genet, 43, pp. 570-573; 
Takata R., Akamatsu S., Kubo M., Takahashi A., Hosono N., Kawaguchi T., Tsunoda T., Nakagawa H., Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population (2010) Nat Genet, 42, pp. 751-754; 
Akamatsu S., Takata R., Haiman C.A., Takahashi A., Inoue T., Kubo M., Furihata M., Nakagawa H., Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese (2012) Nat Genet, 44, pp. 426-429; 
Xu J., Mo Z., Ye D., Wang M., Liu F., Jin G., Xu C., Sun Y., Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4 (2012) Nat Genet, 44, pp. 1231-1235; 
Zheng S.L., Sun J., Wiklund F., Smith S., Stattin P., Li G., Adami H.O., Grönberg H., Cumulative association of five genetic variants with prostate cancer (2008) N Engl J Med, 358 (9), pp. 910-919; 
Xu J., Sun J., Kader A.K., Lindström S., Wiklund F., Hsu F.C., Johansson J.E., Grönberg H., Estimation of absolute risk for prostate cancer using genetic markers and family history (2009) Prostate, 69 (14), pp. 1565-1572; 
Salinas C.A., Koopmeiners J.S., Kwon E.M., Fitzgerald L., Lin D.W., Ostrander E.A., Feng Z., Stanford J.L., Clinical utility of five genetic variants for predicting prostate cancer risk and mortality (2009) Prostate, 69 (4), pp. 363-372; 
Akamatsu S., Takahashi A., Takata R., Kubo M., Inoue T., Morizono T., Tsunoda T., Nakagawa H., Reproducibility, performance, and clinical utility of a genetic risk prediction model for prostate cancer in Japanese (2012) PLoS ONE, 7 (10), pp. e46454; 
Aly M., Wiklund F., Xu J., Isaacs W.B., Eklund M., D'Amato M., Adolfsson J., Grönberg H., Polygenic risk score improves prostate cancer risk prediction: Results from the Stockholm-1 cohort study (2011) Eur Urol, 60 (1), pp. 21-28; 
Kader A.K., Sun J., Reck B.H., Newcombe P.J., Kim S.T., Hsu F.C., D'agostino Jr. R.B., Xu J., Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: Findings from the REDUCE trial (2012) Eur Urol, 62 (6), pp. 953-961; 
Liu F., Hsing A.W., Wang X., Shao Q., Qi J., Ye Y., Wang Z., Xu J., Systematic confirmation study of reported prostate cancer risk-associated single nucleotide polymorphisms in Chinese men (2011) Cancer Sci, 102 (10), pp. 1916-1920; 
Wang M., Liu F., Hsing A.W., Wang X., Shao Q., Qi J., Ye Y., Xu J., Replication and cumulative effects of GWAS-identified genetic variations for prostate cancer in Asians: A case-control study in the ChinaPCa consortium (2012) Carcinogenesis, 33 (2), pp. 356-360; 
Wing C.M., Ray A.M., Lange E.M., Zuhlke K.A., Robbins C.M., Tembe W.D., Wiley K.E., Cooney K.A., Germline mutations in HOXB13 and prostate-cancer risk (2012) N Engl J Med, 366 (2), pp. 141-149; 
Lin X., Qu L., Chen Z., Xu C., Ye D., Shao Q., Wang X., Xu J., A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men (2012) Prostate, , (Online published), doi: 10.1002/pros.22552; 
Kader A.K., Sun J., Isaacs S.D., Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients (2009) Prostate, 69 (11), pp. 1195-1205
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-84884901848&partnerID=40&md5=360981141bc60714c971500989c542cc
ER  - 

TY  - JOUR
TI  - Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations
T2  - Cancer Epidemiology Biomarkers and Prevention
VL  - 22
IS  - 2
SP  - 320
EP  - 323
PY  - 2013
DO  - 10.1158/1055-9965.EPI-12-1182
AU  - Campa D.
AU  - Rizzato C.
AU  - Bauer A.S.
AU  - Werner J.
AU  - Capurso G.
AU  - Costello E.
AU  - Talar-Wojnarowska R.
AU  - Jamroziak K.
AU  - Pezzilli R.
AU  - Gazouli M.
AU  - Khaw K.-T.
AU  - Key T.J.
AU  - Bambi F.
AU  - Mohelnikova-Duchonova B.
AU  - Heller A.
AU  - Landi S.
AU  - Vodickova L.
AU  - Theodoropoulos G.
AU  - Bugert P.
AU  - Vodicka P.
AU  - Hoheisel J.D.
AU  - Delle Fave G.
AU  - Neoptolemos J.P.
AU  - Soucek P.
AU  - Büchler M.W.
AU  - Giese N.
AU  - Canzian F.
N1  - 施引文献 :6
N1  - Export Date: 2 January 2016
TY  - Article
DB  - Scopus
N1  - 参考文献: Ferlay J., Parkin D.M., Steliarova-Foucher E., Estimates of cancer incidence and mortality in Europe in 2008 (2010) Eur J Cancer, 46, pp. 765-781; 
Amundadottir L., Kraft P., Stolzenberg-Solomon R.Z., Fuchs C.S., Petersen G.M., Arslan A.A., Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer (2009) Nat Genet, 41, pp. 986-990; 
Petersen G.M., Amundadottir L., Fuchs C.S., Kraft P., Stolzenberg-Solomon R.Z., Jacobs K.B., A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33 (2010) Nat Genet, 42, pp. 224-228; 
Low S.K., Kuchiba A., Zembutsu H., Saito A., Takahashi A., Kubo M., Genome-wide association study of pancreatic cancer in Japanese population (2010) PLoS One, 5, pp. e11824; 
Wu C., Miao X., Huang L., Che X., Jiang G., Yu D., Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations (2012) Nat Genet, 44, pp. 62-66; 
Campa D., Rizzato C., Capurso G., Giese N., Funel N., Greenhalf W., Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium (2012) Dig Liver Dis., , Nov. 30. Epub ahead of print; 
Rizzato C., Campa D., Giese N., Werner J., Rachakonda P.S., Kumar R., Pancreatic cancer susceptibility loci and their role in survival (2011) PLoS One, 6, pp. e27921
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-84873350555&partnerID=40&md5=07f07932c1bd08b92337bf443d6eafba
ER  - 

TY  - JOUR
TI  - FoxD3 is a novel, epigenetically regulated tumor suppressor in gastric carcinogenesis
T2  - Gastroenterology
VL  - 144
IS  - 1
SP  - 22
EP  - 25
PY  - 2013
DO  - 10.1053/j.gastro.2012.11.014
AU  - Schmid C.A.
AU  - Müller A.
N1  - 施引文献 :6
N1  - Export Date: 2 January 2016
TY  - Review
DB  - Scopus
N1  - 参考文献: Parkin D.M., Bray F., Ferlay J., Global cancer statistics, 2002 (2005) CA Cancer J Clin, 55, pp. 74-108; 
Parsonnet J., Friedman G.D., Vandersteen D.P., Helicobacter pylori infection and the risk of gastric carcinoma (1991) N Engl J Med, 325, pp. 1127-1131; 
Yamaoka Y., Mechanisms of disease: Helicobacter pylori virulence factors (2010) Nat Rev Gastroenterol Hepatol, 7, pp. 629-641; 
Robinson K., Kenefeck R., Pidgeon E.L., Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses (2008) Gut, 57, pp. 1375-1385; 
Arnold I.C., Lee J.Y., Amieva M.R., Tolerance rather than immunity protects from Helicobacter pylori-induced gastric preneoplasia (2011) Gastroenterology, 140, pp. 199-209; 
Toller I.M., Altmeyer M., Kohler E., Inhibition of ADP ribosylation prevents and cures helicobacter-induced gastric preneoplasia (2010) Cancer Res, 70, pp. 5912-5922; 
Toller I.M., Hitzler I., Sayi A., Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model (2010) Gastroenterology, 138, pp. 1455-1467; 
Correa P., Helicobacter pylori and gastric carcinogenesis (1995) Am J Surg Pathol, 19 (SUPPL. 1), pp. 37-S43; 
Rokkas T., Pistiolas D., Sechopoulos P., The long-term impact of Helicobacter pylori eradication on gastric histology: A systematic review and meta-analysis (2007) Helicobacter, 12 (SUPPL. 2), pp. 32-38; 
Chen X., Leung S.Y., Yuen S.T., Variation in gene expression patterns in human gastric cancers (2003) Mol Biol Cell, 14, pp. 3208-3215; 
Sepulveda A.R., Yao Y., Yan W., CpG methylation and reduced expression of O6-methylguanine DNA methyltransferase is associated with Helicobacter pylori infection (2010) Gastroenterology, 138, pp. 1836-1844; 
Peterson A.J., Menheniott T.R., O'Connor L., Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans (2010) Gastroenterology, 139, pp. 2005-2017; 
Tomita H., Takaishi S., Menheniott T.R., Inhibition of gastric carcinogenesis by the hormone gastrin is mediated by suppression of TFF1 epigenetic silencing (2011) Gastroenterology, 140, pp. 879-891; 
Chan A.O., Lam S.K., Wong B.C., Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer (2003) Gut, 52, pp. 502-506; 
Wen X.Z., Akiyama Y., Pan K.F., Methylation of GATA-4 and GATA-5 and development of sporadic gastric carcinomas (2010) World J Gastroenterol, 16, pp. 1201-1208; 
Guo X.B., Guo L., Zhi Q.M., Helicobacter pylori induces promoter hypermethylation and downregulates gene expression of IRX1 transcription factor on human gastric mucosa (2011) J Gastroenterol Hepatol, 26, pp. 1685-1690; 
Cheng A.S.L., Li M.S., Kang W., Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis (2013) Gastroenterology, 144, pp. 122-133; 
Hanna L.A., Foreman R.K., Tarasenko I.A., Cheng, Requirement for Foxd3 in maintaining pluripotent cells of the early mouse embryo (2002) Genes Dev, 16, pp. 2650-2661; 
Sutton J., Costa R., Klug M., Cheng, Genesis, a winged helix transcriptional repressor with expression restricted to embryonic stem cells (1996) J Biol Chem, 271, pp. 23126-23133
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-84871316971&partnerID=40&md5=70bc96c8d28ed9c090fd10e109b6f28f
ER  - 

TY  - JOUR
TI  - Interpretation of genome-wide association study results
T2  - ONCOLOGY
VL  - 24
IS  - 7
PY  - 2010
AU  - Huo D.
AU  - Olopade O.I.
N1  - 施引文献 :3
N1  - Export Date: 2 January 2016
TY  - Short Survey
DB  - Scopus
N1  - 参考文献: Pharoah P.D., Antoniou A.C., Easton D.F., Polygenes, risk prediction, and targeted prevention of breast cancer (2008) N Engl J Med, 358, pp. 2796-2803; 
Zheng W., Cai Q., Signorello L.B., Evaluation of 11 breast cancer susceptibility loci in African-American women (2009) Cancer Epidemiol Biomarkers Prev, 18, pp. 2761-2764; 
Pharoah P.D., Antoniou A., Bobrow M., Polygenic susceptibility to breast cancer and implications for prevention (2002) Nat Genet, 31, pp. 33-36; 
Lichtenstein P., Holm N.V., Verkasalo P.K., Iliadou A., Kaprio J., Koskenvuo M., Pukkala E., Hemminki K., Environmental and heritable factors in the causation of cancer: Analyses of cohorts of twins from Sweden, Denmark, and Finland (2000) New England Journal of Medicine, 343 (2), pp. 78-85. , DOI 10.1056/NEJM200007133430201; 
Hopper J.L., Southey M.C., Dite G.S., Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study (1999) Cancer Epidemiol Biomarkers Prev, 8, pp. 741-747; 
Xu J., Sun J., Kader A.K., Estimation of absolute risk for prostate cancer using genetic markers and family history (2009) Prostate, 69, pp. 1565-1572
UR  - http://www.scopus.com/inward/record.url?eid=2-s2.0-77958048375&partnerID=40&md5=787806dc3a206c68c4e3c9004e9d3e08
ER  - 

